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Abstract 
The marine realm and, in particular, the Antarctic benthos is largely unexplored and 
understudied.  The chemical investigation reported herein reveals not only the 
biodiversity, but how that biodiversity manifests remarkable chemical diversity.  In our 
continuing study of the nudibranch Austrodoris kerguelenensis, we have isolated a 
diverse suite of diterpenoid glyceride esters, palmadorins D - S (2.32 - 2.47), one of 
which is the first reported halogenated diterpene from a dorid nudibranch.  Utilizing 
genomic data from collaborators, we have investigated the chemical diversity from 
phylogenetically unique specimens collected in close proximity to one another.  Chemical 
groupings based on comparison of LC/MS metabolite fingerprints from individual 
organisms correlated well to the genetic data.  Our research shows that A. kerguelenensis 
specimens from the same phylogroups elaborate near identical metabolite profiles to each 
other, but distinct from other phylogroups.  Dendrilla membranosa is a dominant 
demosponge that prior studies have shown is rarely preyed upon and deters feeding 
against amphipods, the principal mesograzers of the Western Antarctic Peninsula.  To 
assess the defensive nature of the pure compounds, artificial food pellets spiked with 
membranolides were evaluated in a feeding assay against the omnivorous amphipod 
Gondogeneia antarctica whereby only artificial pellets containing membranolide 
exhibited significant feeding deterrence.  The research reported herein demonstrates that 
membranolides C and D were originally misassigned.  Reevaluation of new extracts 
evolved additional fused furan membranolides G and H, and allowed for complete 
xiv 
characterization of the four epimers.  Extraction of sponge in CD3OD resulted in 
incorporation of a deuterated methyl group into fragment ions as evidenced from LC/MS 
chromatograms.  Further chemical investigation of D. membranosa without the use of 
methanol revealed that these non-natural products arise from aplysulphurin, a known 
compound originally isolated from the sponge Aplysilla sulphurea, but later isolated from 
D. membranosa.  These studies emphasize the importance of exploring the marine realm 
for the presence of antiviral compounds, not only for identification of small molecules 
but also as a source of potent macromolecules. Subfractions from Gigartina skottsbergii 
possesses strong anti-influenza activity toward both the A/Wyoming/03/2003 (H3N2) 
and A/California/04/2009 (H1N1) virus with EC50 values in the range of 5 to 10 μg/mL.  
The virus-inhibitory effect was selective, dose-dependent, strain-specific and the virus 
induced cytopathogenic effect (CPE) was reduced at non-toxic concentrations of the 
extract. 
 
1 
Chapter 1.  On natural products, marine drugs and Antarctic chemical ecology 
 
Therapeutics derived from plants of the Salix genus have been utilized for centuries, 
eventually leading to the development of Aspirin as illustrated below in Figure 1.1. 
 
 
Figure 1.1.  Illustration of Salix and Aspirin. ©Dov Bock. Used with permission. 
 
1.1 A brief history of natural products 
Flowers, leaves, roots, berries, animal parts and minerals have all been studied as drugs 
by mankind.  Though seemingly unsophisticated, preparations of these crude drugs were 
recognized as having real effects.  The pharmacopoeia of traditional medicine is vast and 
active.
1-2
 Ancient Egyptians, Indians, Chinese and Greeks all possessed some record on 
the use of various plants as therapeutics.  The Sumerians had clay tablets on the study of 
herbs and remedies that dates back to 4000 BC.
3
  Egypt‟s great medical document, the 
“Ebers Papyrus,” is a 66 foot long scroll containing more than 700 medical recipes, 
2 
incantations and spells dating to circa 1550 BC.
4
  Dr. Roger Ebers, a German 
Egyptologist purchased the papyrus in Thebes in the late 19th century.  Many of the 
ancient Egyptian prescriptions bear similarity to modern ones: they prescribed castor oil 
as a laxative and for hair growth, pomegranate root extract to expel intestinal worms, and 
used extract of the Mediterranean sea onion, Urgina maritima, which contains cardiac 
glycosides such as scillaren A (1.1), to treat heart problems.
2
  The Ebers Papyrus lists 
morphine (1.2), the potent analgesic from the opium poppy Papaver somniferum, as an 
essential compound and a “remedy to stop a crying child...”.5   Images of the plant appear 
on ancient Sumerian tablets and refers to it as Hul Gil, the “joy plant”.5   
                        
                                  1.1  Scillaren A                                         1.2  Morphine 
Compiled in approximately 200 BC, the Shen Nong Ben Cao Jing is considered the first 
Chinese herbal book.
6
  In the text, the nature of drugs is divided into three classes: upper, 
middle and lower.
7-8
  The upper class are of a gentle nature, intended to be taken over 
years and months where one‟s health will be improved and the effect of these drugs 
corresponding to Heaven.  One example would be ginseng (Panax ginsing; panaxosides) 
which would “strengthen the mentality, relax stress, calm down the nerves….”.9  The 
middle class is said to be corresponding to Man.  They are more closely the relief of 
suffering and consumed over shorter period of time.  The lower class is the drugs of 
greater potency and used to cure illness quickly.  It is said that they are of the Earth not to 
be consumed over a long period of time since the purpose of the Earth is to detain and 
3 
kill.  The Atharva Veda, dating back to approximately 1200 BC, is one of the four 
primary Vedas (the primary texts of Hinduism).
10
  This ancient India medical text is 
composed of hymns whose contents include atonement ceremonies, maledictions, 
marriage and burial songs, and medical formulas.  Many of the hymns tout the use of 
herbs as therapeutics, including what are likely hallucinogenic plants, Cannabis, Datura 
metel and sarpagandha, later classified as Rauwolfia serpentine, that has been used as a 
treatment against hypertension and insanity for centuries.
11-12
  Researchers would later 
isolate antihypertensive alkaloid reserpine (1.3) and other analogs the roots of Rauwolfia 
in the 1950s.
12-13
  However, the text also lists many incantations or hymns to the gods for 
relief, or suggests treating diseases with plants or other objects simply resembling the 
affliction in color or shape. 
 
1.3  Reserpine 
It was not until the emergence of the Greek civilization where a deeper value for science 
and reason began to show progress towards established, effective treatments.  Among the 
plants Hippocrates (460 - 377 BC) utilized was the white willow (Salix alba), easily 
recognized by its long, drooping branches. Translations for treatments which likely use 
the willow tree appear in ancient Sumerian tablets and the Ebers Papyrus as a therapeutic 
for aches and fever.
14
 The Roman physician, Pedanius Dioscorides, who assembled the 
five-volume De Universa Medicina in the first century AD, noted the astringent qualities 
in describing willow.
14
 There are recorded uses of the plant from across the American 
4 
continent by Native Americans. In Rerum Medicarum Novae Hispaniae Thesaurus, 
Francisco Hernandez compiled an account of Aztec ethnomedicinal history while on a 
16th century Spanish expedition that contains several mentions of willow.
15
 It was not 
until the late 18th century that researchers began to identify the active substance by 
extracting bitter decoctions from the bark. The active substance was finally extracted in 
1827 by a French chemist named Leroux naming it salicin (1.4), for the willow genus 
(Salix).
14
 Salicin is metabolized to salicylic acid (1.5), but this compound has an 
unpleasant taste and causes vomiting.  Bayer‟s researchers continued developing related 
compounds eventually leading to acetylsalicylic acid (1.6, aspirin) a medicine with $673 
million in sales in 2009.
16
 Thus, the global account for the use of plants and other natural 
sources as treatment for disease, and symptoms of disease, is a unifying human trait.
17
 
                                                     
                         1.4  Salicin            1.5  Salicylic acid            1.6  Acetylsalicylic acid 
 
1.2  Conceptual framework of natural products 
The field of natural product chemistry is a basic science which involves the discovery, 
characterization and cataloging of new chemical substances found in nature. It is the 
genesis for the discipline of chemistry; arising from mankind‟s curiosity to understand 
taste, odor and cure for disease from his environment. Natural products are those 
chemicals literally made by living, natural organisms that appear to have no explicit role 
in the internal economy (i.e., primary metabolites) of the producing organism.
18
  All such 
compounds serve the organism by improving their survival fitness at the cost of 
5 
metabolic energy sculpted by millennia of Darwinian pressures so that a natural product 
will have inherent selectivity and potency to specific receptors on competing organisms.
19
  
Chemical diversity is begot by biological diversity; therefore, the forces of evolution 
apply to an organism‟s chemical diversity. Mutations creating new chemical entities will 
survive in the population if the benefits that result from making that molecule outweigh 
the metabolic cost. 
The term secondary metabolite is synonymous with natural product though the use of 
„secondary‟ conveys significance by distinguishing itself from a „primary‟ metabolite; the 
distinctions have been authoritatively reviewed.
20
 Primary metabolites are those involved 
in the normal growth, development or reproduction of organisms, exemplified by amino 
acids, cofactors or lipids providing energy, structure or reproductive capacity, for 
example.  Organisms cannot function without primary metabolites and given that cellular 
processes (DNA replication/repair, enzyme catalysis, protein biosynthesis, etc.) are 
mostly ubiquitous across living things, so are primary metabolites.  Secondary 
metabolites are typically species-specific and found to be associated with an organism‟s 
interaction with its environment.  Therefore, this group of compounds are limited in their 
biological distribution and most often produced by an organism for ecological purposes: 
chemical communication, environmental sensing or as a chemical defense. 
Nobel Prize winning German physiological chemist Albrecht Kössel first proposed two 
distinct types of plant metabolism.
19
 Though not his intention, a schism was formed as 
newly created biochemistry departments would go on to focus on primary metabolites 
believing them to be of greater importance due to their prevalence across all organisms. 
Meanwhile the study of secondary metabolites was left behind to those in the chemistry 
6 
department.  Some believe division of metabolites into these two categories is an 
outmoded theory and fails to provide insight about metabolism evolution or adequately 
classify molecules made by organisms.
19
 
Distinguishing a natural product from a primary metabolite is often a grey area. As an 
advanced stone tool is distinguished from a sharp rock, so too would complexity and 
uniqueness distinguish a natural product from a primary metabolite. The classification of 
secondary metabolites is guided primarily by four schemes: 1) molecular structural class; 
2) bioactivity; 3) biological origin; and 4) by the biosynthetic pathway from which they 
are derived.
1
  Figure 1.2 describes the biosynthetic origin of the major classes of natural 
products.  Simple building blocks like the gases carbon dioxide and nitrogen supply the 
framework for the common biosynthetic pathways.  Their functionality is provided by 
specialized tailoring enzymes that are often unique to the producing organism.
21-22
  It is 
these functionalities - such as the addition of alcohol groups, halogenations, oxidation, 
reduction, stereochemical manipulation or cyclizations which make secondary 
metabolites unique and bioactive. 
7 
 
Figure 1.2.  Biosynthetic origin of the major classes of natural products.
23
 
 
1.3 Marine natural products as drugs 
In the field of natural products, compounds from the terrestrial realm have taken up much 
of the literature due to the accessibility of plants and their use in traditional medicine. It 
was not until the 1950s that the idea of “drugs from the sea” would start to gather 
momentum mostly due to development in collection techniques, i.e. SCUBA diving. 
What blossomed was the opportunity for mankind to take to the seas in pursuit of 
scientific knowledge regarding the chemistry and ecological function of natural products 
from marine organisms. Two pioneers of the field are the late Paul Scheuer (University of 
Hawaii) and the late John Faulkner (Scripps Institute of Oceanography). Collectively, 
8 
they published more than 820 research articles, and more importantly, mentored or 
trained over 230 graduate and postdoctoral students.
24-25
  
Over the past few decades the role of natural products as tools of drug discovery has seen 
several changes.  After expanding over the last half of the 20th century, the field 
experienced a sharp decline as the pharmaceutical industry practically abandoned all 
research in the mid-1990s, focusing much of their efforts towards building massive 
compound libraries via combinatorial chemistry.  However, many researchers have 
continued to find success through advances in culturing of microorganisms, 
developments in analytical techniques (limit of detection, sensitivity) and high-
throughput screening.
26-28
  Over the last 25 years, 70% of all approved drugs have been 
natural products or derived from natural products, while only one de novo combinatorial 
compound has been approved as a drug.
29
  Oceans cover 75% of the Earth‟s surface and 
represent about 80% of its biodiversity.  Yet estimates suggest that only 95% of the 
oceans have been explored leaving a huge reservoir of biodiversity to be studied.  The 
last frontier of natural products rests in the oceans.  In a relatively short period of time, 
the potential for marine natural products as drugs has been realized.  As shown in Figure 
1.3 and Table 1.1, there are several potential therapeutics of diverse chemical class from 
marine sources currently in clinical trials in the United States.
29-31
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Figure 1.3. Selected marine natural products that have advanced as therapeutics 
 
1.7  Hemiasterlin 
1.10  Discodermalide 
1.11  Cryptophycin 
1.12  Dolastatin 10 
1.13  Halichondrin B 
1.14  Kahalalide F 
1.8  Bryostatin 1 
1.15  Phorboxazole A 
1.9  Salinosporamide A 
10 
Table 1.1. Potential therapeutics from marine sources
a
  
Compound Name 
Source 
organism
b
 
Chemical class 
Disease target 
or activity 
Status 
Eribulin Mesylate
32
 sponge macrolide Cancer Phase III 
Soblidotin/TZT-1027
33
 bacteria peptide Cancer Phase III 
DMXBA
34
 worm alkaloid Antipsychotic Phase II 
Plinabulin
35
 fungus diketopiperazine Cancer Phase II 
Plitidepsin
36
 tunicate depsipeptide Cancer Phase II 
Elisidepsin
37
 sea slug depsipeptide Cancer Phase II 
Hemiasterlin (1.7) 
38
 sponge tripeptide Cancer Phase I 
Bryostatin 1 (1.8) 
39
 bryozoan polyketide Cancer Phase I 
Salinosporamide A (1.9) 
40
 bacteria 
β-lactone-γ-
lactam 
Cancer Phase I 
Discodermolide (1.10)
41
 sponge polyketide Cancer Phase I 
Cryptophycin (1.11) 
42
 cyanobacteria peptide Cytotoxin discontinued 
Arenastatin A
43
 sponge depsipeptide   
Dolastatin 10 (1.12) 
44
 sea hare depsipeptide Cancer Phase I and II 
Halichondrin B (1.13) 
45
 sponge 
polyether 
macrolide 
Cancer  Phase I 
Kahalalide F (1.14) 
46
 sea slug/alga depsipeptide Cancer Phase II 
Phorboxazole A (1.15) 
47
 sponge 
polyketide-
alkaloid 
Cancer Pre-clinical 
Pseudopterosins
48
 coral 
diterpene 
glycoside 
Wound healing Pre-clinical 
a
 Adapted, in part, from Molinski et al.
26
 and Mayer et al.
49
 
b 
Either the natural product, analog or derivative thereof. 
 
To date, four marine natural products, or derivatives thereof, have been brought to 
market.  Ziconotide (ω-conotoxin MVIIA, 1.16) was first approved in 2004 and is now 
sold under the trade name Prialt® (Elan Pharmaceuticals; Azur Pharma) for the treatment 
of severe and chronic pain. Researchers isolated the peptide from the venom of the 
Pacific piscivorous cone snail Conus magus,
50
 a genus which elaborates a suite of toxic 
peptides (conotoxins) that immobilize prey. Ziconotide is a linear 25 amino acid, 
multivalent peptide that targets N-type voltage-sensitive calcium channels (NVSCCs)
51
 
with potent selective inhibition (Kd 9 pM).
52
 Researchers first recognized the activity of 
the peptide via a characteristic shaking response from mice following intracerebral 
injection.
53
  After synthetic development of ziconotide, rat studies demonstrated more 
potent and sustained activity for the peptide than morphine (ED50 49 pM versus 2.1 
nM).
54
  One drawback to treatment is that as a result of the high polarity of the peptide, 
11 
the drug must be delivered directly into cerebrospinal fluid.
12
  In 2009, sales for Prialt 
reached $20 million.
55
 
 
1.16  Ziconotide 
Cytarabine (Ara-C, Cytosar-U®, 1.17) and vidarabine (Ara-A, Vira-A®, 1.18) are 
synthetic pyrimidine nucleosides derived from nucleosides originally isolated from the 
Caribbean sponge Tethya crypta.
56
 Initial approval for cytarabine granted in 1969 by the 
Food and Drug Administration (FDA) and along with other derivatives have since gone 
on to be used for treatment of leukemia and other hematological malignancies, viral 
diseases and meningitis. Cytarabine is an S-phase specific antimetabolite cytotoxic agent 
which metabolizes to compete with DNA polymerase and DNA synthesis.
57
  The well-
known drug azidothymidine (AZT) is derived from cytarabine and was the first approved 
treatment for HIV.  Vidarabine was used as an antiviral drug against the herpes simplex 
virus and as an ophthalmic treatment.  Although vidarabine received FDA approval in 
1976, its marketing status is currently listed as discontinued in the US market.
49
 
                                
                         1.17  Cytarabine                                        1.18  Vidarabine 
Ecteinascidin-743 (ET-743, trabectin, Yondelis®, 1.19) is an isoquinoline alkaloid and 
the first direct marine-sourced anticancer compound to be sold. In 1990 Rinehart
58
 and 
Wright
59
 separately published on the structure of ET-743 and ecteinascidin analogs 21 
years after antitumor activity of extracts from the Caribbean tunicate Ecteinascidia 
12 
turbinata was first observed.
60
  Structure elucidation and animal studies were limited by 
low yields, taking years of synthetic and semi-synthetic development to provide multi-
kilogram quantities needed for clinical trials and mechanistic studies.  ET-743 was found 
to selectively alkylate DNA, affect transition-coupled nucleotide excision repair and 
trigger apoptosis.
61
  Currently, trabectin is only sold in the EU, although it is in key Phase 
III studies in the United States.
26
 
 
1.19  Ecteinascidin-743 
 
1.4 Antarctic chemical ecology 
Antarctica is the 5th largest continent and the coldest place on earth as 98% of its surface 
is covered by ice. However, the 11,000 miles of coastline and the world‟s largest 
continental shelf harbor great biodiversity. The Western Antarctic Peninsula (WAP) 
archipelago is a stunning sight of ice and snow-capped mountains extending from frothy 
waters toward grey skies. Underneath the surface however, macroalgal forests dominate 
the shallow benthos and colorful invertebrates cover stunning walls that drop straight to 
the ocean floor. The chemical ecology of the current benthic marine invertebrate fauna is 
largely ancient and endemic as it has separated from the supercontinent Gondwana 130 - 
85 million years ago.
62
  Sculpted by periods of glaciations and strong currents, the 
13 
Southern Ocean is home to a rich and biologically diverse marine environment.
63-67
  
Though studies date back to the nineteenth century, this remote and hostile environment 
remains largely unexplored and relatively little is known about much of its chemical 
ecology. The fauna of the deep sea (typically > 500 m) is the greatest unknown as benthic 
sampling is largely limited to the shelf (average depth 450 m).  The Census of Antarctic 
Marine Life and the Scientific Committee on Antarctic research Marine Biodiversity 
Information Network (SCAR-MarBIN) recently compiled taxonomic lists to form the 
Register of Antarctic Marine Species which includes over 8,100 valid species.
67
  
The Southern Ocean interacts with the deep water circulation in each of the Atlantic, 
Indian and Pacific oceans acting as a major force of global ocean circulation. The 
Antarctic Circumpolar Current (ACC) is the strongest current in the world and 
continuously circles the continent unimpeded by land masses. The Antarctic marine 
ecosystem benefits from the ACC via transportation of nutrients and ocean heat across 
the continental shelf from the world‟s oceans. In general, oxygen, nitrate, phosphate and 
silicate levels are significantly higher than most other regions of the globe, while 
chlorophyll and iron are limited.
64
  The nutrient-rich waters teamed with the extended 
photoperiods and reduced coverage of annual sea ice at the higher Antarctic latitudes 
stimulate a high level of primary production. As a result, seasonally abundant 
phytoplankton blooms and dense macroalgal forests are observed, particularly along the 
WAP which is in close proximity to the ACC.
68
  On sheer vertical rock faces or depths 
below algal cover, a rich invertebrate assemblage comprised of sponges, corals, 
bryozoans, hydroids and ascidians is found. High densities of crustacean mesograzers, 
14 
generalist invertebrate predators (sea stars, sea urchins, brittle stars), and largely krill-
dependent and fish-dependent sea birds are found at the higher trophic levels.
66
 
An estimated 50 to 60 glacial and interglacial cycles have occurred over the last 2.4 
million years around the Antarctic continent.
69
 Although these periods are well known for 
causing widespread extinction on the Antarctic shelf and slope, small refuges from ice 
have aided the existence of small closed populations containing a subset of taxa.  Figure 
1.4 illustrates how allopatric (geographic) speciation can occur as a result from glacial 
cycles. In each of these refuges, different predator-prey „experiments‟ occurred with 
strong selection pressures and unique sets of biotic factors in each refuge. If kept 
separated long enough, major allopatric (geographic) speciation may have been initiated 
(Figure 1.4c). Isolated populations may experience genetic drift which then creates 
phenotypic divergence as mutations arise in the gene pools.
70-71
  After retreat of the ice 
sheets, the refuges no longer existed and the taxa were able to move freely and members 
of two populations may emerge as different species if the isolated groups are unable to 
mate.  This process where repeated glaciations evolve phenotypic divergences has been 
termed the Antarctic biodiversity pump phenomenon.
72
 
 
              a                                     b                                     c                                     d 
Figure 1.4.  Illustration of allopatric (geographic) speciation whereby a) an original 
population experiences b) geographic isolation (e.g., period of glaciation). If kept 
separated long enough, c) a new species may evolve forming two distinct species once d) 
the barriers are removed (retreat of ice sheets). 
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Numerous reports of chemical defenses among sessile and slow-moving Antarctic marine 
invertebrates have now established that despite theoretical predictions to the contrary,
73
 
the incidence of chemical defenses against predation is comparable to temperate and 
tropical marine environments. Palmerolide A (1.20)
74
 is a macrolide polyketide from the 
colonial tunicate Synoicum adareanum collected in the waters near Palmer Station that 
exhibits potent cytotoxicity toward certain mammalian cell lines (18nM inhibition of 
UACC-66 melanoma). Although no ecological role has been ascribed to the 
palmerolides, S. adareanum elaborates a series of ecdysteroids (e.g. abeohyousterone 
(1.21)
75
), compounds utilized by crustaceans as molting regulators.
66
  With the high 
abundance of amphipods (crustacean mesograzers) along the WAP, ecdysteroids likely 
play an important ecological role for the tunicate.
76
 
           
                        1.20  Palmerolide A                                       1.21  Abeohyousterone 
The red encrusting sponge Crella sp. has been found to elaborate a family of highly 
oxidized anti-infective steroids named the norselic acids.
77
 Both the lipophilic and 
hydrophilic extracts of Crella sp. were significantly deterrent in feeding assays with the 
omnivorous amphipod Gondogeneia antarctica.
78
  Norselic acid A (1.22) displays broad 
antibiotic activity, including methicillin-resistant Staphylococcus aureus (MRSA), as 
well as activity against the Leishmania parasite and low micromolar concentrations.
77
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                                                        1.22  Norselic acid A 
The demosponge Latrunculia apicalis was determined to sequester feeding deterrent 
secondary metabolites (discorhabdin G (1.23)) at the surface of the sponge.
79
  When 
samples comprised of inner layer sponge tissue spiked with discorhabdin G were 
introduced to the tube feet of Perknaster fucus, they were rejected significantly more than 
samples not spiked with pure compound.
79-80
  The tryptophan catabolite erebusinone 
(1.24), a pigment isolated from the yellow sponge Isodictya erinacea, caused 
significantly reduced molting and increased mortality when fed to sympatric predatory 
amphipods.
81
 
                                 
                       1.23  Discorhabdin G                               1.24  Erebusinone 
 
1.5 Research objectives 
The marine realm and, in particular, the Antarctic benthos is largely unexplored and 
understudied.  This research provides one of the most comprehensive studies on Antarctic 
nudibranch chemistry to date.  Antarctic natural products have provided promising 
biologically active leads.  Organisms of the Antarctic benthos have evolved under a 
unique set of ecological pressures and these conditions have afforded tremendous 
17 
biodiversity.  The chemical investigation reported herein reveals not only the 
biodiversity, but how that biodiversity manifests the remarkable chemical diversity. 
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Chapter 2.  Chemical investigation of Austrodoris kerguelenensis 
Austrodoris kerguelenensis is a dorid nudibranch found all around the Antarctic continent 
(see Figure 2.1). 
 
Animalia 
Mollusca 
Gastropoda 
Nudibranchia 
Doridae 
Austrodoris 
kerguelenensis 
 
 
Figure 2.1.  Austrodoris kerguelenensis and its representative chemistry. 
 
2.1 Introduction to nudibranchs 
Nudibranchs are one of the most visible creatures on the marine benthos due to their 
often magnificent, bright coloration and remarkable form. These hermaphroditic 
mollusks are soft-bodied with visible branchial plumes; Nudibranchia translates to 
“naked gills.” Although they lack physical protection (shell) and possess very limited 
mobility, they are rarely preyed upon due to the presence of chemical defenses.  Some 
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3,000 species of opisthobranch nudibranchs have been described from waters all over the 
globe and their chemistry and ecological function has been reviewed.
1-5
 Nudibranchs 
frequently derive and sequester their defensive metabolites from their diet, such as 
sponges or soft corals, but are known to be capable of de novo biosynthesis of their own 
defensive chemistry.
6
  All major classes of natural products have been elaborated from 
nudibranchs, though diterpenoid and sesquiterpenoid are most often observed.
7
 
Nudibranchs represent approximately a quarter of the reported chemistry of the Mollusca 
phylum with just over 350 reported compounds, and the Dorid nudibranchs comprise 
about a tenth of the known nudibranch chemistry.
7
  The taxonomy of the Nudibranchia is 
still under investigation; formerly an order, authorities have recently classified 
Nudibranchia as a taxonomic clade.
8
 
 
2.2 Chemistry of Doridae 
Of the opisthobranchs, Dorid nudibranchs have received the most attention from 
chemists; chemical, pharmacological and ecological roles of nudibranch diterpene 
glycerides from dorid nudibranchs have been well studied.
3,9-12
  Diet-derived secondary 
metabolites from sponge feeding have been shown to deter predators and appear to have 
led to the evolutionary loss of physical protection (shell).
2
  That Dorid nudibranchs have 
further evolved to be capable of de novo biosynthesis of their defensive chemistry is an 
adaptive trait that enables nudibranchs to be unconstrained by any diet-derived chemical 
defense.
2-3,9-10,13-14
  Cimino et al. demonstrated that three species of Dorid nudibranchs 
(Dendrodoris limbata, D. grandiflora and D. arborescens) incorporated 
14
C labeled 
mevalonic acid or 
14
C and 
13
C labeled glucose into sesquiterpenoid esters with a drimane 
24 
 
skeleton (i.e., polygodial (2.1) and a mixture of esters (2.2)) via the mevalonate 
pathway.
15-19
  Stable isotope incorporation into nanaimoal (2.3) and isoacanthodoral (2.4) 
was observed from [1,2-
13
C2]acetate injections into Acanthodoris nanaimoensis.
20
  
Researchers note their strategy of handling the nudibranchs prior to injection to stimulate 
an ecological response of activation and release of defensive secondary metabolites 
proved effective. 
                          
2.1  Polygodial                     2.2                    2.3  Nanaimoal       2.4  Isocanthodoral 
From Archidoris montereyensis and A. odherni, low levels of mevalonic acid 
incorporation into sesquiterpenoid and diterpenoid acid glycerides (i.e, 2.5, 2.6 and 2.7) 
were reported.
21
  d 
   
2.5                              2.6                                                             2.7 
Hodgsonal (2.8), a sesquiterpene isolated from the Antarctic nudibranch Bathydoris 
hodgsoni exhibited significant feeding deterrence towards the sympatric omnivorous sea 
star Odontaster validus. Furthermore, researchers hypothesized that hodgsonal is 
biosynthesized de novo, since it was not detected in the viscera (internal organs), and 
found in consistent concentrations across locations and depths in the mantle.
22
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2.8  Hodgsonal 
2.3  Chemistry of Austrodoris kerguelenensis 
The chemistry of the Austrodoris genus is dominated by diterpenoids of the four related 
carbon skeletal backbones clerodane (2.9), labdane (2.10), halimane (2.11) and 
iscopalanes (2.12).
23-31
   
          
        2.9  Clerodane          2.10  Labdane            2.11  Halimane       2.12  Iscopalane 
Austrodoris kerguelenensis Bergh 1884, is the most common nudibranch species found in 
Antarctic waters.
32
 For consistency with chemical literature, the taxonomic classification 
used herein will be the more traditional genus, Austrodoris, though some authorities have 
started classifying them within the Doris genus.
33-35
  From coastline to continental shelf, 
A. kerguelenensis has been collected from diverse sites around the Antarctic continent, 
across the Scotia Arc and even into deeper waters off Argentina and Chile. Organisms 
from McMurdo Sound, the Weddell Sea shelf and the Western Antarctic Peninsula 
(WAP) have been found to yield diterpene glycerides with diverse skeletal backbones 
(see Figure 2.1 for map and examples). 
The Italian scientists Margherita Gavagnin and Guido Cimino have contributed 
substantially to the field of Antarctic nudibranch chemistry; many of the compounds 
reported herein arise from their research.  Austrodoral (2.13) and its oxidized derivative 
26 
 
austrodoric acid (2.14) were isolated from specimens collected at depths of 10 - 20 m by 
SCUBA off Terra Nova Bay, Antarctica.
36
 These compounds are the only nor-
sesquiterpenes reported to date; researchers provided relative stereochemistry. 
                                    
2.13  Austrodoral; R = CHO 
2.14  Austrodoric acid; R = CO2H 
 
Isocapalanes austrodorin-A (2.15) and austrodorin-B (2.16) were isolated from specimens 
collected by trawling (exact depth not provided), south of Livingston Island (South 
Shetland Islands, Antarctica).
25,31
 
               
2.15  Austrodorin-A                                       2.16  Austrodorin-B 
 
From a collection acquired from dredging at 70 m in Tethys Bay, Antarctica, the 
halimane austrodorin (2.17) was isolated and characterized from its diacetyl deriviative.
26
 
Halimane 2.18 was isolated from Terra Nova Bay via SCUBA at depths of 10 - 20 m.
24
  
From specimens collected via trawling the South Shetland Islands, halimane 2.19 was 
isolated with a proposed structure containing a 2,3-sn-glycerol.
31
 This compound was 
later re-isolated from specimens collected from Terra Nova Bay and revised to the 1,2-sn-
glycerol halimane 2.20.
24
 The 1,3-sn glycerol derivative of austrodorin, halimane 2.21 
was isolated from the same collection in the South Shetland Islands that afforded 
iscopalanes austrodorin-A, austrodorin-B and halimane 2.19.
31
 
27 
 
The only clerodane diterpenoid isolated from outside the WAP was identified from a 
Terra Nova Bay collection.  Clerodane 2.22 was reported with relative chemistry and 
from the same collection as halimanes 2.18 and 2.20, and labdane 2.29.
24
  From 
specimens collected near Palmer Station, Antarctica along the WAP, palmadorins A 
(2.31), B (2.32) and C (2.33) were elaborated.
30
 
 
                        
2.17  Austrodorin; R1 = H; R2 = H   2.18  R = H 
2.19  R1 = Ac; R2 = H     2.20  R = Ac 
        (originally proposed)            (revised) 
2.21  R1 = H; R2 = Ac 
 
              
2.22    2.23  Palmadorin A; R = H 
    2.24  Palmadorin B; R = Ac 
 
2.25  Palmadorin C 
 
Labdanes 2.26, 2.27, 2.28 and 2.29 were isolated from specimens collected by SCUBA 
(25 - 35 m) at Cape Armitage, McMurdo Sound, Antarctica.
23
 Similar to the 
reassignments described above, 2.28 was originally assigned as a 2,3-sn-glycerol, then 
later revised to 2.29 based on new collections from Terra Nova Bay (SCUBA; 10 - 20 
28 
 
m).
24
  Stereochemistry about C-13 was determined as R was based on IR, 
1
H NMR 
spectral and optical rotation data comparison with a known methyl ester after 
saponification and methylation of 2.28.
23
  Labdanes 2.26 and 2.29 were re-isolated from 
specimens collected across the continent via trawling in the Weddell Sea.
31
 
                
2.26  R1 = H; R2 = H; R3 = Ac 
2.27  R1 = ═O; R2 = H; R3 = H 
2.28  R1 = H; R2 = Ac; R3 = H   2.29 
        (originally proposed)                                       (revised) 
 
Arising from oxidation of the Δ8,9 bond of labdanes 2.26 and 2.28, diketones 2.30 and 
2.31 were isolated from the same Cape Armitage collections.
23
  Though never reassigned, 
it is most probable that 2.31 exists as the 1,3-sn-glycerol given that no 2,3-sn-glycerols 
have since been identified.. 
 
2.30  R1 = H; R2 = Ac 
2.31  R1 = Ac; R2 = H 
 
2.3  Results and discussion for new palmadorins D - S (2.32 - 2.47) 
Austrodoris kerguelenensis are typically bright white, especially when collected at 
greater depths (>100 m).  Palmer Station area specimens exhibit a broad range of solid 
coloration from white to pale yellow to bright orange (author’s personal observations; see 
Figure 2.20 for examples).  These molluscs may vary in size from 1 to 16 cm and weigh 
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as much as 125 g.  Gavagnin and coworkers
25
 recognized that distinct collections of A. 
kerguelenensis have elaborated different metabolite patterns and this present collection 
from close proximity (< 3.5 km) to Palmer Station, Antarctica, is no exception.  In the 
austral summer of 2007 and 2008 approximately 200 A. kerguelenensis specimens were 
collected from the benthos at depths ranging from 1 to 40 m (see Scheme 2.1). The 
nudibranchs were immediately frozen and later extracted with CH2Cl2:MeOH (1:1). From 
the lipophilic extracts of A. kerguelenensis, 16 new diterpene glycerides, palmadorin D 
(2.32), E (2.33), F (2.34), G (2.35), H (2.36), I (2.37), J (2.38), K (2.39), L (2.40), M 
(2.41), N (2.42), O (2.43), P (2.44), Q (2.45), R (2.46) and S (2.47), were isolated using 
flash chromatography and repeated iterations of HPLC separations. In addition, three 
known compounds were isolated and identified as palmadorins A (2.23), B (2.24) and C 
(2.25).
30
 The new diterpenes fall into three structural classes, clerodane (9/16), labdane 
(5/16) and halimane (2/16) and are primarily mono-acyl glycerides (13/16). All but two 
display a β-methyl-α,β-unsaturated ester motif first observed in WAP diterpene 
glycerides,
30
 and one bears chlorine, representing the first example of a halogenated 
diterpene from A. kerguelenensis. 
30 
 
 
Scheme 2.1.  Isolation scheme and HPLC chromatogram for palmadorins D - S (2.32 - 
2.47). 
 
Palmadorin  JEKI                SG C F    Q R H L  P   AMDNBO
aqueous crude
A        B       C       D       E        F       G       H        I     wash
RP HPLC                                   
40% MeOH:H2O-MeOH                   750 mg        
~ 70 organisms, 660 g Austrodoris kerguelenensis
organic crude
1) 35 g; 2) 2.5 g
1) CH2Cl2:MeOH (1:1);
2) EtOAc:H2O partition
NP MPLC
hexanes-EtOAc-MeOH
1 2      3      4      5      6      7      8      9     10    11     12   13    14    15    16
J     E      K     I       S     G      F     Q      R     H     L      P     M     D     N     O
0.9  3.0   0.6  1.9   2.4   1.5   2.9    1.3    2.1   3.7  0.8    1.4  10.1 36.2  9.8  5.0
fractions
mg
Palmadorin:
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Table 2.1.  Palmadorins D - S (2.32 - 2.47) 
 
Clerodane 
 
 
Labdane 
 R1 R2 R3 R4    R1 R2  
2.32 H H H CH2OH Δ
4,18
  2.41 CH2OH H  
2.33 =O OH H CH2OH Δ
3,4
  2.42 H CH2OH  
2.34 H OH H CH2OH Δ
3,4
  2.43 CH2OAc H  
2.35 =O H H CH2OH Δ
3,4
  
 
2.36 H OH CH2OAc H Δ
3,4
  
2.37 =O =O H CH2OH Δ
3,4
  
2.38 =O OH CH2OH H Δ
3,4
  
2.39 =O =O CH2OH H Δ
3,4
  
       2.44  8β-OH 
 
 2.45  8α-OH 
 
 
 
 
 
2.40  
       Halimane 
       2.46  R1 = Ac 
       2.47  R1 = H 
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Table 2.2. 
13
C NMR Data and Multiplicity of Palmadorins D - S (2.32 - 2.47)
a
 
position 2.32 2.33 2.34 2.35 2.36 2.37 2.38 2.39  
1 21.7 CH2 34.8 CH2 17.9 CH2 35.0 CH2 18.0 CH2 35.1 CH2 34.9 CH2 35.1 CH2 
2 28.7 CH2 200.0 C 26.7 CH2 200.1 C 26.7 CH2 198.4 C 200.2 C 198.5 C 
3 33.0 CH2 125.0 CH 119.8 CH 125.5 CH 119.8 CH 126.0 CH 125.0 CH 126.0 CH 
4 160.4 C 172.8 C 144.9 C 172.6 C 144.9 C 169.3 C 172.9 C 169.4 C 
5 40.0 C 39.4 C 37.6 C 39.9 C 37.6 C 44.3 C 39.4 C 44.3 C 
6 37.3 CH2 41.4 CH2 42.9 CH2 35.5 CH2 42.9 CH2 51.1 CH2 41.4 CH2 51.1 CH2 
7 27.4 CH2 73.1 CH 73.7 CH 26.8 CH2 73.7 CH 210.6 C 73.1 CH 210.7 C 
8 36.7 CH 38.9 CH 39.3 CH 36.0 CH 39.3 CH 50.1 CH 38.9 CH 50.1 CH 
9 39.4 C 38.4 C 38.3 C 38.8 C 38.3 C 44.3 C 38.4 C 44.3 C 
10 48.7 CH 45.9 CH 46.6 CH 45.7 CH 46.6 CH 45.7 CH 45.9 CH 45.7 CH 
11 36.2 CH2 36.4 CH2 37.4 CH2 35.4 CH2 37.3 CH2 35.8 CH2 36.3 CH2 35.6 CH2 
12 34.6 CH2 34.3 CH2 34.9 CH2 34.1 CH2 34.9 CH2 34.4 CH2 34.3 CH2 34.4 CH2 
13 163.4 C 161.7 C 163.2 C 162.0 C 163.2 C 160.4 C 161.8 C 160.6 C 
14 114.2 CH 114.9 CH 114.4 CH 114.8 CH 114.5 CH 115.4 CH 115.2 CH 115.4 CH 
15 167.1 C 166.8 C 167.1 C 166.9 C 166.1 C 166.6 C 166.5 C 166.6 C 
16 19.4 CH3 19.3 CH3 19.4 CH3 19.4 CH3 19.4 CH3 19.3 CH3 19.4 CH3 19.0 CH3 
17 16.0 CH3 12.4 CH3 12.7 CH3 15.7 CH3 12.5 CH3 7.8 CH3 12.4 CH3 7.8 CH3 
18 102.6 CH2 19.0 CH3 18.0 CH3 19.0 CH3 17.9 CH3 18.8 CH3 19.0 CH3 18.9 CH3 
19 20.8 CH3 20.1 CH3 21.8 CH3 18.3 CH3 21.8 CH3 19.4 CH3 20.1 CH3 19.3 CH3 
20 18.1 CH3 19.5 CH3 20.0 CH3 17.8 CH3 20.0 CH3 19.0 CH3 19.5 CH3 19.0 CH3 
1′ 64.5 CH2 64.6 CH2 64.5 CH2 64.6 CH2 62.4 CH2 64.7 CH2 62.9 CH2 62.7 CH2 
2′ 70.4 CH 70.4 CH 70.4 CH 70.3 CH 71.4 CH 70.3 CH 74.6 CH 74.7 CH 
3′ 63.3 CH2 63.3 CH2 63.3 CH2 63.3 CH2 61.7 CH2 63.3 CH2 62.7 CH2 62.7 CH2 
CO2CH3         171.0 C         
CO2CH3         20.8 CH3          
a
 125 MHz, ppm in CDCl3 
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Table 2.2 continued. 
13
C NMR Data and Multiplicity of Palmadorins D - S (2.32 - 2.47)
a
 
position 2.40 2.41 2.42 2.43 2.44 2.45 2.46 2.47 
1 21.0 CH2 36.7 CH2 36.7 CH2 36.8 CH2 39.2 CH2 39.2 CH2 121.9 CH 121.9 CH 
2 21.5 CH2 19.1 CH2 19.1 CH2 19.1 CH2 18.2 CH2 18.4 CH2 200.3 C 200.6 C 
3 30.5 CH2 42.6 CH2 42.6 CH2 42.6 CH2 42.0 CH2 41.9 CH2 47.0 CH2 47.0 CH2 
4 75.2 C 33.2 C 33.2 C 33.2 C 33.4 C 33.4 C 34.4 C 34.5 C 
5 42.1 C 45.8 CH 45.8 CH 45.8 CH 55.9 CH 56.1 CH 45.7 CH 45.8 CH 
6 31.6 CH2 23.5 CH2 23.6 CH2 23.6 CH2 18.1 CH2 20.5 CH2 29.8 CH2 29.8 CH2 
7 27.0 CH2 31.5 CH2 31.5 CH2 31.5 CH2 42.3 CH2 44.8 CH2 30.6 CH2 30.6 CH2 
8 35.9 CH 148.7 C 148.7 C 148.7 C 73.1 C 74.3 C 45.9 CH 45.8 CH 
9 39.0 C 57.8 CH 57.8 CH 57.9 CH 58.8 CH 61.4 CH 44.8 C 44.8 C 
10 40.7 CH 38.0 C 38.0 C 38.0 C 39.0 C 39.7 C 173.6 C 173.7 C 
11 36.5 CH2 24.2 CH2 24.1 CH2 24.2 CH2 23.5 CH2 24.1 CH2 28.9 CH2 28.9 CH2 
12 34.8 CH2 39.8 CH2 39.8 CH2 39.9 CH2 44.7 CH2 44.5 CH2 30.7 CH2 30.6 CH2 
13 163.5 C 163.2 C 163.0 C 163.2 C 162.5 C 163.2 C 31.1 CH 31.3 CH 
14 114.4 CH 114.5 CH 114.4 CH 114.4 CH 114.3 CH 114.2 CH 41.5 CH2 41.7 CH2 
15 167.1 C 166.8 C 167.2 C 166.2 C 167.1 C 167.2 C 173.1 C 173.4 C 
16 19.4 CH3 19.4 CH3 19.3 CH3 19.4 CH3 19.3 CH3 19.4 CH3 19.9 CH3 19.9 CH3 
17 15.9 CH3 109.9 CH2 110.0 CH2 109.9 CH2 30.6 CH3 23.6 CH3 16.1 CH2 16.1 CH2 
18 53.3 CH2 22.1 CH3 22.1 CH3 22.1 CH3 21.6 CH3 21.5 CH3 28.4 CH3 28.4 CH3 
19 17.3 CH3 33.4 CH3 33.5 CH3 33.5 CH3 33.3 CH3 33.2 CH3 27.6 CH3 27.6 CH3 
20 18.4 CH3 22.3 CH3 22.3 CH3 22.3 CH3 15.1 CH3 15.4 CH3 22.8 CH3 22.8 CH3 
1′ 64.5 CH2 62.3 CH2 64.4 CH2 62.5 CH2 64.5 CH2 64.5 CH2 65.0 CH2 65.1 CH2 
2′ 70.4 CH 74.2 CH 70.4 CH 71.3 CH 70.4 CH 70.4 CH 68.3 CH 70.2 CH 
3′ 63.3 CH2 62.3 CH2 63.4 CH2 61.7 CH2 63.3 CH2 63.3 CH2 65.3 CH2 63.4 CH2 
CO2CH3             171.0  C         171.0 C     
CO2CH3             20.8  CH3         20.8 CH3     
a
 125 MHz, ppm in CDCl3 
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2.3.1  Characterization of substructure A 
The most unique feature to all but two of the palmadorins is the β-methyl-α,β-unsaturated 
ester, C-13 - C-16. This motif, found only in WAP-derived A. kerguelenensis, is easily 
distinguishable by 
1
H and 
13
C NMR data, with only small differences in shifts (standard 
deviations < 0.40).  Table 2.3 lists averaged 
1
H and 
13
C NMR data of substructure A; 
Figure 2.2 illustrates key shifts for substructure A utilizing spectra from selected 
palmadorins.  Vinylic proton H-14 (δH 5.69 ± 0.019) exhibits HMBC correlations to ester 
carbonyl C-15 (δC 166.8 ± 0.39), vinyl methyl C-16 (δC 19.4 ± 0.20) and the β position at 
C-13 (δC 162.7 ± 1.05). Vinyl methyl H3-16 (δH 2.15 ± 0.013) displays HMBC 
correlations to C-13, C-14 (δC 114.8 ± 0.69) and C-15. The C-13 - C-14 olefin is defined 
as E via ROESY correlations from H2-12 to H-14. 
Table 2.3. Averaged 
1
H and 
13
C NMR Data of Substructure A
a
 
 
 
 
Substructure A 
 2.32 - 2.47 clerodanes 
2.32 - 2.40 
labdanes  
2.41 - 2.45 
halimanes
b
 
2.46 - 2.47 
position δC δH δC δH δC δH δC δH 
11 31.5 1.47 36.4 1.43 24.0 1.57 28.9 1.49 
12 36.3 1.85 34.6 1.95 41.7 2.05 30.7 0.96 
13 162.7  167.3  163.0  31.2  
14 114.8 5.69 115.1 5.68 114.4 5.70 41.6 2.20 
15 166.8  166.8  166.9  173.3  
16 19.4 2.15 19.4 2.15 19.4 2.15 19.9 0.9 
a
 HMBC →. 500 MHz, for 1H NMR ppm in CDCl3. 
b
 Halimanes 2.46 and 2.47 lack Δ13,14 
 
Figure 2.2.  
1
H and 
13
C NMR data illustrating characteristic shifts for substructure A. 
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2.3.2  Characterization of substructures B - E 
The glycerol substructures from A. kerguelenensis diterpenes have been well described 
and exhibit little variation, making assignment for this portion straightforward.
23-24
  Only 
four modifications of this moiety have been identified in this species and palmadorins are 
no exception.  Table 2.4 provides HMBC and COSY correlations along with averaged 
1
H 
and 
13
C NMR data among the glycerol substructures.  The 1′-substitued glycerol, 
substructure B, can be established by observation of HMBC correlations between H2-1′ 
(δH 4.18 ± 0.01) to ester carbonyl C-15 and methine C-2′ (δC 70.4 ± 0.14).  In addition, 
correlations from H-2′ (δH 3.93 ± 0.01) to methylene C-3′ (δC 63.4 ± 0.10) were observed, 
as was COSY correlations of H-2′ to protons H2-1′ and H2-3′ (δH 3.64 ± 0.02).  
Substructure C, 2′-substituted glycerol, exhibits HMBC correlations from methine H-2′ 
(δH 4.92 ± 0.01) to the ester carbonyl C-15 and chemically equivalent methylenes C-1′ 
and C-3′ (δC 62.6 ± 0.35). Additional COSY correlations of H-2′ to H-1′/H-3′ (δH 3.83 ± 
0.00) complete assignment of substructure C.  The mono-acetylated variation of 1′-
substitued glycerol, substructure D, is an 1′,3′-sn-substituted glycerol found only in 
palmadorin R (2.46).  Methylene H2-1′ (δH 4.14) shows HMBC correlation to the ester 
carbonyl C-15 and with C-2′ (δC 68.3). Further connectivity is established by COSY 
correlations of H-2′ (δH 4.06) to methylenes H2-1′ and H2-3′ (δH 4.13), and HMBC 
correlation of H-2′ to C-3′ (δC 65.3). Additional HMBC correlations from H2-3′ to ester 
carbonyl CO2CH3 (δC 171.0) and from methyl singlet CO2CH3 (δH 2.08) to CO2CH3 
denotes the presence of the acetyl group in substructure D. Substructure E, 1′,2′-sn-
substituted glycerol, represents the mono-acetylated form of 2′-substituted glycerol. 
Methine H-2′ (δH 5.10 ± 0.02) exhibits HMBC correlations to the ester carbonyl C-15 as 
36 
 
well as C-1′ (δC 62.4 ± 0.02) and C-3′ (δC 61.7 ± 0.02). Further COSY correlations of H-
1′ (δH 4.29 ± 0.02) and H-3′ (δH 3.76 ± 0.02) with H-2′ establish the glyceride moiety. 
The presence of an acetyl group in substructure E is realized by the observation of 
HMBC correlations from H2-1′ to ester carbonyl CO2CH3 (δC 171.0 ± 0.0) and from 
CO2CH3 to methyl singlet CO2CH3 (δH 2.08 ± 0.03). 
Table 2.4. HMBC and COSY Correlations and Averaged 
1
H and 
13
C NMR Data Among the 
Glycercerol Substructres B - E
a
 
 
 
 
 
 
 Substructure B Substructure C Substructure D Substructure E 
 1′-glycerol 2′-glycerol 1′,3′-sn-glycerol 1′,2′-sn-glycerol 
position δC δH δC δH δC δH δC δH 
1′ 64.6 4.18 62.6 3.83 65.0 4.14 62.4 4.29 
2′ 70.4 3.93 74.4 4.92 68.3 4.06 71.4 5.10 
3′ 63.4 3.64 62.6 3.83 65.3 4.13 61.7 3.76 
CO2CH3     171.0  171.0  
CO2CH3     20.8 2.08 20.8 2.08 
a HMBC →. COSY▬. 500 MHz, ppm in CDCl3 
 
2.3.3  Characterization of palmadorin D (2.32) 
Compound 2.32 (palmadorin D) was obtained as a clear oil with its molecular formula 
established as C23H38O4 through HRESIMS ([M+H]
+
: m/z 379.2848), identical to 
palmadorin A (2.23).
30
 The 
1
H and 
13
C NMR data of 2.32 exhibited general features 
similar to those observed for 2.23 including the characteristic set of signals for 
substructure A, but differs by the presence of substructure B, rather than substructure C 
found in 2.23. Key signals from the 
1
H NMR spectrum include a broad methylene singlet 
at δH 4.52 (H2-18) corresponding to C-18 (δC 102.6) which denotes the presence of an 
exo-methylene, three methyl singlets at δH 2.16 (H3-16), δH 1.06 (H3-19) and δH 0.76 (H3-
20) and a methyl doublet at δH 0.82 (H3-17, J = 6.4 Hz). Based on these similarities and 
37 
 
from HSQC assignments, 
13
C NMR data comparison to that of palmadorin A was 
transparent. As shown in Figure 2.3, the only significant differences are found along the 
glycerol portion from C-1′ (± 1.8 ppm), C-2′ (± 3.9 ppm) and C-3′ (± 0.7 ppm) 
underscoring the difference in a 1′- versus 2′- substituted glycerol. All other signals differ 
less than ± 0.5 ppm allowing assignment of 2.32 as 5S, 8S, 9R and 10S based on similar 
NMR data, optical rotation and biosynthetic consideration.
30
 
 
Figure 2.3.  
13
C NMR data comparison of 2.32 versus 2.23. 
 
2.3.4 Characterization of palmadorin E (2.33) 
The molecular formula of C23H36O6 for palmadorin E (2.33) was deduced from 
HRESIMS ([M+H]
+
: m/z 409.2581). Palmadorin E contains substructures A and B as 
shown via 
1
H and 
13
C NMR data. The 
1
H NMR spectrum revealed the presence of four 
methyl singlets at δH 2.18 (H3-16), δH 1.94 (H3-18), δH 1.42 (H3-19) and δH 1.11 (H3-20) 
and a methyl doublet at δH 1.07 (H3-17, J = 7.1 Hz). The additional sp
2
 methyl singlet H3-
18 and its HMBC correlations to C-4 (δC 172.8) and C-3 (δC 125.0) denotes the presence 
of an β-methyl-α,β-unsaturated ketone in the A ring of the diterpene. This motif proved 
common in a number of clerodane palmadorin compounds 2.35, 2.37, 2.38, and 2.39. 
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Furthermore, analysis of the 
13
C NMR data revealed the presence of hydroxy methine C-
7 (δC 73.1) and along with its HMBC correlation to the methyl doublet a H3-17 
established its location in ring B. Comparison of the 
13
C NMR data of 2.33 with known 
clerodane compound ent-7β-hydroxy-2-oxo-3-clerodane-15-oic acid (2.48)37 isolated 
from Nuxia sphaerocephala, a shrub collected from the eastern rainforests of 
Madagascar, reveals a strong similarity whereby carbon shifts differ less than ± 1.1 ppm 
for C-1 - C-11 and C-16 - C-20 (Figure 2.4). The differences for C-12 - C-15 can be 
accounted for by the presence of substructure A in 2.33 allowing assignment as 5S, 7S, 
8R, 9S and 10S based on NMR comparison, optical rotation and biosynthetic 
consideration with other A. kerguelenensis clerodanes.   
  
Figure 2.4.  
13
C NMR data comparison of 2.33 versus 2.48. 
 
2.3.5  Characterization of palmadorin F (2.33) 
Compound 2.34 (palmadorin F), is isomeric with 2.25 (palmadorin C)
30
 and shares 
common spectroscopic features. The molecular formula, C23H38O5, was determined by 
HRESIMS ([M+Na]
+
: m/z 417.2619).  
1
H and 
13
C NMR data comparison to that of 2.25 
revealed many of the key signals including substructure A, the singlet at δH 5.17 (H-3) 
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corresponding to C-3 (δC 119.8) with HMBC correlations between methyl H3-18 (δH 
1.64) within ring A. Additional key signals include three methyl singlets at δH 2.18 (H3-
16), δH 1.31 (H3-19) and δH 1.03 (H3-20), and a methyl doublet at δH 1.04 (H3-17, J = 7.1 
Hz). As shown in Figure 2.5, the 
13
C NMR data differed less than ± 0.1 ppm for the 
diterpenoid core (C-1 - C-20) with the difference in the glycerol portion arising from the 
presence of substructure B, instead of substructure C found in 2.25. Based on NMR 
comparison, optical rotation and biosynthetic consideration 2.34 is assigned as 5S, 7S, 
8R, 9S and 10S. 
 
Figure 2.5.  
13
C NMR data comparison of 2.34 versus 2.25. 
 
2.3.6 Characterization of palmadorin G (2.35) 
A molecular formula of C23H36O5 for compound 2.35 (palmadorin G) was determined by 
HRESIMS analysis ([M+H]
+
: m/z 393.2629), a mass unique to all known palmadorins. 
Though the molecular formula is distinct, 2.35 contains characteristic motifs including 
substructures A and B, as well as spectroscopic features similar to ring A observed in 
2.33 (palmadorin E). Key signals in the 
1H NMR spectrum include a broad singlet at δH 
5.73 (H-3) corresponding to C-3 (δC 125.5) which exhibits HMBC correlations to C-1 (δC 
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35.0), C-5 (δC 39.9) and C-18 (δC 19.0), which along with the HMBC correlation from 
methylene H2-1 (δH 2.37) to ketone C-2 (δC 200.1) establishes the presence of the keto 
functionality in ring A. Additional key signals include methyl singlets at δH 1.90 (H3-18), 
δH 1.13 (H3-19) and δH 0.83 (H3-20) and a methyl doublet at δH 0.85 (H3-17, J = 6.2 Hz). 
Comparison of the 
13
C NMR data of 2.35 versus 2.33 reveals significant differences 
along ring B at C-6 (± 5.9 ppm), C-7 (± 46.3 ppm), C-8 (± 3.8 ppm) and C-17  (± 3.3 
ppm), which illustrates the lack of a hydroxyl group at C-7 and was confirmed by 
differences observed in mass spectrometry. Further support for the structure was made by 
comparison of the 
13
C NMR data with known compound 15-oate[methyl-Δ13,14-2-
oxokolavenoate] (2.49),
38-39
 a clerodane isolated from the roots of Aristolochia 
esperanzae collected in Brazil, which contains the identical clerodane diterpene core 
where observed shifts differ by less than ± 0.1 ppm for the decalin core and ± 1.8 ppm 
throughout the diterpene (Figure 2.6). Based on NMR comparisons, optical rotation and 
biosynthetic consideration the absolute configuration of 2.35 is assigned as 5S, 8S, 9R, 
and 10S. 
 
Figure 2.6.  
13
C NMR data comparison of 2.35 versus 2.49. 
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2.3.7 Characterization of palmadorin H (2.36) 
The molecular formula C25H40O6 for palmadorin H (2.36) was deduced through 
HRESIMS ([M+Na]
+
: m/z 459.2715). Via 
1
H and 
13
C NMR data comparison we could 
confirm a very strong similarity to known compounds palmadorins C (2.25)
30
 and F 
(2.34). Key 
1
H NMR shifts include those for substructure A along with a broad singlet at 
δH 5.17 (H-3), three additional methyl singlets at δH 1.64 (H3-18), δH 1.30 (H3-19), δH 
1.03 (H3-20)) and a methyl doublet at δH 1.04 (H3-17, J = 6.0 Hz). 
13
C NMR data 
comparison of 2.36 to 2.25 only differed by ± 0.95 ppm within the diterpene. Via mass 
spectrometric and 
1
H and 
13
C NMR data we could visualize substructure E to complete 
the planar structure of 2.36. The absolute configuration of 2.36 is assigned as 5S, 7S, 8R, 
9S and 10S based on NMR comparison, optical rotation and biosynthetic consideration. 
 
2.3.8 Characterization of palmadorin I (2.37) 
Palmadorin I (2.37) was obtained as a clear oil with a molecular formula of C23H34O6 as 
determined by HRESIMS ([M+Na]
+
: m/z 429.2248). Though the molecular formula is 
unique, 2.37 contains the characteristic motif of substructures A and B and an 
α,β(methyl)-unsaturated ketone in ring A similar to 2.33, 2.35, 2.38 and 2.39 as observed 
via 
1
H and 
13
C NMR data. The ketone is identified by the broad singlet H-3 (δH 5.81) 
which exhibits HMBC correlations to methylene C-1 (δC 35.1), bridgehead quaternary C-
5 (δC 44.3) and methyl C-18 (δC 18.8). Ketone C-2 (δC 198.4) shows HMBC correlation 
between methylenes H2-1a (δH 1.54) and H2-1b (δH 2.47). Further comparison of the 
13
C 
NMR data of 2.37 versus 2.33 reveals significant differences, especially within ring B. 
The presence of an unaccounted low-field sp
2
 signal at δC 210.6 (C-7), unique among 
42 
 
palmadorins, along with the HMBC correlations between the unusually high-field 
methylene H2-6 (δHa 2.48; δHb 2.60), methine H-8 (δH 2.63) and doublet methyl H3-17 (δH 
0.99 J = 6.6 Hz; δC 7.8) provided evidence of a ketone  C-7 in ring B. Comparison to 
known compound ent-2,7-dioxo-3-clero-den-15-oic acid
37
 (2.50), also identified from N. 
sphaerocephala,  confirmed the di-keto clerodane core structure as shift differences are 
no greater than ± 0.69 ppm for C1 - C-11 and C-16 - C-20 (Figure 2.7). Based on NMR 
comparison, optical rotation and biosynthetic consideration the absolute configuration of 
2.37 is assigned as 5S, 8R, 9S, and 10S. 
 
Figure 2.7.  
13
C NMR data comparison of 2.37 versus 2.50. 
 
2.3.9 Characterization of palmadorin J (2.38) 
Palmadorin J (2.38) has a molecular formula of C23H46O6 via HRESIMS ([M+Na]
+
: m/z 
431.2422) and is isomeric with palmadorin E (2.33).  The 
1
H and 
13
C NMR data of 2.38 
were similar to those of 2.33 and 2.35 with distinguishing signals including those of 
substructures A and C, three methyl singlets at H3-18 (δH 1.93), H3-19 (δH 1.41) and H3-
20 (δH 1.10), methyl doublet at H3-17 (δH 1.07; J = 7.2 Hz), hydroxy methine H-7 (δH 
4.11) and the α,β-unsaturated ketone motif of C-2 (δC 200.2), C-3 (δC 125.0), and C-4 (δC 
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172.9).  Comparison of the 
13
C NMR data to that of 2.33 varied less than ± 0.36 ppm for 
C-1 - C-20 with the differences for C-1′ - C-3′ accounted for by the presence of 
substructure C as shown via 
1
H and 
13
C NMR data.  Based on NMR comparisons, optical 
rotation and biosynthetic consideration the absolute configuration of 2.38 is assigned as 
5S, 8S, 9R, and 10S. 
 
2.3.10 Characterization of palmadorin K (2.39) 
Palmadorin K (2.39), by virtue of its isomeric nature, shared common spectroscopic 
features to palmadorin I (2.37). Its molecular formula was established as C23H38O4Na 
through HRESIMS ([M+Na]
+
: m/z 429.2256). Via 
1
H and 
13
C NMR data comparison we 
could confirm a very strong similarity to 2.37. Key signals from the 
1
H NMR spectrum 
include those of substructure A, a broad singlet at δH 5.81 (H-3), three methyl singlets at 
δH 2.19 (H3-16), δH 1.90 (H3-18), δH 1.12 (H3-19) and δH 0.82 (H3-20) and a methyl 
doublet at δH 0.99 (H3-17, J = 6.6 Hz). Comparison to that of 2.37 was transparent as the 
13
C NMR data differed less than ± 0.77 ppm for C-1 - C-20. The differences for C-1′ - C-
3′ can be accounted for by the presence of characteristic shifts representative of 
substructure C. Based on NMR comparison, optical rotation and biosynthetic 
consideration the absolute configuration of 2.39 is assigned as 5S, 8R, 9S, and 10S. 
 
2.3.11 Characterization of palmadorin L (2.40) 
Palmadorin L (2.40) was obtained as a clear oil with a molecular formula established as 
C23H39
35
ClO5 through HRESIMS ([M+Na]
+
: m/z 453.2392). Though the presence of 
chlorine is unique among Austrodoris diterpenes, 2.40 contains characteristic motifs 
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including substructures A and B based on analysis of 
1
H and 
13
C NMR data. The 
13
C 
NMR spectrum of 2.40 displayed 23 carbon signals.  Excluding the carbons from 
substructures A and B, no olefinic carbons or low field carbons were present and only 
one quaternary sp
3
 carbon-bearing oxygen signal (δC 75.2) remained unassigned. The 
1
H 
NMR spectrum showed characteristic methyl shifts for a clerodane diterpene, including 
doublet methyl H3-17 (δH 0.80; J = 6.6 Hz), and singlet methyls H3-19 (δH 0.99) and H3-
20 (δH 0.74). Other clerodane palmadorins have contained hydroxy methine groups at C-7 
(2.33, 2.34, 2.36, 2.38; δC 73.6 ± 0.3) which show HMBC correlations with doublet 
methyl H3-17. However, 2.40 showed no such correlation; instead, quaternary carbon (δC 
75.2) exhibited HMBC correlations between H2-3 (δHa 1.52; δHb 1.82), H-10 (δH 1.92), H-
18a (δH 3.62), H-18b (δH 3.83) and H3-19, establishing its position at C-4 (δC 75.2) within 
ring A. Both methylene H2-18 and methyl H3-19 have HMBC correlations to quaternary 
C-5 (δC 42.1) and C-6 (δC 31.6) thereby extending ring A into ring B. Methylene H2-6 
(δHa 1.32; δHb 1.83) display HMBC correlation to C-5 and COSY correlation to H2-7 (δH 
1.40). Methylene H2-3 extends ring A via HMBC correlation to C-2 (δC 21.5) and COSY 
correlations to methylene H2-2 (δH 1.64). The sharp doublet methyl H3-17 was key to 
constructing much of ring B and establishing connectivity to substructure A via HMBC 
correlations to methylene C-7 (δC 27.0), methine C-8 (δC 35.9) and quaternary carbon C-9 
(δC 39.0). Methyl singlet H3-20 exhibits HMBC correlations to methylene C-8, 
quaternary C-9 and methine C-10 (δC 40.7) providing the upper portion of ring B. 
Correlations from H3-20 to C-11 (δC 36.5) established connectivity to substructure A. The 
A/B ring junction was completed based on further HMBC correlations from methine H-
10 (δH 1.92) to methylenes C-1 (δC 21.0), C-6 and C-18 (δC 53.3), and quaternary C-5. 
45 
 
Further exploration of the mass spectrometric data for 2.40 revealed characteristic 3:1 
ratios for M+ and M+2, which along with unaccounted mass of 35 amu and an unusual 
open valence at C-18 confirmed the presence of a chloromethyl group at C-18.  While 
there has been reports of chlorinated isocopalanes from Archidoris carvi, A. tuberculata
40
 
and Doris verrucosa,
41
 this is the first example of a diterpene bearing a halogen isolated 
from Austrodoris kerguelenensis. As shown in Figure 2.8, assignment of the 
chloromethyl group as equatorial is 
based on ROESY correlations from H-
18a to axial methyl H3-19 and from H-
18b to equatorial proton H-6a. 
Furthermore, the shifts of axial protons 
H-6b and H-10 are downfield from other 
clerodane diterpenes as a result from the 
diaxial interactions with the axial hydroxy on C-4. Via NMR data, optical rotation and 
biosynthetic consideration 2.40 is assigned as 4R, 5S, 8S, 9R, 10S. 
 
2.3.12 Characterization of palmadorin M (2.41) 
Compound 2.41 (palmadorin M) was obtained as a clear oil and its molecular formula 
was established as C23H38O4 through HRESIMS ([M+Na]
+
: m/z 401.2648). The 
13
C NMR 
spectrum of 2.41 displayed only 22 carbon signals, including those of substructure A and 
substructure C which contains two coincident signals, thus accounting for all carbons 
confirming the mass spectrometric data. The 
1
H NMR spectrum of 2.41 showed two 
distinct signals at δH 4.71 (H-17b) and δH 4.52 (H-17a) integrating for one proton each 
Figure 2.8.  Key ROESY correlations for 
2.40. 
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and both exhibiting a HSQC correlation to carbon C-17 (δC 109.9) suggesting the 
presence of an exomethylene. Methylene C-17 did not exhibit any HMBC correlation to 
methyl signals, further distinguishing itself from the exomethylenes of the clerodane 
diterpenes in ring A for compounds 2.38, 2.23, and 2.24. Instead, H2-17 showed HMBC 
correlations to methylene C-7 (δC 31.5), quaternary sp
2
 C-8 (δC 148.7) and methine C-9 
(δC 57.8). On the basis of additional HMBC correlations from methine H-9 (δH 1.51) to 
quaternary carbon C-10 (δC 38.0), methylene carbons C-11 (δC 24.2) and C-12 (δC 39.8), 
as well as methyl C-20 (δC 22.3) the upper portion of ring B extending into substructure 
A was envisioned. The remaining methyl singlets H3-18 (δH 0.81) and H3-19 (δH 0.88) 
both exhibited key HMBC and COSY correlations to methylene C-3 (δC 42.6), 
quaternary carbon C-4 (δC 33.2), methine C-5 (δC 45.8), and to each other revealing 
characteristic cross peaks for gem-dimethyl motif of labdane diterpenes. The planar 
structure for ring A could be completed on the basis of HMBC correlations of methylene 
H2-3 (δHa 1.18; δHb 1.42) to C-1 (δC 36.7) and C-2 (δC 19.1) along with HMBC 
correlations of the singlet methyl H3-20 (δH 0.92) to C-1 at the A/B ring junction. The 
methine H-5 (δH 1.28) at the ring junction exhibits HMBC correlations to C-6 (δC 23.5), 
which shares HMBC correlations between C-7 completing the assignment of 2.41. 
Comparisons of the 
13
C NMR data with labdanes containing trans-decalin motifs are 
significant as exemplified with verrucosin-5,
41
 a monoacetylated glycerol diterpenoid 
from a Mediterranean nudibranch with an identical diterpenoid planar structure to 2.41. 
Positions C-5 (± 9.7), C-7 (± 6.8), C-17 (± 3.6) and C-20 (± 7.8) exhibit the largest 
differences and this trend is consistent to other known trans-decalin labdanes.
38,42-43
 The 
chemical shifts for C-5 (δC 41.0) and the angular methyl C-20 (δC 22.3) suggest a cis-
47 
 
4,4,10-trimethyl-decalin configuration for 2.41 (c. δC 55 and δC 14 for trans-decalin, 
respectively).
44-45
 As shown in Figure 2.9 key ROESY and NOE enhancement 
correlations include H3-20/H-2b, H3-20/ H3-19, H3-20/H-9, H3-18/H-3b, H3-18/H-6b, H3-
18/ H3-19, H3-19/H-2b, H-7b/H-17b and H-7b/H-5. 
Comparison of the 
13
C NMR data of 2.41 
with that of peyssonal A (2.51), a 
brominated sesquiterpenes with a cis-
decalin labdane core isolated from the 
sponge Peyssonnelia sp., highlights 
similarities at key positions C-5 (± 0.2), C-
7 (± 0.7), C-9 (± 0.5), C-10 (± 1.0), C-17 
(± 1.5) and C-20 (± 0.2) (Figure 2.10). Based on these correlations and comparison to 
literature values the absolute configuration of 2.41 is assigned as 5R, 9R and 10S. 
 
Figure 2.10.  
13
C NMR data comparison of 2.41 versus 2.51. 
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ROESY correlations for 2.41. 
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2.3.13 Characterization of palmadorin N (2.42) 
Palmadorin N (2.42) is isomeric with palmadorin M (2.41) as deduced via HRESIMS 
([M+H]
+
: m/z 379.2841) with a molecular formula of C23H38O4. As such, 
1
H and 
13
C 
NMR data exhibited many similarities to 2.41 most notably the exomethylene H2-17 (δHa 
4.51; δHb 4.72) and the three methyl singlets found in the diterpene core including gem-
dimethyls H3-18 (δH 0.82) and H3-19 (δH 0.89), and H3-20 (δH 0.94). The 
13
C NMR data 
varied less than ± 0.4 ppm for C-1 - C-20 compared to 2.41; the differences for C-1′ - C-
3′ can be accounted for by the presence of characteristic shifts and correlations 
representative of substructure C. The absolute configuration of 2.42 is assigned as 5R, 9R 
and 10S based on NMR comparison, optical rotation and biosynthetic consideration. 
 
2.3.14 Characterization of palmadorin O (2.43) 
A molecular formula of C25H40O5 for compound 2.43 (palmadorin O) was determined by 
HRESIMS analysis ([M+Na]
+
: m/z 443.2759), a molecular weight unique to the 
palmadorins. The 
1
H and 
13
C NMR data comparison revealed a very strong similarity to 
2.41 and 2.42; key signals include substructure A, exomethylene C-17 (δC 109.9) and 
gem-dimethyls C-18 (δC 33.5) and C-19 (δC 22.1). The 
13
C NMR data differed less than ± 
0.2 ppm for C-1 - C-20 except for C-15 (± 1.0 ppm). The differences for C-15, C-1′ 
through C-3′ can be accounted for by the presence of characteristic 1H and 13C NMR 
signals for acetylated substructure D. Based on NMR comparison, optical rotation and 
biosynthetic consideration the absolute configuration of 2.43 is assigned as 5R, 9R and 
10S  
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2.3.15 Characterization of palmadorins P (2.44) and Q (2.45) 
Palmadorin P (2.44) and Palmadorin Q (2.45) were identified as diastereomers with a 
common molecular formula of C23H40O5 established through HRESIMS ([M+Na]
+
: m/z 
419.2772 and [M+Na]
+
: m/z 419.2778, respectively), a formula unique to previously 
isolated palmadorins. From the 
1
H and 
13
C NMR data for 2.44 we could identify 
substructures A and B, and observed characteristic signals for labdane diterpenes via 
HMBC cross-peaks indicative of a gem-dimethyl at C-4 (δC 33.4) which bears methyl 
singlets H3-18 (δH 0.84) and H3-19 (δH 0.88). Further HMBC correlations of bridgehead 
methine H-5 (δH 0.86) to the quaternary C-4, methylene C-7 (δC 42.3) and singlet methyl 
C-20 (δC 15.1) help establish the core structure. Ring A is completed by the observation 
of COSY correlations from methylene H2-3 (δHa 1.14; δHb 1.41) to methylene H2-2 (δH 
1.53), and from H2-2 to H2-1 (δHa 0.87; δHb 1.68). Further HMBC correlations between C-
10 (δC 39.0) and H2-1, H3-20 (δH 0.96) and H-9 (δH 0.82) extend ring A into ring B. 
Compounds 2.44 and 2.45 differ from other palmadorin labdanes (2.41 - 2.43) by the lack 
of an exomethylene at C-8, instead containing carbon-bearing oxygen within ring B at 
quaternary C-8 (δC 73.1). This carbon also bears methyl singlet H3-17 (δH 1.16) as shown 
by HMBC correlations to C-7 (δC 42.3), C-8 and methine C-9 (δC 58.8). Furthermore, the 
shifts at C-5 (δC 55.9), C-9 (δC 58.8) and C-10 (δC 39.0) for 2.44 (as listed) and 2.45 are 
indicative of trans-decalin labdanes
46
 indicating these compounds do not arise via 
hydration to the cis-decalin palmadorins 2.41 - 2.43. The equatorial orientation of H3-17 
is confirmed by the absence of ROESY correlation to angular methyl H3-20 and the 
observation of a correlation to methine H-9. From these motifs and ROESY correlations 
we could assign configuration for 2.44 as 5S, 8S, 9R and 10S. As shown in Figure 2.11, 
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comparison of the 
13
C NMR data of 2.44 with labdane Δ13,14-ent-labd-8β-ol-15-oic acid38 
(2.52) notably differs at key positions near the tertiary alcohol: C-7 (± 2.5 ppm), C-8 (± 
1.1 ppm), C-9 (± 2.6 ppm) and C-17 (± 7.0 ppm).  
 
Figure 2.11.  
13
C NMR data comparison of 2.44 versus 2.52. 
Key 
1
H and 
13
C NMR data for 2.45 include those of substructures A and B, four methyl 
singlets in the decalin core H3-17 (δH 1.14), gem-dimethyls H3-18 (δH 0.77) and H3-19 (δH 
0.85), and H3-20 (δH 0.78) as well as the carbon-bearing oxygen quaternary C-8 (δC 74.3). 
As shown in Figure 2.12 the 
13
C NMR data of 2.45 exhibits very strong shift similarity to 
known compound Δ13,14-ent-labd-8β-ol-15-oic acid (2.52)38 in particular to C-7 (± 0.1), 
C-8 (± 0.1), C-9 (± 0.1) and C-17 (± 0.4) supporting an α-orientation of hydroxyl group at 
C-8.  Furthermore, ROESY correlation from H3-17 to angular methyl H3-20 establishes 
these methyl groups as axial and on the same face of the trans-decalin. Based on ROESY 
correlation and 
13
C NMR data analogy with 2.52 we could assign configuration for 2.45 
as 5S, 8R, 9R and 10S. 
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Figure 2.12.  
13
C NMR data comparison of 2.45 versus 2.52. 
 
2.3.16 Characterization of palmadorin R (2.46) 
Palmadorin R (2.46) was obtained as a clear oil with a molecular formula established as 
C25H40O6 through HRESIMS ([M+H]
+
: m/z 437.2911). The 
1
H and 
13
C NMR data of 2.46 
exhibits many key differences from previously isolated palmadorins by lacking 
characteristic signals for substructure A however substructure E could be easily 
distinguished. The 
13
C NMR spectrum of 2.46 displayed 25 carbon signals. Excluding the 
carbons from substructure E, five methyl carbons, but only four olefinic carbons were 
observed. HMBC correlations from ester carbonyl C-15 (δC 173.1) to methine H-13 (δH 
1.88), methylene H2-14 (δHa 2.14; δHb 2.34), and doublet methyl H3-16 (δH 0.94; J = 6.6 
Hz) envisioned a saturated C-11 - C-15 chain similar to A. kerguelenensis diterpenes 
previously isolated outside of the WAP. The COSY correlations from H-13 to methylene 
H2-12 (δHa 0.84; δHb 1.19) and H-12 to methylene H2-11 (δHa 1.19; δHb 1.83) establishes 
the chain extending from ring B. Connectivity to the ring from methylene H2-11 is seen 
via HMBC correlations to quaternary C-9 (δC 44.8), sp
2
 quaternary C-10 (δC 173.6) and 
singlet methyl C-20 (δC 22.8). Additional HMBC correlations from H3-20 to C-8 (δC 
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45.9), C-9, and C-10 establish C-9 as bearing methyl C-20, a motif featured for clerodane 
and halimane diterpenes.  Compound 2.46 distinguished itself as a halimane diterpene by 
exhibiting characteristic HMBC cross-peaks for gem-dimethyl functionality at C-4 (δC 
34.4) which bears singlet methyls H3-18 (δH 0.99) and H3-19 (δH 1.02). With C-10 
established, two low-field sp
2
 carbons remained unaccounted for. Via HMBC correlation 
from methine H-1 (δH 5.87) to C-10 and C-3 (δC 47.0), and from H2-3 (δHa 2.03; δHb 2.33) 
to ketone C-2 (δC 200.3), an α,β-unsaturated ketone in ring A was envisioned. Ring A is 
completed by HMBC correlations between C-4 and methylene H2-3 and methine H-5 (δH 
1.55). Continuing to ring B, C-5 (δC 45.7) shows HMBC correlations between methylene 
H2-6 (δHa 1.29; δHb 2.03), which shows COSY correlations to methylene H2-7 (δHa 1.55; 
δHb 1.62). Assignment of 2.46 is completed via HMBC correlation from C-7 (δC 30.6) to 
methine H-8 (δH 1.39) and from C-8 to doublet methyl H3-17 (δH 0.94, J = 6.8 Hz).  The 
identical diterpenoid core was reported from Relhania acerosa, a flowering plant of the 
daisy family; however, only 
1
H NMR data was provided.
47
  Further comparison of the 
1
H 
and 
13
C NMR data to literature revealed similarity to halisulfate 8 (2.53),
48
 a spongian, 
sulfated sesterterpene which shares the same core ring structure and supports the 
assignment of the α,β-unsaturated halimane core as 5R, 8S, and 9S, despite that the 
spectra was acquired in CD3OD (Figure 2.13). 
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Figure 2.13.  
13
C NMR data comparison of 2.46 versus 2.53 
 
2.3.17 Characterization of palmadorin S (2.47) 
Palmadorin S (2.47) was obtained as a clear oil with a molecular formula established as 
C23H38O5 through HRESIMS ([M+Na]
+
: m/z 417.2612). The 
1
H and 
13
C NMR data of 
2.47 revealed near identical shifts to those observed for 2.46 (shifts differ by ± 0.89 ppm 
for the diterpenoid core), but differs by the presence of substructure B rather than 
substructure E.  Key 
1
H NMR shifts include a broad singlet at δH 5.87 (H-1), three methyl 
singlets at δH 0.99 (H3-18), δH 1.02 (H3-19), δH 1.10 (H3-20) and two methyl doublets at 
δH 0.95 (H3-16, J = 5.7 Hz) and δH 0.93 (H3-17, J = 6.0 Hz).  Based on NMR comparison, 
optical rotation and biosynthetic consideration we assign configuration of 2.47 as 5R, 8S, 
and 9S. 
 
2.4  Metabolomic investigation of A. kerguelenensis 
The concentration and organization of metabolites within an organism is the direct 
response of the biological system to genetic or environmental changes.  An organism’s 
metabolome is the set of metabolites produced by a biological system.  Therefore, 
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metabolomics is the systematic study of the unique metabolite fingerprint that cellular 
regulatory processes leave behind.
49-50
  Metabolomic analysis requires careful 
consideration of sample preparation, data acquisition and data analysis.  Previous studies 
have found that direct field sampling minimized metabolic variability and that species 
and phenotype must be known for meaningful interpretation of metabolomics.
51
  
Metabolomics has been applied to the environmental sciences for characterization of the 
interaction of organisms with their environment; particularly in the fields of 
ecophysiology, ecotoxicology and ecotoxicogenomics.
52-53
  Statistical grouping from 
LC/MS profiling data has proven to be an effective approach to metabolomics.
54
  NMR-
based metabolomics have been used to distinguish biochemical profiles between 
organisms and for biomonitoring (e.g., identification of metabolic biomarkers or 
characterization of effects of environmental stressors).
55
  The field of natural products has 
utilized metabolomics to monitor medicinal plants for quality control, and to examine 
metabolism and biosynthetic pathways.
54
  Some researchers have suggested 
implementing metabolic as a tool for lead-generation of anticancer compounds.
56
 
Chemotaxonomy (chemosystematics) is the classification of organisms based on 
differences and similarities in their biochemical composition, often from the content of 
proteins, peptides and amino acids. Metabolomics has been employed for 
chemotaxonomic profiling for strain differences in plants where, for example, 
1
H NMR 
data analysis was used to differentiate between Ephedra species.
57
 Other 
chemotaxonomic techniques have been used to identify varieties of shellfish,
55
 to 
distinguish between fungal strains
58-59
 and to discriminate between nonpathogenic and 
pathogenic strains of Bacillus cereus isolated from meningitis patients.
60
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The waters around Palmer Station (≤ 3.5 km) afford nudibranch specimens with 
significant variations in size and color (bright orange to white). Some collection sites 
(e.g., Kristie Cove) have nudibranchs with the same color, although most sites exhibited a 
wide variety of size and color (authors personal observations). There is no limit to the 
coverage of A. kerguelenensis as specimens have been collected near the surface and in 
deep water trawls, although all specimens presented herein were all collected by SCUBA 
at depths of 3 - 40 m. With reports of genetic divergences within populations of A. 
kerguelenensis
61
 and the observation of diverse diterpenoid chemistry we began to frame 
our studies in the context of a metabolomic analysis. Whereas previous collections 
involved bulk collection and processing, specimens were processed individually. 
 
2.4.1 Genetic studies to establish phylogroups 
Immediately after collection, small excisions were taken from the foot of each 
nudibranch for genetic studies conducted in the lab of our collaborator Nerida Wilson 
(Australian Museum, formerly of Scripps Institute of Oceanography).  A 627 base pair 
fragment of the mitochondrial Cytochrome Oxidase I gene (COI) was examined 
recovering 23 mitochondrial COI haplotypes forming 10 phylogroups (PG), three of 
which represent new PGs.  Phylogroups are defined as “geographically coherent subsets 
of biological species in which mtDNA haplotypes exhibit reciprocal monophyly.”62 The 
10 sub-species isolated within the Palmer Station aera, identified with color bars in 
Figure 2.14, represent 36% of the known PGs. Wilson and coworkers
61
 utilized data from 
our collections and those around the continent including southern South America to ask 
three questions: 1) if the deepwater Drake Passage and Antarctic Circumpolar Current 
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(ACC) are barriers to dispersal for A. kerguelenensis populations; 2) how the populations 
were structured; 3) and are cryptic species present.  Research revealed strong 
mitochondrial divergences within populations on both sides of the Drake Passage and that 
South American animals formed 
multiple sister-group relationships with 
Antarctic animals.  Glaciation events in 
Antarctica appear to have increased 
genetic diversity as evidenced by the 
diverse lineages found in A. 
kerguelenensis implying multiple 
refuges during glaciation events 
combined with limited subsequent 
dispersal.  Genetic diversity in 
Antarctic marine invertebrates appears 
greater than expected from 
morphological analyses and supports 
the Antarctic biodiversity pump 
phenomenon.   
 
2.4.2 Generation of LC/MS chromatogram library 
Two lipophilic extracts from each individual, an external (whole organism) extract, 
followed by an internal (viscera) extract generated from macerated organisms were 
prepared. Extracts were partitioned between EtOAc and water, the organic layer was 
Figure 2.14.  COI dendrogram for A. 
kerguelenensis with Palmer Station PGs 
color coded.  Size of color bars in proportion 
to number of identified organisms.  (Nerida 
Wilson, Australian Museum). 
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removed and filtered over silica gel and C18.  Each extract was next submitted to LC/MS 
analysis in triplicate to generate an extensive chromatographic metabolite library.  The 
MS detector settings and elution profile of the extracts were adjusted so that palmadorins 
would respond most sensitively and elute as broad of range as possible, while keeping the 
run length manageable (see section 5.2.2 for method detail).  From this method, the 
retention times (RT) and major ions from each palmadorin were extracted to establish 
standards for analysis of extracts as shown in Table 2.5. 
Comparison of external versus internal extracts from the same specimens revealed no 
significant differences in metabolites, only a lower yield from internal extracts.  For 
example, as shown in Figure 2.15 external extract PSC10-8-A displayed an 
approximately 5:1 ratio in total ion current (TIC) response over the internal extract from 
the same specimen. 
Table 2.5.  LC/MS Palmadorin Retention Times 
Palmadorin RT (min) M+H M+Na M-H2O 
A 11.89  401.2  
B 13.63  443.3  
C 6.75  417.2 377.2 
D 12.44  401.2  
E 2.97 409.3 431.2 391.2 
F 6.96  417.2 377.2 
G 6.56 393.2 415.2 375.2 
H 9.05  459.3 419.3 
I 3.20 407.2 429.2 389.2 
J 2.85  431.2 391.2 
K 3.13 407.2 429.2 389.2 
L 9.22  453.2  
M 12.43 379.3 401.2  
N 12.89  401.3  
O 14.02  443.3  
P 9.24  419.3  
Q 8.28  419.3  
R 8.57 437.3 459.3  
S 6.40 395.2 417.3  
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As shown in Figure 2.16, visual inspection of the mass spectrometric TIC for individual 
chromatograms displayed some trending towards groupings. Individuals generally 
displayed unique fingerprints, but over the entire collection we could organize samples 
into roughly ten groups. However, simple visual comparison fails to qualitate all the data 
in significant detail; therefore, clustering software by MsMetrix® was used to analyze 
LC/MS data generated from individual external extracts. 
 
Figure 2.15.  Comparing external (top) versus internal (bottom) extracts from the DAD 
and MS TIC chromatograms. 
 
 
Figure 2.16.  Examples of MS TIC for six different individuals under identical analytical 
condition.  Specimens B, D and AD align, as do AT, AU and AV. 
PSC08-6-B
PSC08-6-D
PSC08-6-AD
PSC08-6-AT
PSC08-6-AU
PSC08-6-AV
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2.4.3  Data clustering 
As shown by the matrix of several samples of LC/MS data, Figure 2.17 illustrates how 
MSMetrix® software can process data in different directions. The TIC is generated by 
summing all mass intensities from a single scan at a given RT point; the TIC 
chromatogram is created by looking at all TICs for all scans as shown in frame B in 
Figure 2.17. Therefore, TIC chromatograms are 1D using time as the x-axis.  However, if 
there are any shift differences from multiple samples, multivariate analysis techniques 
(e.g., clustering or Principal Component Analysis (PCA)) cannot be used from these 
chromatograms. Total Chromatogram Mass (TCM) is a term unique to MSMetrix. TCM 
traces are not true chromatograms, but essentially the average mass spectra of a sample as 
a 1D-trace with m/z on the x-axis. Frame C in Figure 2.17 illustrates the extraction of 
TCM spectra where each m/z value of interest (m/z 200 - 500) is summed at that value.  
Doing this for all m/z values with a RT of 2 - 17 min creates a mass spectrum with, in this 
case, 300 m/z values along the x-axis. The multivariate analysis is based on TCM spectra 
because they are not influenced by chromatographic shifts. 
MSMetrix® software generates clustering coefficients based on comparison of TCM 
spectra shapes shown in Figure 2.18 visualized as a correlation heat map (top) and 
dendrogram (bottom) for individual A. kerguelenensis specimens from the 2008 
collection.  Color coded bars generated from PG data illustrate correlations from 
metabolomic to genomic data. Correlation values of one (unity) score as red and indicate 
an identical correlation, hence the red diagonal where the same samples align.  The 
larger, red rectangles going diagonally through the map indicate groupings of high 
correlation, visualized on the dendrogram going left to right. The vertical scale of the 
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dendrogram indicates amounts of similarity. As evidenced by the tight groupings formed 
from the correlations, the individual LC/MS chromatogram generated a reliable 
mechanism to rapidly assign phylogeny. 
 
Figure 2.17.  LC/MS data processing where different analytical data modes can be used 
to detect unique features.  A)  Peak detection methods that directly operate on the raw 
data; B) extracting TIC chromatograms; and C) using average mass spectra to generate 
TCM chromatogram.   
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Figure 2.18.  Correlation map (top) and dendrogram (bottom) of TCM clustering with 
PG. 
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2.4.4 Discussion of outliers within clustering results 
From PG 29, only one specimen (BD) fell outside the chemical groupings.  Specimen BD 
contains two unknown peaks not present in other PG 29 specimens, m/z 467 at 14.8 
minutes and m/z 485.1 at 11.9 min.  This specimen was collected from Norsel Point, the 
same location as four other PG 29 specimens of similar size and color. 
PG 30 contains a total of four specimens (AD, AI, AJ and BI) which do not correlate 
chemically as one group, but instead as two distinct pairs, AD and AJ, and AI and BI (AI 
and AJ were collected on the same dive).  LC/MS data from PG 30 contains several 
uncharacterized peaks not observed in other PGs.  Specimen AI exhibits LC/MS peaks 
characteristic of halimane palmadorins R (2.46) and S (2.47), while major palmadorins A 
(2.23) and D (2.32) are present in trace quantities.   Though paired with specimen AI, 
specimen BI contains palmadorin A and D in appreciable quantities, but lacks peaks for 
palmadorins R and S.    Specimen AD contains LC/MS peaks indicative of palmadorin S 
and labdane palmadorins M (2.41) and N (2.42); however, specimen AJ only contains 
peaks for palmadorin S.  All nudibranchs from PG 30 were collected from Stepping 
Stones Is. with the exception of specimen AD, collected from Hermit Is.  Despite the 
significant differences in palmadorins and the presence of several unknown metabolites 
in the LC/MS profile from the organisms in PG 30, both the genetic data and TCM 
spectral correlations support the grouping of PG 30.  Therefore, several other unknown 
metabolites should be identified from PG 30. 
Specimen H is the lone member from PG 27, yet was clustered chemically within PG 4.  
Only three palmadorins were evident from LC/MS, palmadorins S and palmadorins M 
and N.  The closest correlating specimen is PG 4 member, specimen N which displays 
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several clerodane palmadorins (E (2.33), J (2.38), I (2.37), F (2.34), C (2.25), A and D) 
based on LC/MS data.  As described below in section 2.4.4, PG 4 specimen PSC10-10-A 
(see section 2.4.4 and Figure 2.21) also elaborates the same clerodane palmadorins.  
Figure 2.19 illustrates why specimen H, despite significant differences in palmadorin 
profile, is grouped within PG 4 as portions of its TIC does match well (12 - 14 min), 
while still containing significant differences near 6 and 15 min.  Analysis by comparison 
of TCM spectra is limited as traces are not sensitive to groups of peaks having the same 
m/z value since it will sum the overall intensities. 
 
Figure 2.19.  TIC for PG 4 and specimen H (PG 27). 
 
2.4.5 Investigation of phylogroups 4, 20, 29 and 32 
Ten specimens varying in location, size and color were selected from the 2010 collection 
to investigate what specific palmadorins elaborated from their respective PGs.  Despite 
the range of location, size and coloration the organisms arose from just four PGs as 
shown in Figure 2.20 and Table 2.6. 
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Figure 2.20.  Specimens PSC10-10-I, -K, -CJ and -A 
Table 2.6.  LC/MS Data Results for Selected PSC10-10 Specimens 
Specimen PG Collection Site Palmadorins 
CJ 4 Norsel Point C, F 
A 20 Norsel Point C, F, E, J, I, R, A, D 
B 29 Dock NR 
K 29 Hermit Is A, D, M, N 
BQ 29 E. Litchfield Is A, D, M, N 
AY 29 Janus Is A, D, M, N 
DZ 29 Litchfield Is A, D, M, N 
DD 29 Stepping Stones A, D, M, N 
C 29 Dock NR 
I 32 Kristie Cove A, D, C, F 
 
Specimens I, K, CJ and A were extracted as previously described then purified using RP 
HPLC chromatography.  LC/MS data was consistent with metabolite fingerprints derived 
from 2008 data as shown in Figure 2.21. 
I: Kristie Cove PG32
V. Orange – 5 x 2
Wet = 6.6 g
Crude = 137 mg
Post Silica = 59 mg
K: Hermit Island PG29
Lt. Org – 4.7 x 2.7
W = 3.1 g
C = 81 mg
P = 15 mg
CJ: Norsel Point PG4
Lt. Org – 2.7 x 1.2
W = 2.1 g
C = 89 mg
P = 14 mg
A: Norsel Point PG20
Lt. Org – 6.8 x 2.8
W = 17.8 g
C = 650 mg
P = 110 mg
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Figure 2.21.  LC/MS TIC chromatograms of specimens PSC10-10-I, -K, -CJ and -A. 
Specimen CJ (PG 4) clearly elaborated palmadorins C and F as the major metabolites 
based on LC/MS and 
1
H NMR data; however, palmadorins A and D or M and N could 
not be unambiguously distinguished as these signals were present in trace amounts.  
Complete analysis of this specimen was limited by low yield of extract. 
Analysis of specimen I (PG 32) showed clerodane palmadorins F, C, D and A which 
were observed in nearly equal proportion as evidenced by LC/MS and 
1
H NMR data. 
Specimen K, a member of PG 29, the most prolific PG from the waters near Palmer 
Station was the only specimen to not elaborate palmadorins C and F as evidenced via 
LC/MS data.  Despite different skeletal backbones palmadorins A and M, and D and N 
have identical molecular weights and co-elute.  
1
H NMR data can readily distinguish 
these metabolites via their respective shifts of the exomethylene protons.  The clerodane 
exomethylene H2-18 (δH 4.52) resolves as a broad singlet, integrating for two protons; 
however, labdane exomethylene H2-17 (δHa 4.51; δHb 4.72) resolves as separate signals.  
PSC10-10-CJ
PSC10-10-I
PSC10-10-K
PSC10-10-A
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As shown in Figure 2.22, 
1
H NMR spectroscopic investigation revealed that specimen K 
elaborated both pairs of skeletal backbones. 
 
 a               b 
Figure 2.22.  
1
H NMR data of specimen K fraction revealing presence of two diterpenoid 
backbones. 
 
Specimen PSC10-10-A (PG 20) exhibited molecular ions for a wide range of palmadorins 
as shown in via LC/MS data (Figure 2.21) and 
1
H NMR data (Figure 2.23).  Palmadorins 
C and F were evident from LC/MS data and confirmed by 
1
H NMR data of HPLC 
fractions.  Specimen A proved to be proficient in elaborating mono-keto clerodane 
palmadorins E and J (see Figure 2.23a), and small quantity of di-keto clerodane 
palmadorin I.  Palmadorins A and D were both identified, although in trace amounts.  In 
another case of a different diterpenoid skeletons present in the same organism, halimane 
palmadorin R was identified via LC/MS and confirmed by 
1
H NMR data (see Figure 
2.23b).  Additionally, small quantities of unknown analogs of palmadorin A and E could 
be observed from LC/MS and 
1
H NMR data. 
PSC10-10-K-12
Palmadorin G
Palmadorin A
PSC10-10-K-13
Palmadorin N
Palmadorin D
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a      b 
Figure 2.23.
  1
H NMR data of specimen A revealing presence of two diterpenoid 
backbones. 
 
It is not uncommon for clerodanes, halimanes and labdanes with related structures to be 
elaborated from the same organism, since it is thought that the clerodane and halimane 
skeletons biogenetically derive from labdane via a series of methyl and hydride shifts 
(Figure 2.24).
63-64
  Furthermore, this “molecular promiscuity” may be evolutionary 
advantageous as a diversity-model of biosynthesis.
65
  Organisms which have the ability to 
make multiple molecules have an increased likelihood of producing a useful, biologically 
active compound.
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Figure 2.24.  Simplified biosynthetic pathway for labdane, clerodane and halimane 
diterpenes. 
 
2.5 Research summary and future directions 
In our continuing study of the nudibranch Austrodoris kerguelenensis, we have further 
isolated a diverse suite of diterpenoid glyceride esters, palmadorins D - S (2.32 - 2.47), 
one of which is the first reported halogenated diterpene from a dorid nudibranch.  This 
research herein has described the isolation, structure elucidation and stereochemical 
analysis of 16 new palmadorins using a combination of one- and two-dimensional NMR 
spectroscopy.  Previous collections from McMurdo Sound, the Weddell Sea shelf and the 
Western Antarctic Peninsula have afforded similar, yet distinct, diterpene glycerides, a 
compound class implicated as a chemical defense in nudibranchs.  Utilizing genomic data 
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from collaborators, we have investigated the chemical diversity from phylogenetically 
unique specimens collected in close proximity to one another.  Groupings based on 
comparison of LC/MS metabolite fingerprints from individual organisms correlated well 
to the genetic data.  Our research shows that A. kerguelenensis specimens from the same 
phylogroups elaborate near identical metabolite profiles to each other, but distinct to 
other phylogroups.  This enables future studies to target the complete metabolome of PGs 
so that minor metabolites unique to some PGs can be targeted.  Of the ten identified PGs 
located near Palmer Station, four have been investigated through LC/MS, HPLC and 
1
H 
NMR data analysis to catalog their palmadorin library.  Of palmadorins not yet identified 
from analysis of individuals, two are di-acyl glycerides, two are the labdanes P and Q, 
and also the chlorinated palmadorin L.  The full extent of PG chemistry remains to be 
identified from the 2010 collection of nudibranchs which contains a tremendous coverage 
of organisms that will allow for a detailed comparison of location and PG.  The molecular 
promiscuity of some PGs (i.e., 4 and 20) appears greater than others and further 
investigation is warranted to verify if the number of identified metabolites correlates to 
any genomic promiscuity.  Genetic studies are still ongoing as our collaborators have yet 
to characterize the nudibranchs from 16S rRNA molecular markers.  The extent to which 
this clarifies any phylogenetic assignments is yet to be determined. 
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Chapter 3:  Chemical investigation of Gigartina skottsbergii 
 
The red marine algae Gigartina skottsbergii in its fertile stage is shown below in Figure 
3.1. 
 
 
Plantae 
Rhodophyta 
Florideophyceae 
Gigartinales 
Gigartinaceae 
Gigartina 
skottsbergii 
 
Figure 3.1.  Fertile G. skottsbergii (image by Bill Baker) 
3.1  Influenza 
Man, plants, insects and other animals are all susceptible to viral infection; therefore, 
prevention and control of viral disease carries important health and economic 
implications.
1
  The common cold, acquired immune deficiency syndrome (AIDS), herpes 
and several cancers are all carried by a virus.  Insects and animals both have the ability to 
transfer viral diseases to humans and other animals.
2
  Significant advances have been 
made towards antiviral research as many treatments have been shown to control, inhibit 
or destroy a virus, but the need for additional antiviral medicines still remains.
3
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Influenza is an enveloped RNA virus infecting birds and mammals.  The World Health 
Organization (WHO) estimates 3 to 5 million infections and half a million deaths per year 
resulting from influenza.
4
 
Seasonal epidemic influenza usually occurs in a very predictable way: in winters for each 
hemisphere and throughout the year in tropical regions usually leaving some immunity 
over from previous seasons.
5
  In seasonal influenza, healthy people are not typically at 
risk except for the very young, the elderly and the immuno-compromised. This is in sharp 
contrast to pandemic influenza where healthy people are at high risk. For pandemic 
influenza, there is generally no immunity.  The potential for epidemics and pandemics 
pose great risks; both the recent avian influenza A(H5N1) (552 cases; 322 deaths) and 
pandemic 2009 A(H1N1) (swine flu) have killed thousands of people and caused the 
slaughtering of millions of birds and mammals.
6
  Though the virulence of avian influenza 
A(H5N1) is high (lethality approximately 60%), the very low person-to-person 
transmission has prevented a devastating pandemic.  In contrast, the virulence of the 2009 
A(H1N1) pandemic has turned out to be relatively low, it is easily transmittable.  
Pandemic influenza is an epidemic influenza that occurs across the globe infecting a large 
population. Only three pandemics have been identified from the 20th century: the 1918 
H1N1 Spanish Flu, the 1957 H2N2 Asian Influenza and the 1968 H3N2 Hong Kong flu.
7
 
What these pandemics lacked in frequency, they made up for in morbidity. The deadliest 
outbreak ever recorded, 1918 Spanish Influenza, killed about 40-50 million people 
worldwide, including an estimated 650,000 in the United States.
8
 The United States 
Centers for Disease Control and Prevention (CDC) estimated that 2009 A(H1N1) 
pandemic influenza resulted in 61 million infections, 274,000 hospitalizations and 12,470 
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deaths worldwide.
9
 Future pandemics could result in thousands of deaths and hundreds of 
billions of dollars in direct and indirect costs.
1
 Furthermore, the potential for viruses to 
mutate into easily transmittable and/or drug-resistant strains and the fact that formulated 
vaccines may be ineffective in the following year underscore the critical need for new 
treatment options. 
 
3.1.1   Conceptual framework of influenza virus 
Influenza exists in nature in three forms recognized as types A, B and C.
10
 Type A 
influenza viruses are mostly carried by birds, but they can infect all animal species.  
Types B and C infect only humans, although type C rarely causes disease and has not 
been linked to major outbreaks.  Influenza type B has only been isolated from epidemics, 
having not been associated with pandemics, yet is still dangerous and connected to infant 
mortality and morbidity.  A broad spectrum of diseases is seen from influenza types A 
and B, including lower respiratory infections, pneumonia, and encephalitis.
11
 
The justification for the differences in influenza viruses A, B and C is based on antigenic 
differences in several viral proteins.
12
 Influenza type A is a virus with the greatest genetic 
diversity and is associated with most infections in humans. Type A has been further sub-
classified based on two glycoproteins, hemagglutinin (HA) and neuraminidase (NA), 
both of which are very important for infectivity. HA is significant to the initial stage of 
the infection when the virus attaches to the respiratory epithelia on the host cells.
13
 As 
shown in Figure 3.2, spikes representing HA (attachment points) bind to sialic acid, the 
host cell receptor.  After receptor proteins allow viral docking, the virus enters the host 
cell nucleus, replicates, and the mRNA constructs the viral proteins creating progeny 
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virions (new, single infective virus particles).  These new viruses remain attached to the 
host cell unreleased, and consequently cannot transmit the disease.  The second 
glycoprotein, neuraminidase, severs the sialic acid receptor, releasing progeny viruses 
into the infected host creating a whole new wave of virus.
14
 Thus, NA (shown as pink 
bulbs in Figure 3.2) is more involved in the subsequent spread of the virus from cell-to-
cell as it infects tissues within the 
organism. 
This is important not just for 
pathogenesis (mechanism of disease), but 
for the genetic specificity of these 
glycoproteins as their differences can 
create different types of viruses.  The 
nomenclature of the influenza virus is 
described in terms of these two 
glycoproteins, whereby “H3” denotes HA 
type 3, and “N2” denotes NA type 2.7  Of the known 16 HA and 9 NA subtypes, it is  H 
1, 2 and 3, and N 1 and 2 that are usually found in humans.
15
 
Influenza type A virus can create completely novel sets of HA and NA within a virus 
generating potential for pandemic outbreak when a whole segment of the human 
population is exposed.  Relatively few amino acid changes are required for a non-
pathogenic virus to become a very virulent one.  For example, when just one mutation on 
a protein, glutamic acid to lysine, occurred in 1918 the deadly Spanish Flu outbreak 
resulted.
8
 Glutamic acid controls temperature during viral replication at a rather high 
Figure 3.2.  Illustration of influenza virus. 
Courtesy of NIAID. Used with permission. 
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temperature of  41°C, but when mutated to lysine it can replicate at 33 °C, a temperature 
much closer to that of the human body. 
Influenza virus has the ability to incorporate mutations rapidly via two general processes 
involving the organization and replication of its genome: antigenic shift and antigenic 
drift.
12,16
  Antigenic shift is a process of gene re-assortment of influenza A viruses 
whereby segments of the RNA genome, consisting of 8 single strands, may be exchanged 
with those from another virus during co-infection of the same host organism.  Wild birds 
are asymptomatic natural reservoirs for the virus, frequently transmitting virus to 
domestic birds and pigs.  The latter (described below) constitute good mixing vessels for 
genetic re-assortment. It becomes a matter of time for a genetically new influenza virus 
for which humans have no immunity, to jump the species barrier and cause human 
infection and illness.  When two viruses inside the same organism can potentially 
generate 256 (2
8
) different combinations, this provides a very powerful mechanism for 
genetic diversity.  The process of antigenic drift results from the fact that viral RNA-
dependent RNA polymerases lack the ability to genetically proofread.
16
  As the virus 
replicates, there are errors that are not corrected and this error prone replication in 
influenza virus is responsible for discrete mutations that are gradually incorporated into 
the viral genome.  Therefore humans who have gone through an infection may again 
become susceptible to new, circulating strains. 
Pandemic influenza is a zoonotic infection which presents an important aspect for human 
outbreak.
17
  Human viruses typically only bind to sialic acid with α-2,6 glucose linkages 
found on human epithelial cells, while avian viruses have a receptor for sialic acid with 
α-2,3 glucose linkages found on avian epithelial cells.  This is thought to be one of the 
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factors that restrict viruses to infecting the same species.  However, pig epithelial cells 
contain both types of sialic acid receptors - α-2,3 and α-2,6 - which makes the swine 
particularly susceptible to infection to both avian and human influenzas, explaining why 
pigs are often envisioned as mixing vessels.  People living or working at the interface of 
animal and human play a key role in the spread of pandemic influenza and should be 
targets of early efforts to prevent the spread of infection. 
 
3.1.2 Drugs for influenza 
The emergence of new influenza viral strains for which the population is 
immunologically naïve, represents an undeniable challenge and a continued threat to the 
population.  Although vaccinations present the best option for prevention and control of 
pandemic influenza, concerns over vaccine safety and the amount of time (frequently 
exceeding 6 months) between virus identification and vaccine distribution necessitate an 
effective antiviral therapy for short-term prevention and infection.
18
  With the large 
variety of influenza strains that man is exposed to and the development of drug-resistant 
variants, new anti-influenza drugs must possess broad activity against all strains and 
subtypes, or at the least be effective as part of a combination drug therapy. 
Viruses have the ability to overtake and manipulate our body‟s healthy cells with their 
own machinery; thus, developing therapies to treat viral disease without harming our own 
cells becomes very difficult.  The list of FDA-approved drugs effective against seasonal, 
avian and the most recent pre-pandemic swine influenza is brief and have significant 
limitations.
19
  Two drugs are neuraminidase inhibitors, oseltamivir (3.1, Tamiflu®) and 
zanamivir (3.2, Relenza®), both derived from the same chemical scaffold based on sialic 
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acid (3.3).  The two M2 ion-channel inhibitors, amantadine (3.3) and rimantadine (3.4) 
have limited efficacy against influenza A viruses and are ineffective against influenza B 
and H1N1 2009 pandemic influenza. 
                          
3.1  Oseltamivir                 3.2  Zanamivir            3.3  Sialic acid 
                                                
3.3  Amantadine           3.4  Rimantadine 
Active only against influenza type A, amantadine and rimantadine have been shown to 
exhibit two important mechanisms: they inhibit the M2-ion channel at the stage of viral 
nucleocapside release thereby blocking virus replication
20
 and alter the conformation of 
the HA which prevents release of the virus.
21-22
  Despite the effectiveness of these drugs, 
the rapid emergence of virus strains resistant to the M2 inhibitors has been a major 
concern.  A 2005 study showed that transmittable, amantadine-resistant influenza strains 
have increased their prevalence throughout the globe, even where the use of M2 
inhibitors were minimal.
23
  In fact, this drug resistance caused the CDC to discourage the 
use of this class of drug, instead recommending the use of NA inhibitors to treat the 2009 
H1N1 pandemic virus.
24
  The NA inhibitors zanamivir and oseltamivir work by entirely 
different mechanisms.
25
  These compounds inhibit the release of virions from infected 
cells which interrupts established infections.  Zanamivir and oseltamivir are sialic acid 
analogs that bind to virus NA some million times more powerfully than sialic acid, 
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effectively preventing release of the virions and further infection by causing aggregation 
of previously released virions.
26
  Unfortunately, both natural and drug-induced resistance 
to these treatments is widespread and possible links to the appearance of neurological 
side-effects from NA inhibitors have been reported.
11,27-28
 
Current antiviral drugs undergoing Phase III clinical trials include the neuraminidase 
inhibitors laninamivir, favipiravir and the once abandoned peramivir (3.5).
29
  These 
compounds are all formulated as injectable versions to overcome poor bioavailability.
30
  
The synthetic ribosyl purine analog ribavirin (3.6) is currently approved to treat influenza 
in Mexico and has been used to treat various viral infections (hepatitis C, viral 
hemorrhagic fevers, and human respiratory syncytial virus (RSV).
31-32
  Virus-targeting 
agents include the hemagglutinin inhibiting protein cyanovirin-N (see sect. 3.2.2), the 
sialidase fusion protein DAS181 and thiazolides (e.g., nitazoxanide  (3.7)) are in early 
clinical trials.
29
 
                 
             3.5  Peramivir                     3.6  Ribavirin                       3.7  Nitazoxanide 
 
3.2 Proteins as therapeutics 
The development of proteins as therapeutics challenges the conventional wisdom of drug 
discovery and paradigm of small molecule high-throughput screening.  “Lipinski‟s Rule 
of 5” has been utilized by drug developers to evaluate the likelihood that a chemical 
entity can become a drug.  Developed in 1997 by Christopher Lipinski, the formulation is 
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based on the observation that the majority of drugs are relatively small and lipophilic 
molecules.
33
  In brief, the rule states that an orally active drug has no more than one 
violation of the following criteria: 1) not more than 5 hydrogen bond donors; 2) not more 
than 10 hydrogen bond acceptors; 3) a molecular weight under 500 daltons; and 4) an 
octanol-water partition coefficient log P less than 5.  Despite violating these rules, 
proteins have proven to be effective biomolecules.  Table 3.1 lists examples of bioactive 
proteins on the market. 
Table 3.1.  Examples of Bioactive Proteins on the Market. 
Protein Treatment  Protein Treatment 
Insulin Diabetes  Growth Hormone
34
 Short Stature 
Epogen®
35
 Anemia  G-CSF
36
 WBC stimulation 
Thrombopoietin
37
 Platelet 
stimulation 
 Factor VIII
38
 Hemophilia 
Interferon β-1α39 Multiple 
Sclerosis 
 β-Glucocerebrosidase40 Gaucher‟s disease 
Herceptin®
41
 Breast cancer  Etanercept
42
 Inflammation 
 
3.2.1 Lectins 
The human immune system often has a difficult time detecting viruses because their 
surface is covered by carbohydrates; however, one class of proteins has a remarkable 
ability to distinguish these highly conserved sugary surfaces.  In the late 1800s while 
working with castor bean extracts, Peter Stillmark isolated the toxic protein ricin in what 
is considered to be the first description of a lectin.
43
  Lectins are defined as a class of non-
immuno proteins which bind carbohydrates, agglutinate cells and precipitate 
polysaccharides and glycoproteins.
44
  Structurally lectins are very diverse, varying in 
amino acid composition, metal requirement, domain organization, three dimensional 
structure and in the arrangement of their combining sites.  In general, they are oligomeric 
proteins comprised of subunits with one or more sugar-binding sites, lacking any 
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catalytic activity and found ubiquitously in nature.  Interest in lectins dwindled until the 
late 1960s when they were shown to possess the ability for detection, isolation and 
characterization of sugar-containing molecules and cellular structures, most notably 
glycoproteins.
45
 
The biological function of lectins in nature is diverse and based on the ability to 
recognize and bind carbohydrate molecules in solution or on cell surfaces.  Functions 
include defense against predators (insecticidal, arthotoxic and phytopathogens), 
mediators of plant symbiosis with nitrogen-fixing bacteria, control of lymphocyte 
migration, glycoprotein biosynthesis, and induction of apoptosis and angiogenesis.
46
 
 
3.2.2 Potent antiviral lectins 
From the NCI natural product screening process, three potent antiviral lectins have been 
isolated and characterized.  Cytoprotective activity against HIV-1 was observed from an 
aqueous extract of the red alga Griffithsia sp. collected off the coast of New Zealand.  
Using a combination of precipitation and chromatographic procedures, researchers were 
able to isolate a 12.8 kD (121 amino acids) lectin known as griffithsin (GRFT) with EC50 
values ranging from 0.043 to 0.63 nM against HIV strains without any cytotoxicity to 
healthy cells.
47
  The primary amino acid sequence of GRFT was determined by a 
combination of N-terminal Edman degradation, MALDI-TOF MS of intact GRFT and 
analysis of a series of overlapping peptide fragments generated by chemical and 
enzymatic cleavages from endoproteinase digestion (CNBr, Lys-C, Arg-C, and Asp-N).  
GRFT binds to three mannose groups, often as dimers, effectively locking up mannose 
binding sites on the viral surface.  IC50 values for GRFT against Severe Acute 
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Respiratory Syndrome (SARS) is approximately 50 nM and 380 nM for Ebola virus.  
Efforts are underway to develop a microbicide formulation for GRFT application.
48
 
Cyanovirin-N (CV-N) is a potent antiviral lectin isolated from the cyanobacterium 
Nostoc ellipsosporum as part of a screening program at the NCI to develop antiviral 
microbicides.
49-50
  First reported in 1997, CV-N is an 11 kDa protein that binds to 
carbohydrates found on the surface of viruses, in particular HIV and herpes viruses.  
Strains of both type 1 and 2 HIV are rendered irreversibly inactive and healthy cells 
survive continuous, two day exposure to high concentrations of CV-N.
49,51
 CV-N 
strongly interacts with the viral surface envelope glycoprotein gp120 and is highly 
resistant to physiochemical denaturation.  Purification of the protein was achieved by RP 
HPLC of an aqueous cellular extract of the cultured blue-green algae. N-terminal Edman 
degradation of both the intact protein and endoproteinase digestion peptide fragments 
afforded sequencing of the 101 amino acid protein.  Four cysteine residues create two 
intrachain disulfide bonds, the locations of which were determined by fast atom 
bombardment mass spectral studies of peptide fragments.  The anti-HIV activity is lost 
when these disulfide bonds are reduced.  Though HIV infection was the initial reason for 
development of CV-N, the protein also has been shown to possess potent antiviral 
activity against strains of influenza A and B viruses.
49,52
 
From an aqueous extract of the cultured cyanobacterium Scytonema varium, the potent 
anti-HIV protein scytovirin (SVN) was isolated.  SVN is a 95-amino acid (9.7 kDa) chain 
that binds to viral coat proteins and displays anticytopathic activity towards strains of 
HIV-1 with EC50 values from 0.3 to 22 nM.
51
  While SVN is not technically a lectin, it 
does contain a primary structure motif similar to lectins.  These three antiviral proteins 
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inhibit HIV-1 infection by cross-linking to multiple mannose-rich glycans on the HIV-1 
envelope glycoproteins.
53
  Human proteins also have mannose-rich regions; however, 
mannose is typically modified later by the Golgi apparatus, leaving viral proteins 
uniquely susceptible to compounds targeting mannose-rich sugar complexes on proteins. 
Despite advances in the development of proteins as effective therapeutics, there remain 
are several disadvantages.
54
  Many require production in cultured mammalian cells or 
transgenic animals and are thus difficult to manufacture.  Inhomogenous N- and O- 
linked oligosaccharides may suffer from proteolytic cleavages and rendered inactive.  
Proteins are often difficult to purify, unstable or have low oral bioavailability and must be 
injected.  Also, many proteins are immunogenic and often side effects arise if 
administered systemically. 
 
3.3 Marine red algae: a dominant source of natural products 
With over 1750 compounds reported, the secondary metabolite chemistry of Rhodophyta 
is richer than other macroalgae, both in terms of abundance and diversity.
55
  All major 
classes of natural products (see Figure 3.3 for selected chemistry) are represented among 
the Rhodophyta (with the exception of phlorotannins), predominantly elaborating 
isoprenoid and acetogenin derivatives, along with some amino acid, shikimate and 
nucleic acid derivatives.  What truly distinguishes red algae is that they are impressive 
producers of halogenated compounds with over 90% of those reported containing 
bromine or chlorine, compared to only 7% of green algal compounds and less than 1% of 
those from brown algae.
56
  These halogenated terpenoids have shown only a paucity of 
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non-ecological bioactivity, which may explain the decline in interest in red algal 
chemistry.
57
 
More than half of the reports of Rhodophyta chemistry come from the Rhodomelaceae 
class and the vast majority of that represents chemistry of the genus Laurencia, which 
produces a wealth of halogenated sesquiterpenes and C15 acetogenins, along with a few 
higher terpenes (C20 and greater).  Laurencia sesquiterpenes, like those from several other 
rhodomelacean genera, are typically cyclized, often polycyclic, as seen in laurinterol 
(3.8)
58
 and pacifenol (3.9).
59
  Chemically unusual spiro-ring fusions, rings connected 
through just one atom, observed in elatol (3.10)
60
 are not uncommon among Laurencia 
sesquiterpenes.  Diterpenes are primarily monobrominated polycycles, such as irieol 
(3.11)
61
 while triterpenes are most often polyether in nature, such as callicladol (3.12).
62
  
Sesterterpenes are not represented in the Rhodophyta.  Laurencia is nearly alone in 
elaborating a rather unique series of C15 acetogenins, such as laurepinnacin (3.13).
63
 
Three other Rhodophyta families, Rhizophyllidaceae, Plocamiaceae and Delesseriaceae, 
distinguish themselves from the Rhodomelaceae by producing largely halogenated 
monoterpenes.  The Rhizophyllidaceae genera Chondrococcus, Desmia, and Ochtodes, 
the plocamiacen Plocamium, and the delesseriacean Pantoneura, are, with few 
exceptions, the only sources of monoterpenes among the red algae.  These red algal 
monoterpenes are often highly halogenated linear (3.14)
64
 or monocyclic (3.15).
65
  One 
notable exception is the rhizophyllidacean Portiera, which elaborates one of the most 
intensely studied red algal anticancer metabolites, halomon (3.16).
66
 
A few other genera in the Rhodomelacea (for example, Odonthalia, Polysiphonia, 
Rytiphloea, Vadalia, Symphyocladia) elaborate brominated phenols.  The genus 
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Acanthophora stands out as a producer of non-halogenated steroids.  Several genera in 
the Bonnemaisoniaceae (Delesea, Asparagopsis, Bonnemaisonia, Ptilonia) are notable as 
producers of small, linear halongenated ketones and branched lactones.  The fimbrolides, 
for example (3.17), are a series of halogenated furanones from Delisea pulchra
67
 that 
have been shown to interfere with signaling in bacteria and provide an antifouling 
defense by functioning as an intracellular signal antagonist.
68
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Figure 3.3.  Representative red algae compounds. 
 
3.3.1 Chemistry of the genus Gigartina 
Gigartina is widely cultivated as a source of carrageenans (3.18) for the food additive 
industry.  Carrageenans are a family of linear sulfated polysaccharides found in many red 
algae. 
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3.18  Carrageenan 
The genus is comprised of approximately 46 species, though only a few, G. stellata, G. 
chamissoi, G. tenella and G. skottsbergii, are farmed for commercial use, the majority 
cultivated from suspended rafts along the coasts of Chile.
69
  These carbohydrates are 
gelatinous and stable under stress and have been used in the food industry as thickening 
and stabilizing agents.  Carrageenans are also used in the production of desserts, beer, 
toothpaste, various gels, shampoo, marbling, shoe polish, diet soda, soy milk, pet food, 
personal lubricants and even as a health supplement. 
Dietary supplement producing companies are currently marketing a Gigartina-based red 
marine algal (RMA) extract as a “flu fighter,” with the claims of sulfated polysaccharides 
boosting immune response and fighting influenza, though they acknowledge these claims 
have not been evaluated by the Food and Drug Administration (FDA).
70
  RMA are 
known to contain significant amounts of sulfated polysaccharides which have 
demonstrated a broad range of biological activities, most notably against HIV, Herpes 
simplex virus (HSV) types 1 and 2 and RSV
71
 as well as variable effects on the immune 
system and anticoagulant activity.
72-73
  Though algae of the genus Gigartina is 
widespread, very little small molecule chemistry has been elaborated from any species. 
G. skottsbergii was originally identified in South America by Setchell and Gardner in 
1936
74
 and can be found in South America, around Antarctica and the subantarctic 
islands.
75
  The namesake, Carl Skottsberg was a botanist on an early 20th Century 
Swedish Antarctic exploration.  It is of note that although this alga in Antarctica is 
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morphologically very similar to G. skottsbergii from Chile, recent molecular taxonomic 
studies indicate that it is probably a distinct species.
76-78
  Nevertheless, until a new 
species designation is formally proposed and published, G. skottsbergii remains the 
correct name for this entity. 
 
3.4 Results and discussion 
In preparation for this project, an extensive screening of extracts against influenza was 
undertaken.  Marine invertebrates, algae and microorganisms from the shallow water 
environment of the Western Antarctic Peninsula, where recent efforts have revealed a 
diverse fauna replete with defensive chemistry.
79
 Screening from these organisms against 
influenza viruses has revealed that the red marine alga Gigartina skottsbergii elaborates 
potent anti-influenza chemistry.   
 
3.4.1 Primary and secondary screening of extract library 
Initial screening of lipophilic and hydrophilic extracts against influenza A/WY/03/2003 
(H3N2) were selected from a library of diverse marine invertebrates, algae and 
microorganisms. The primary influenza screen used in this study begins with a 
microscopic evaluation of the cytopathic effect (CPE) of extracts on virus-infected 
mammalian cells and is quantified by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) stain. Primary screening results were visualized via crystal 
violet stained plates and optical reading of the corresponding cell viability assay from a 
sample plate of marine extracts (Figure 3.4).  From 800 screened extracts only one, well 
A4 in Figure 3.4, which is the crude, lipophilic (1:1, CH2Cl2:MeOH) extract from G. 
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skottsbergii displayed complete protection against influenza induced CPE using light 
microscopy and cell viability assay at 100 µg/mL.  For comparison, healthy, unaffected 
cells in this assay stain violet, as shown both in well A4 and along the control lane, 
column 12 which contains uninfected cell control (wells A-C12) and control drug 
ribavirin (5 µg/mL; wells D-F12).  Extract E3 exhibited partial protection against CPE. 
The active extract from G. skottsbergii was advanced into secondary screening, which 
includes confirmation of activity observed during the primary screen using an expanded 
range of concentrations (dose response), plaque inhibition assay, and a one step growth 
inhibition and testing of additional influenza viruses. As shown in Figure 3.5a the 
quantitative dose response assay was used to assess the potency of two extracts, A4 
(active) and F2 (ineffective).  The extract A4 displayed activity against H3N2 influenza 
virus in vitro in a dose dependant manner as visualized by the decreasing amounts of 
violet stain going across the well plate. A plaque reduction assay was also conducted; 
demonstrating that extract A4 performed almost as well as the control drug ribavirin (see 
Figure 3.5b). Briefly, a plaque assay is a method whereby infected cells forms plaques 
shown here as the circular holes in the stain allowing quantification of the effectiveness 
of the drug by looking at both the size and number of the plaques formed. The active 
extract A4 induced formation of smaller plaques than the untreated or ineffective extract 
controls.  Additional assays included a selectivity evaluation and cytotoxicity assay 
where both good selectivity and low cytotoxicity were documented. The extract was also 
tested on unrelated viruses and other influenza viruses. 
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Figure 3.4.  Primary screening results for library of marine extracts.  The crude extract in 
position A4 (G. skottsbergii) was determined to protect against influenza induced CPE 
using light microscopy and cell viability assay at 100 µg/mL. The extract in position E3 
partially protected against CPE. Wells A-C12 contained uninfected cell control, D-F12 
contained control drug ribavirin at 5 µg/mL and G12 and H12 are virus infected control 
(Alberto van Olphen (AVO), USF). 
Figure 3.5.  (a) Microtiter plate showing dose response data from an extract of G. 
skottsbergii (A4), as well as unrelated and ineffective extract from well F2; (b) Plaque 
reduction assay using same extracts (AVO, USF).  
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3.4.2 Initial purification of active extract 
Initial purification attempts focused on efforts to elaborate small molecule chemistry 
from active fractions.  Bioassay guided isolation began with thawed alga vigorously 
extracted in methanol and partitioned between organic solvents and water to derive five 
fractions of which the three organic fractions (A, B and C) exhibited antiviral activity 
(see Scheme 3.1a). 
 
Scheme 3.1.  Bioassay guided isolation schemes for G. skottsbergii: (a) the initial small 
molecule isolation scheme for 2007 collections of the alga (PSC07-52) (PSC08-08).  
Active fractions circled; EC50 values reported in red. 
 
Fraction A with an EC50 value of 39 μg/mL was further purified into subfractions via NP 
MPLC with polar fraction PSC07-52-A-I exhibiting the strongest activity with an EC50 
value of 28 μg/mL. RP HPLC evolved eight fractions; however, when these fractions 
were submitted for bioassay activity was lost.  The HPLC fractions were recombined, but 
antiviral activity did not return.  Traditional spectroscopic and spectrometric techniques 
(NMR, MS) did not provide insight into the nature of the active fraction PSC07-52-A-I.  
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Concentration of the active fractions with high molecular weight filters (30 kDa and 10 
kDa cut-offs) and SDS-PAGE gel electrophoresis provided evidence that the active 
fraction could be protein or polymeric in nature as faint bands were visualized near 13 
kDa ladder (see Figure 3.6).  Sequencing 
data from the active fraction, though not 
yet conclusive, exhibited some slight 
homology with actins and/or lectins at 85% 
confidence levels or lower.  
Due to the failure to evolve further active 
fractions from traditional small molecule 
purification schemes (Scheme 3.1), chromatographic methodology for proteins was 
undertaken.  Having exhausted our collection of G. skottsbergii from 2007 (PSC07-52), 
alga collected from the most recent field season at the time (PSC08-08).  As shown in 
Scheme 3.2, thawed algae was blended and extracted in water, then adsorbed onto XAD 
1180 resin multiple times to eventually yield four fractions. Fraction PSC08-8-3 which 
eluted with 1 M NaOH exhibited anti influenza activity.  This fraction eluted for proteins 
and peptides as described by the manufacturer‟s protocol.  Chromatography on a size 
exclusion column (SEC) afforded 10 fractions. Subfraction PSC08-8-3-A was active 
toward both the A/Wyoming/03/2003 (H3N2) virus as well as H1N1 with EC50 values of 
30 ug/mL and 10 ug/mL, respectively. Although activity is reproducible among the 
disparate separation methods, a pure, active compound in appreciable mass could not be 
obtained.  Despite the failure to characterize a single active entity from these initial  
H   I     J   K 20KD
13KD
Ladder
PSC07-52-A-
Figure 3.6.  SDS-PAGE of NP MPLC 
fractions. 
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purifications; the chromatographic purifications and SDS-PAGE supports that activity 
arises from a proteinaceous entity and not entirely from sulfated polysaccharides. 
Scheme 3.2.  Alternative protein isolation scheme using algae from 2008 collections of 
G. skottsbergii. 
 
3.4.3 Hemagglutination assay and drug combination studies 
Hemagglutination is the agglutination involving red blood cells (RBC) whereby proteins 
on the surface of the virus bind to the neuraminic acid receptors on RBCs allowing for 
quantification of viral dilution and infection.  Hemagglutination assays have provided 
some insight into the possible mechanism of action.  Active fraction PSC07-52-A-I was 
utilized in these experiments as they were conducted before isolation of active fractions 
generated from 2008 collections.  As shown in Figure 3.7a, positive hemagglutination 
results in a suspension of RBCs in the test wells as compared to the negative results 
whereby a visible settling of the RBCs is observed as a solid red ring.  As shown in the 
top row of Figure 3.7a, hemagglutination occurs when untreated cells are infected with 
virus, resulting in a suspension of the bound virus and erythrocyte in solution. Cells 
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treated with the active subfraction PSC07-52-A-I (second row Figure 3.7a) exhibit 
agglutination as well, whereby the extract is protecting the uninfected cell from virus by 
blocking viral entry.  Rows three and four are controls used for quantification of the 
assay.  Hemagglutination assays using the antiviral compounds ribavirin, amantadine, 
rimantadine and zanamivir without virus do not cause hemagglutination and RBCs settle 
to the bottom of the well as shown in Figure 3.7b.  The bottom row illustrates that RBCs 
and the active subfraction PSC07-52-A-I do hemagglutinate suggesting that the active 
fraction works by a different mechanism than control drugs. 
 
Figure 3.7.  Hemagglutination assay results whereby active subfraction PSC07-52-A-I 
causes (a) hemagglutination with infected and (b) uninfected cells (AVO, USF). 
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Drug combination assays with the active 
subfraction (Figure 3.8) and the drugs 
zanamivir and ribavirin consistently 
observed protection greater than the sum 
of each.  As shown in Figure 3.8a, 
zanamivir (2.5 μg/mL) displayed 10.4% 
percent protection, PSC07-52-A-I (8.8 
μg/mL) exhibited 41.1% protection, but 
together proved to protect 59.1% of the 
cells from infection. Experiments with 
ribavirin showed even greater increased 
response. Ribavirin (1.25 μg/mL) and 
PSC07-52-A-I (8.8 μg/mL) displayed 38.0% and 32.6% protection independently (Figure 
3.8b), but in combination exhibited complete protection suggesting a synergistic effect 
and perhaps offering potential value in drug combination therapies. 
 
3.4.4 Bioassay guided isolation at NCI-Frederick 
In the summer of 2010, an eight week collaboration with the laboratory of Dr. Barry 
O‟Keefe at the National Cancer Institute (NCI) in Frederick, Maryland was begun, a 
facility that specializes in the purification of proteins.  As shown in Scheme 3.2, aqueous 
extracts of G. skottsbergii were reduced under vacuum leaving a pink, fluffy solid.  The 
solid was resuspended in 50% aq. EtOH, precipitated overnight and centrifuged.  The 
supernatant was decanted, dried and brought to 75% saturation with (NH4)2SO4.  This 
Zanamivir     
(2.5 µg/ml)
PSCO7-52-A-I  
(8.8 µg/ml)
Combination 
% Protection 10.4 41.1 59.2
0.0
20.0
40.0
60.0
80.0
100.0
120.0
P
e
rc
e
n
ta
ge
 p
ro
te
ct
io
n
a
Ribavirin     
(1.25 µg/ml)
PSCO7-52-A-I  
(8.8 µg/ml)
Combination
% Protection 38.0 32.6 112.0
0.0
20.0
40.0
60.0
80.0
100.0
120.0
P
e
rc
e
n
ta
ge
 P
ro
te
ct
io
n
b
Figure 3.8.  Percent protection data for 
combination drug assays with PSC07-52-A-I 
and (a) zanamivir, and (b) ribavirin (AVO, 
USF). 
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process was done 15 times on extracts varying in mass from 1-55 g.  Following 
precipitation, the supernatant was decanted and the remaining white pellet was 
resuspended and applied to a hydrophobic interaction (HIC) column.  Additional 
chromatography utilizing an ion exchange column (IEC) followed by RP HPLC afforded 
active fractions D, E and F. 
 
Scheme 3.2.  Bioassay (gp120 binding) guided isolation scheme with active fractions 
outlined in red.   
 
Progress of precipitations and chromatography was monitored by SDS-PAGE and 
Bradford assay.  As shown in Figure 3.9a lanes 1-6, (NH4)2SO4 precipitation of algal 
extracts was inconsistent and low yielding as each lane represents a different extraction 
and precipitation from unique extract.  Lack of bands in lanes 7 and 10-13 were expected 
as these lanes contained ethanolic pellet and (NH4)2SO4 supernatants.  Initial 
chromatography using HIC also provided low yields and inconsistent bands as shown in 
Figure 3.9b, lanes 3-5 and 7-10.  Figure 3.10 provides an example of a chromatogram 
A B C D A B C D
HIC HPLC with POROS PE column; 3M (NH4)2SO4 to 100% H2O
IEC HPLC with POROS HQ column; 0-100% 1M NaCl pH 8.0
RP HPLC with PRP-3 column; H2O to ACN 
A B C D E F G H I
A B C D
Gigartina skottsbergii 
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2) 10K rpm, 30 minutes
50% EtOH precipitation
Supernatant retained
1) 24 hrs at 4 C st 80% saturation;
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(NH4)2SO4 precipitation
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using HIC run.  While successive HIC runs were not consistent, most peaks evolved after 
100% H2O (i.e., 319A-47B). 
 
a      b 
Figure 3.9.  Representative SDS-PAGE gels for (a) (NH4)2SO4 pellets (lanes 1-6), EtOH 
pellet (lane 7) and (NH4)2SO4 supernatants (lanes 10-13), and (b) fractions evolved from 
HIC (see Figure 3.10; lane 3: unbound injection 319A-47inj, lane 4: 319A-47A, lane 5: 
319A-48B). 
 
 
Figure 3.10.  Chromatogram 319A-47 from HIC. 
 
 
Active fraction passed through IEC began to reveal clean bands as shown in Figure 3.11a, 
although variations were still evident even from fractions with similar elution profiles 
(see Figure 3.12).  Chromatograms from IEC were also inconsistent, but generally 
unresolved peaks evolved just as the linear gradient introducing 1 M NaCl began.  
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Progress into RP HPLC evolved more consistent behavior as fractions eluting at 50% 
CH3CN/H2O exhibited similar bands as shown in lanes one, six and seven in Figure 
3.10b. 
 
 
a     b 
Figure 3.11.  Representative SDS-Page gel of (a) IEC fractions (see Figure 3.12; lane 2: 
319A-80B, lane 3: 319A-80C) and (b) RP HPLC fractions (see Figure 3.13; lanes 3-9: 
AM5-65-fractions C-I). 
 
 
Figure 3.12.  Chromatogram 319A-80 from IEC. 
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Figure 3.13.  Chromatogram AM5-65 from RP HPLC.  Red box emphasizes ~14 kD 
band on Figure 3.12. 
 
3.4.5 Immunoblot assay and RP HPLC fractions 
Binding activity was monitored using an immunoblot assay, whereby binding to HIV 
gp120 was visualized (see Figure 3.14).  Briefly, this assay involved spotting a fraction 
onto a protein-binding PVDF membrane, blocking the remaining membrane with inactive 
bovine serum albumin (BSA), introducing conjugated gp120 protein with horse radish 
peroxidase (HRP) which can be easily visualized.  Fractions binding gp120 are visualized 
as red spots on the membrane (see positions 1 and 20 in Figure 3.14a).  To explain the 
numbering system, in Figure 3.14b, „319A‟ refers to notebook, followed by page number, 
followed by fraction described on that page number. 
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Figure 3.14.  (a) gp120 dot blot assay results and (b) SDS-PAGE and immunoblot assay 
activity of RP HPLC fractions in lanes 1-12. Active fractions in red. 
3.4.6 Characterization of Gigartinin 
From fraction 319A-103E (see Figure 3.14b, lane 1) a 14.5 kDa protein which we‟ve 
named Gigartinin ith significant antiviral activity has been isolated.  To data fractions 
sequencing efforts from the various purification attempts have identified some homology 
to lectin and a ubiquitin-like protein.  Insight into size and AA content has arisen from 
spectroscopic data acquired with fraction 310A-103E.  Matrix-assisted laser desorption 
ionization-time of flight mass spectrometry (MALDI-TOF-MS) reveals a peak at 14.5 kD 
as shown in Figure 3.15a.  ESIMSMS confirmed a molecular ion with m/z 14490.4 for 
fraction 319A-103E (Figure 3.15b and c). 
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Figure 3.15.  Spectrometric data for fraction 319A-103E: (a) MALDI mass spectrum of 
fraction 319A-103E; (b) ESIMS mass spectrum of the charge state distribution (n = 16) 
of a 14.5 kDa protein and (c) ESIMS spectrum after deconvolution reveals MW of 
14490.4 amu. 
 
MS/MS analysis of the tryspin digest from fraction 319A-103 afforded a fragment ion 
with m/z 856.9 identified an 18 amino acid (in yellow) sequence with homology to that of 
GRFT (see Figure 3.16). 
 
Figure 3.16.  MS/MS spectrum of fragment ion m/z 856.9 and identification of 18 amino 
acid fragment shown in yellow. 
 
GRFT is a 121 amino acid containing protein with a molecular weight of 12.8 kD.  The 
difference between gigartinin and GRFT is 1720 amu.  Using 120 amu as the average 
MW of an amino acid, leaves approximately 14 additional residues.  Active fractions 
from G. skottsbergii were run against GRFT-antibodies and exhibited no binding.  If 
gigartinin does share several residues with GRFT, it is possible, though not certain, that 
binding should have been observed.  Unfortunately these inconsistent results did not 
progress the complete characterization of the protein. 
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3.6 Research summary and future directions 
These results emphasize the importance of exploring the marine realm for the presence of 
antiviral compounds, not only for identification of small molecules but also as a source of 
potent macromolecules. Mori et al.
80
 have reported a potent antiviral lectin griffithsin 
from the red alga Griffithsia sp., which is perhaps similar in nature to the active 
component of Gigartina skottsbergii, hereby named gigartinin. Subfractions from G. 
skottsbergii possesses strong anti-influenza activity toward both the A/Wyoming/03/2003 
(H3N2) and A/California/04/2009 (H1N1) virus with EC50 values in the range of 5 to 10 
μg/mL.  The virus-inhibitory effect was selective, dose-dependent, strain-specific and the 
virus induced cytopathogenic effect (CPE) was reduced at non-toxic concentrations of the 
extract.  Insight into the mechanism of action via hemagglutination and plaque assay 
suggests cell protection by interference of viral docking and combination drug assays 
imply a synergistic effect between control drugs and the active fraction towards 
influenza.  To date, poor yields have hampered efforts to purify gigartinin in sufficient 
yields to unequivocally deduce a sequence.  Slight modifications on future extraction and 
chromatographic procedures could increase efficiency.  Initial extractions should use 
finely blended algae in ethanolic solvents, although this will prove difficult as the high 
concentration of sugars prevents facile maceration.  Activity of gigartinin has been 
maintained over various solvent conditions; therefore, exploiting the lowered solubility of 
sugars and nucleic acids ethanol will improve initial extractions.  IEC and RP HPLC 
proved most effective as chromatographic methods to purify protein; robust columns 
could allow generation of enough material to afford a sequence. 
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Future efforts toward the rapid identification of organisms with viral binding activity 
from proteins can be implemented via the gp120 dot blot assay.  Traditional extraction 
procedures must be adjusted so that first pass extraction techniques efficiently solubilize 
proteins without denaturing them (i.e., aqueous solvents). 
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Chapter 4. Chemical investigation of Dendrilla membranosa 
The cactus-like bulbs of Dendrilla membranosa surrounded by red algae and bryozoans 
(Figure 4.1). 
 
Animalia 
Porifera 
Demospongiae 
Dendroceratida 
Darwinellidae 
Dendrilla 
membranosa 
 
Figure 4.1.  Dendrilla membranosa (image by Bill Baker). 
4.1  Introduction 
Along the Western Antarctic Peninsula (WAP) macroalgal forests dominate the shallow 
benthos and colorful invertebrates cover stunning walls that drop straight to the ocean 
floor.  The chemical ecology of the current benthic marine invertebrate fauna is largely 
ancient and endemic as it separated from Gondwana 130-85 million years ago.
1
  The 
diversity rivals that of temperate and tropical climates, though key differences in ecology 
dictated by physical pressures such as the Antarctic Circumpolar Current (ACC) and 
repeated periods of glaciations have sculpted a unique environment.
2
  Predatory and 
114 
 
competitive relationships for resources are substantial along the WAP and have driven 
the evolution of chemical defenses in many sessile or slow-moving invertebrates and 
macroalgae.
2
  While tropical organisms face intense predation from fish, the WAP is 
largely devoid of fish although the benthos does contain vast numbers of amphipods.
3
 
Within nearshore peninsular communities, amphipods display tremendous densities 
reaching up to an estimated 308,000 individuals m
-2
.
3
  These crustacean mesograzers 
likely play a key role in sculpting the pressure of algal and sponge ecology within the 
WAP.  Gut content analysis of amphipods reveal a highly varied diet: sponge spicules, 
diatoms, filamentous macroalgae, thalli and larger macroalgae, bryozoans, crustacean 
parts and other non-diatom epiphytic unicellular algae have been identified.
4-5
  The 
feeding habits of the amphipods also show great diversity including necrophagy, 
carnivory, herbivory, suspension feeding, detritivory and omnivory.
6-15
  Sponge-
amphipod associations are wide-ranging with sponges serving as habitat, reproduction 
sites, refuge and as direct or indirect sources of nutrition.
16-18
  Little is known about the 
extent of sponge-amphipod associations in nearshore polar communities, although, such 
associations have been described for tropical, temperate and polar deep water trawl 
samples.
19-20
  The ecological relevance of these associations are important with sponges 
covering up to 55% of the Antarctic benthos and being significant contributors to the 
Antarctic benthic community.
7,21
  Our research group has been investigating the trophic 
interactions of Antarctic invertebrates for over a decade.  Previous studies have examined 
sponge-amphipod interactions by developing a bioassay to examine the feeding deterrent 
properties of sponge extracts and compounds.
4
  Of 12 species of common demosponges, 
only two exhibited significant feeding deterrence against the amphipod Gondogeneia 
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antarctica: both the lipophilic and hydrophilic extracts from Crella sp. and the lipophilic 
extract from Dendrilla membranosa (P = 0.022). From the lipophilic extract of D. 
membranosa, eight fractions were generated via NP MPLC, four of which exhibited anti-
feeding activity.  The spectroscopic data from these active fractions showed characteristic 
signals of the membranolides, a series of diterpenoids previously implicated in the 
chemical defense of D. membranosa. 
 
4.2  Background 
The chemical arsenal of sessile or slow moving invertebrates is vast.  Biological and 
behavioral defenses or physical adaptations like hard shells or spicules are common 
defense mechanisms.  Chemical defenses are employed by either dietary sequestering or 
de novo biosynthesis of deterrent secondary metabolites which may be simply taste 
deterrent or toxic to predators. Few studies have examined palatability of pure 
compounds against marine organisms, especially against marine amphipods. The 
Antarctic sponge Latrunculia apicalis was determined to sequester feeding deterrent 
secondary metabolites at the surface of the sponge.  When samples comprised of inner 
layer sponge tissue spiked with discorhabdin G (1.24) were introduced to the tube feet of 
the sea star Perknaster fucus, they were rejected significantly more than samples not 
spiked with pure compound.
22-23
  Shahamin C (4.1), a diterpenoid from the sponge 
Aplyssilla polyhaphis was found to inhibit feeding of the wrasse Thalossoma 
lucasanum.
24
  Lippert et al. investigated chemical defenses against predators in a sub-
Artic fjord in identifying two pure compounds exhibiting feeding deterrence from 
Haliclona viscose and a feeding deterrent fraction from Hormanthia nodosa.
10,25
  The 
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tryptophan catabolite erebusinone (1.25), a pigment isolated from the yellow sponge 
Isodictya erinacea, caused significantly reduced molting and increased mortality when 
fed to sympatric predatory amphipods.
26
  Brown algal sex pheromones, a series of C11 
metabolites (4.2) and their degradation products, have been shown to frequently suppress 
amphipod feeding of the herbivorous amphipod Ampithoe longimana.
27
 
                         
4.1  Shahamin C     4.2 
 
4.3   Spongian diterpenoids from Dendrilla membranosa 
Sponges and sponge-consuming nudibranchs have been found to be a source of 
functionalized diterpenoids with a unique polycyclic carbon framework theoretically 
derived from the common spongian skeletal precursor 4.3.
28
 Gracilane (4.4), 
aplysulphurane (4.5) and glaciolane (4.6) represent degraded or rearranged backbones of 
spongian-derived precursor. These backbones have been isolated from several sponges, 
including Spongionella gracilis, Aplysilla glacialis, A. sulphuera and Dendrilla 
membranosa. The order Dictyoceratida has elaborated graciolane-derived compounds 
while all three backbones have been identified from the order Dendroceratida.
29
   
                         
   4.3  Spongian          4.4  Gracilane    4.5  Aplysulphurane     4.6  Glaciolane      
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D. membranosa is a unique sponge in the WAP community exhibiting tremendous 
coverage at depths from 2 to at least 40 m.  The slow growing, bright yellow sponge is a 
dominant sponge along the peninsula and around the continent rarely exhibiting signs of 
predation.
7
  The first reports of secondary metabolites from D. membranosa were from 
the laboratory of John Faulkner in 1987,
30
 several studies from around the Antarctic 
continent have elaborated additional chemistry from D. membranosa.
29-34
  From sponge 
collected in McMurdo Sound, Antarctica at a depth of 40 m, membranolide (4.7), 9,11-
dihyrogracilin A (4.8) and an anti-bacterial pigment (4.9) were isolated.
30,33
  Both 
diterpenoids exhibited mild anti-bacterial properties, and were suggested to serve as 
defensive metabolites though no ecological roles were studied at the time.
30
 
                                     
4.7  Membranolide      4.8  9,11-Dihyrogracilin A                     4.9 
 
Dendrillin (4.10) was also isolated from sponge collected near McMurdo Sound via 
SCUBA at depths near 40 m.
32
  Although MeOH extracts from D. membranosa displayed 
significant feeding deterrence towards the sea star Perknaster fuscus, a known Antarctic 
sponge predator, no deterrent effect was observed when samples spiked with dendrillin 
were introduced to the chemosensory tube-feet of the sea star.  From Terra Nova Bay at a 
depth of 60 m, researchers isolated dendrinolide (4.11) along with the known compound 
9,11-dihydrogracillin A.
34
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4.10  Dendrillin             4.11  Dendrinolide  
The first D. membranosa compounds reported from the Antarctic Peninsula were from 
specimens collected off King George Island in the South Shetlands, Antarctica, at depths 
of 35 m. Norditerpene gracilane 4.12, three aplysulphurane derivatives 4.13, 4.14, and 
4.15, along with known compounds membranolide and polyrhaphin D (4.16)
35
 were also 
isolated.
29
 
                         
            4.12                                       4.13          4.14 
                        
4.15   4.16  Polyrhaphin D 
 
From D. membranosa collected near Palmer Station, Ankisetty et al.
31
 isolated 
membranolides B (4.17), C (4.18), and D (4.19), along with known and related 
compounds membranolide, tetrahydroaplusulfurin-1 (4.20)
36
 and aplysulfurin (4.21).
37
  
Compounds 4.18 and 4.19 exhibited mild Gram-negative and antifungal activities.
31
  That 
aplysulfurin was found in collections with membranolides is noteworthy.   Originally 
isolated from the sponge Aplysilla sulphuvea from the waters of Eastern Australia, it was 
later isolated from the morphologically similar sponge Darwinella sp. collected from 
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New Zealand coastal waters.
36-37
  Stereochemical assignment for membranolides was 
based on ROESY correlations and from comparison to NMR data of aplysulfurin whose 
absolute configuration was demonstrated by X-ray crystallography. 
                         
4.17  Membranolide B              4.18  Membranolide C         4.19  Membranolide D     
 
                       
4.20  Tetrahydroaplysulfurin-1  4.21  Aplysulfurin 
               
4.4  Results and discussion on the characterization of the membranolides 
The impetus of the present study was to assess the feeding deterrent properties of the 
membranolides using a common sympatric omnivorous amphipod as a model consumer 
via feeding assays conducted in the field during the austral summer of 2010 (see section 
4.5). Efforts toward the isolation and characterization of the membranolides took part in 
two phases. In preparation for the 2010 field season, Dr. Jaime Heimbegner Noguez 
prepared several crude HPLC fractions consisting primarily of membranolide (4.7) and 
membranolide B (4.17) along with a mixture of unresolved membranolides to be used in 
bioassays.  Further HPLC separation in the field elaborated pure fractions of 4.7 and 4.17 
in addition to an impure fraction consisting of a mixture of membranolides.  At the time, 
lack of spectroscopic instrumentation in the field prevented full characterization of the 
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impure fraction. Upon returning to the home laboratory, additional iterations of RP HPLC 
on the impure fraction afforded membranolides E (4.22) and F (4.23). Additionally, 
LC/MS identified membranolide C and D (or epimers thereof, see sections 4.4.4 - 4.4.7) 
as minor metabolites from this fraction. 
                 
4.22  Membranolide E        4.23  Membranolide F 
As illustrated in Scheme 4.1, the second phase of isolation involved purification of NP 
MPLC fractions generated by Jason Cuce from D. membranosa collected in 2010.  
Additional NP MPLC (20% EtOAc/hexanes) followed by RP HPLC (60% ACN/H2O) 
provided new membranolides G (4.24; fraction F, Scheme 4.1; 22.2 mg) and H (4.25; 
fraction E, 5.3 mg), known compounds membranolide (4.7; fraction G, 19.3 mg), 
membranolides C (4.18; fraction D, 19.9 mg) and D (4.19; fraction C, 4.8 mg), and 
tetrahydroaplysulfurin-1 (4.20; fraction H, 52.3 mg), and an impure, uncharacterized 
compound (fraction B; 11.4 mg). 
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Scheme 4.1.  Isolation scheme and HPLC chromatogram for D. membranosa.  
 
 
aqueous crude
A       B       C       D       E        F       G       H        I         J        K
1.8     352    183   418    507    135     72      80     284     579  2600
RP gHPLC 60% CH3CN-100% CH3CN   400 mg
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organic crude
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CH2Cl2:MeOH (1:1)
NP gMPLC silica gel 
hexanes-EtOAc-MeOH
B     C     D      E      F      G     H      
11.4  4.8  19.9  5.3  22.2  19.3  52.3
mg
NP gMPLC 20% EtOAc-hexanes  1.2 g
fraction
mg
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4.4.1  Characterization of membranolide E (4.22) 
Membranolide E (4.22) was isolated as a clear oil with a molecular formula of C21H28O4 
established through HRESIMS ([M+H]
+
 : m/z 345.2060, calc. 345.2074), identical to 
membranolide B (4.17). The 
1
H and 
13
C NMR data exhibited general features similar to 
those observed for 4.17 including an aldehyde singlet H-16 (δH 10.1), doublet methyl H3-
17 (δH 1.88; J = 7.1 Hz), gem-dimethyl groups H3-18 (δH 0.60) and H3-19 (δH 0.99), 
singlet methyl H3-20 (δH 1.34) and methoxy H3-21 (δH 3.50). The only significant 
differences observed via NMR data is about C-15 and C-21, where the methine shift at δH 
7.24 (H-15) differs by ± 0.44 ppm compared to 4.17 suggesting 4.22 is an epimer. Aside 
from C-15 and C-21, all other carbon shifts differ by less than ± 1.1 ppm. Based on 
biosynthetic arguments and similarities to 
1
H and 
13
C NMR data about other stereocenters 
found in the membranolides, 4.22 is assigned as 7R, 10S and 15S.  To date, loss of sample 
has prevented full 2D data analysis and assignment of C-15 and C-21.  The only 
unaccounted for carbon shift is 29.7 ppm, a shift not within the expected range of 
methoxy carbon.  Table 4.1 lists NMR data tables for membranolides E (4.22) and F 
(4.23). 
            
4.22  Membranolide E        4.23  Membranolide F 
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Table 4.1.  NMR Data (CDCl3) of Membranolides E (4.22) and F (4.23)
a
 
 membranolide E (4.22) membranolide F (4.23) 
 δC δH δC δH HMBC 
1 39.8 1.51 (1H, m) 41.2 1.50 (1H, m) 20 
  2.24 (1H, m)  2.32 (1H, m)  
2 19.9 1.67 (1H, m) 19.9 1.65 (1H, m)  
  1.74 (1H, m)  1.83 (1H, m)  
3 39.8 1.33 (2H, m) 39.7 1.33 (2H, m) 19 
4 31.8   31.8   18,19 
5 50.5 1.58  50.6 1.56 (1H, m) 19, 20 
  2.07 (1H, m)  2.14 (1H, m)  
6 174.3  (1H, m) 177.6    
7 39.5 4.58  40.8 4.73 (1H, q, 6.7) 6, 8, 9, 14 
8 138.2  (1H, m) 137.5    
9 154.4   154.9    
10 40.5   40.3    
11 128.4 7.77  130.3 7.75 (1H, q, 8.3) 8, 10, 13 
12 134.1 7.75 (1H, m) 123.9 7.75 (1H, q, 8.3) 9, 14, 16 
13 130.5  (1H, m) 126.0    
14 134.0   145.1    
15 92.9 7.24  103.6 6.14 (1H, s) 13, 16, 21 
16 192.5 10.1 (1H, s) 168.6    
17 24.2 1.88 (1H, s) 17.7 1.73 (3H, d, 7.1) 6, 7, 8 
18 28.2 0.60 (3H, d, 7.1) 27.3 0.48 (3H, s) 19 
19 32.2 0.99  32.7 0.95 (3H, s)  
20 32.4 1.34  32.7 1.42 (3H, s) 9, 10 
21 und 3.50  56.5 3.59 (3H, s)  
22    56.5 3.59 (3H, s)  
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
 
4.4.2  Characterization of membranolide F (4.23) 
Membranolide F (4.23) was isolated as a clear oil with a molecular formula established as 
C21H28O5 through HRESIMS ([M+H]
+
 : m/z 361.1994, calc. 361.2010). The 
1
H NMR 
spectrum exhibited several key signals characteristic with that of the membranolide series 
including two protons δ 7.74 (H-11; H-12; J = 8.3 Hz) consistent with a tetrasubstituted 
benzene ring, doublet methyl H3-17 (δC 1.73; J = 7.1), gem-dimethyl groups H3-18 (δH 
0.48) and H3-19 (δH 0.95), and singlet methyl H3-20 (δH 1.42). The 
1
H NMR spectrum for 
H3-18 and H3-19 showed characteristic HMBC cross-peaks indicative of gem-dimethyl 
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motif at C-4 (δC 31.8) within the 1′,3′,3′-trimethylcyclohexane moiety.  The anomalous 
high-field chemical shift at H3-18 (observed for all membranolides) of the C-4 axial 
methyl signal in the cyclohexane ring is indicative of 1′,3′,3′-
trimethylcyclohexylbenzenes due to the proximity of that methyl in the anisotropic 
shielding zone of the aromatic ring.
30
 Assignment of this moiety was completed via 
HMBC correlations and comparison of 
13
C NMR data to that of all membranolides.
30-31
 
Connectivity to the aromatic ring from C-10 (δC 40.3) was established via HMBC 
correlations from H3-20 to aromatic C-9 (δC 154.9) (see Figure 4.2). Methine singlet H-
15 (δH 6.14) displays HMBC correlations to C-16 (δC 168.6) and C-21 (δC 56.5); three 
bond coupling to C-13 (δC 126.0) establishes the connectivity of the methoxy furanone 
moiety to the aromatic ring. Consistent with previous studies, spatial arrangement of 
methyl doublet H3-17 (δH 1.73; J = 7.1 Hz) and methine quartet H-7 (δH 4.73; J = 6.7) 
was established via ROESY correlations of H-7 to H-5b 
(δH 2.14), H3-20 and H-5a (δH 1.50) (in order of 
intensity).
31,38
 The stereochemistry of the methoxy 
furanone was established by observation of a ROESY 
correlations between H3-17 and H3-21 (δH 3.59), allowing 
for assignment as 7R, 10S and 15S. 
 
4.4.3 Characterization of fused furan membranolides 
From efforts to evolve pure membranolides for field assays, additional membranolides 
were isolated bearing two acetal carbons and two methoxyl signals with the same 
molecular formula (C22H32O5) and MS properties as membranolides C and D. 
Figure 4.2.  Key HMBC and 
COSY correlations for 
membranolide F (4.23). 
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4.4.4 Characterization of membranolide G (4.24) 
Membranolide G (4.24) was obtained as a faint, yellow oil with spectral data very similar 
to that of membranolide C (4.18). A formula of C22H32O5 was established via HRESIMS 
([M+Na]
+
: m/z 399.2158, calc. 399.2142). Key 
1
H NMR signals include gem-dimethyl 
groups H3-18 (δH 0.47) and H3-19 (δH 0.92), singlet methyl H3-20 (δH 1.38), doublet 
methyl H3-17 (δH 1.67; J = 7.2), quartet methine H-7 (δH 4.62, J = 6.7) and the pair of 
aromatic protons H-11 (δH 7.54) and H-12 (δH 7.20).  Two acetal methine signals H-15 
(δH 6.14) and H-16 (δH 6.30), along with two methoxyl methyl groups H3-21 (δH 3.40) 
and H3-22 (δH 3.31) are also characteristic of the fused furan membranolides C and D.  
From HSQC connectivity, COSY and HMBC correlations, the planar structure for 
membranolide G, and all fused furan membranolides, is established as shown in Figure 
4.3. 
 
Figure 4.3.  Key HMBC (→) and COSY (▬) correlations for fused furan 
membranolides. 
 
As previously discussed, the aplysulphurane core is stereodefined about C-10 and C-7 as 
all isomers exhibit the same spectroscopic characteristics about these centers.  ROESY 
correlations from H-7 to H-5b and H3-20 provide the spatial orientation to establish C-7 
as R.  The remaining two stereocenters (acetals C-15 and C-16) can be assigned on the 
basis of 2D-NOE experiments for the four possible isomers. ROESY correlations of H3-
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17 to either methine H-15 or methoxy H3-21 establish orientation about C-15.  The 
orientation of C-16 can be deduced from either ROESY correlations across the furan ring 
with H-16 or based on the strength of correlation from H-16 to H-12. As shown in Figure 
4.4 the α-orientation of methoxy H3-21 was established via ROESY correlation to H3-17, 
and from H3-17 to H3-18. Strong ROESY correlations of H-15 and H-16 along with weak 
correlation of H-12 to H-16 provide establish the α-orientation of methoxy H3-22.  
ROESY correlations of H3-21 to H3-22 appear to be present, but given that shifts for the 
two methoxy groups are close, distinguishing correlation from noise is difficult. The 
absolute configuration of 4.24 is therefore assigned 7R, 10S, 15S and 16R. 
 
Figure 4.4.  Key ROESY correlations for membranolide G (4.24). 
 
4.4.5 Characterization of membranolide H (4.25) 
Membranolide H (4.25) was obtained as a faint, yellow oil with spectral data highly 
similar to that of membranolide C (4.18) and G (4.24). As with 4.24, a formula of 
4.24 Membranolide G
H-15/H-16
H3-17/H3-21
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C22H32O5 was established via HRESIMS ([M+Na]
+
: m/z 399.2154, calc. 399.2142).  The 
1
H and 
13
C NMR data and 2D NMR connectivity and correlations unambiguously 
establish the planar structure for membranolide H as that of the fused furan 
membranolides. As shown in Figure 4.5, ROESY correlations from H3-17 (δH 1.57; J = 
7.2) to H3-18 (δH 0.35) and to acetal methine H-15 (δH 6.04) establish the β-orientation of 
methoxy H3-21 (δH 3.38). Strong ROESY correlations from H-12 (δH 7.19) to H-16 (δH 
5.97) imply a β-orientation of methoxy H3-22 (δH 3.34). And though not clearly 
distinctive given the proximity in shift, correlations from H-15 to H-16 appear present. 
The proximity in shift of acetal methoxyl methyl groups do not allow for assignment of a 
correlation. The configuration of 4.25 is therefore assigned 7R, 10S, 15R and 16S. 
 
Figure 4.5.  ROESY correlations and spectrum for membranolide H (4.25). 
4.25 Membranolide H
H-12/H-16 H3-17/H-15
H-15/H-16
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Thus, after careful interpretation of the data 4.25 is assigned the same configuration as 
membranolide D necessitating a reinvestigation of the original NMR data for 
membranolides C and D. 
4.4.6 Reinvestigation of membranolides C and D 
Comparison of the spectral data on file for membranolide C (“DM-2 30 May 03 
Membranolide C”) with that reported by Ankisetty et al.31 finds discrepancy for H3-17 
whereby the reported shift of 1.59 ppm is found at 1.72 ppm (see Figure 4.6).  As to 
whether this error arises from a clerical error, or if the data file is mislabeled in unknown. 
 
Figure 4.6.  
1
H NMR expanded for region of interest from membranolide C data file. 
 
Ankisetty et al. goes on to assign stereochemistry “by observation of a NOESY 
correlation from H-15 to H3-22. The relative position of H-15 to the remaining 
stereocenters was suggested by a NOESY correlation to H3-17.” As shown in Figure 4.7, 
the NOESY data is of poor quality and difficult to interpret; however, some observations 
can be made. The NOESY spectrum does not contain a correlation from H-15 to H-17 
and any correlation assigned from acetal methines to methyoxy groups are ambiguous. H-
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15 and H-16 overlap and there will be correlations from the methoxy group to the 
methine that share the same carbon masking any correlations about the furan ring. 
 
Figure 4.7.  NOESY spectrum from membranolide C data file. 
The spectral data for membranolide D was acquired in C6D6 to resolve coincident signals 
for methines H-15 and H-16 (δH 6.2) in CDCl3.  Researchers do not mention if C6D6 was 
able to resolve coincident signals for membranolide C.  Ankisetty et al. again comment 
“the NOESY data confirmed the stereochemistry around C-16 in which the methoxy 
group is β. NOESY correlations were observed from H-15 to H-16 and -17 and from H-7 
to H3-22.”  Investigation with the NMR data on file revealed several issues.  Of data 
acquired in C6D6 only DM-2, the name used for membranolide C, was present.  Chemical 
shifts from this data match that reported in the article for membranolide D, creating a 
possibility that data for membranolide C was reported twice.  Furthermore, only ROESY 
is found within the data folder.  Finally, as shown in Figure 4.8, reported correlations 
from H-15 to H-16 and H3-17 are not present; however, correlations from H3-17 to H3-22 
are.  The reported correlation from H-7 to H3-22 is not real as evidenced with orientation 
X
H3-17
H-15
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of the red line in Figure 4.8; this correlation is very unlikely given the known spatial 
orientation of H-7 and distance to H3-22. 
 
Figure 4.8.  ROESY spectrum for DM-2 (membranolide D) acquired in C6D6. 
 
4.4.7 Revision of membranolide C (4.26) 
Fraction AM5-100-D exhibits near identical 
1
H NMR and 
13
C NMR data to that reported 
for membranolide C as shown in Figure 4.9. 
XX
X
4.19 Membranolide D (proposed)
H-15/H-16
H3-21/H-7
H3-22/H-7
H3-17/H3-21
H3-17/H-15
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Figure 4.9.  Comparison of 
1
H NMR spectrum for AM5-100-D (top) versus 
membranolide C (bottom). 
 
ROESY correlations from H3-17 (δH 1.66) to H3-18 (δH 0.47) and to H3-21 (δH 3.41) 
establish the α-orientation of the methoxy group and strong correlation from H-12 (δH 
7.22) to H-16 (δH 5.84) establish the β-orientation of methoxy H3-22 (δH 3.49) as shown 
in Figure 4.10. Additional ROESY correlations across the furan ring (shown in zoomed 
region of Figure 4.10) are difficult to resolve given the fact that correlations from the 
methine proton to the methoxy group (i.e., H-15 to H3-21) on the same carbon are strong 
and the proximity of shift of the two methoxy groups are very similar. However, close 
inspection of the ROESY spectrum appears to provide evidence that correlations across 
the furan ring from H-15 to H3-22 are present. Stereochemical reassignment of 
membranolide C (4.26) is therefore 7R, 10S, 15S and 16S. 
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Figure 4.10.  ROESY spectrum of membranolide C (4.26). 
 
4.4.8 Revision of membranolide D (4.27) 
Fraction AM5-100-Cb exhibits near identical 
1
H NMR (see Figure 4.11) and 
13
C NMR 
data to that found in data files for membranolide D. ROESY correlations for AM5-100-
Cb agree with the only remaining unassigned furan epimeric configuration.  Correlations 
from H3-17 (δH 1.57; J = 7.2) to H3-18 (δH 0.36) and to H-15 (δH 6.32) establish 
orientation at C-15 (δC 106.2). As discussed in section 4.4.7 disambiguating ROESY 
correlations across the furan ring (shown in zoomed region of Figure 4.12) are difficult to 
resolve. However, close inspection of the ROESY spectrum appears to provide evidence 
that correlations across the furan ring from H-15 to H3-22 and from H-16 to H3-21 are 
present as correlations extend to both methoxy groups from the methine protons. Lack of 
strong correlations from H-12 (δH 7.23) to H-16 (δH 6.24) suggest a R configuration for 
4.26 Membranolide C
H-12/H-16
H3-17/H3-21
H-15/H3-21
H-16/H3-22
H-15/H3-22
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C-16 (δC 105.9).  Methoxy H3-21 and H3-22 (δC 3.40) resolve within 0.03 ppm leaving 
assignment of correlations about the furan ring ambiguous. 
 
Figure 4.11.  
1
H NMR comparison of AM5-100-Cb (top) and membranolide D (bottom) 
in CDCl3. 
 
 
Figure 4.12.  ROESY spectrum of membranolide D (4.27). 
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4.4.9 Characterization of membranolides as artifacts from extraction 
The evolution of additional epimeric membranolide compounds bearing the fused furan 
ring rekindled concern as to whether they are artifacts of the isolation process.  In the 
original study, Ankisetty et al.
31
 tested that theory by extracting sponge in ethanol, but 
found no evidence of metabolites bearing the ethyl acetal group. In our current study, a 
comparison of extracts using MeOH or CH2Cl2 noted significant differences via LC/MS 
chromatography. As shown in Figure 4.13 frame a, extraction in MeOH evolved 
approximately 5 peaks from RT 3 - 8 min. Extraction in CH2Cl2 (frame b) elaborate only 
3 significant peaks within the same RT. Furthermore, the uncharacterized peak eluting at 
6.3 min (m/z 313.1) is found in much greater abundance than the methanolic extract. As 
shown in frame C, treatment of the extract generated from CH2Cl2 with MeOH (48 hours) 
evolves additional peaks not found within initial extracts and the loss of m/z 313.1. 
Investigation of the additional peaks reveals characteristic ions for the fused furan 
membranolides (i.e., m/z 345.2 (see 4.28) and m/z 399.2). 
 
Figure 4.13.  LC/MS chromatogram comparison of extraction methods. 
MeOH extracted
CH2Cl2 extracted
CH2Cl2 extracted
MeOH treatment
a
b
c
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The evolution of m/z 348.3 (4.28) representing a molecular formula of C21H26D3O4 was 
identified after treatment of extract with CD3OD verifying that the fused furan 
membranolides are non-natural products that result from extraction in methanol. 
 
4.28 
To determine what compound(s) membranolides C, D, G and H derive from, lyophilized 
sponge was processed as described by Scheme 4.1 with the exclusion of methanol during 
the extraction. A fraction (AM590D2) with the same molecular ion via LRESIMS (m/z 
313.3) that was lost during treatment with MeOH was isolated.  Via 
1
H and 
13
C NMR 
data comparison, the compound was identified as that of known compound aplysulphurin 
(4.21) as shown in Table 4.2. From HRESIMS, the molecular formula of C22H28O5 
([M+H]
+
: m/z 373.2030, calc. 373.2030) was verified.  Figure 4.14 illustrates a 
mechanism for methanolysis of the acetals of aplysulfurin to provide the methoxyl 
groups, acetals and carboxylic acid of membranolides C, D, G and H. 
 
4.21  Aplysulphurin 
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Table 4.2.  Comparison of 
1
H and 
13
C NMR Data of Aplysulfurin (4.21) and 
AM590D2 in CDCl3
a 
position 4.21 δC 4.21 δH AM590D2 δC AM590D2 δH Δ δC  Δ δH  
1 38.6 1.45 38.6 1.39 0.0 0.06 
  2.27  2.22  0.05 
2 19.1 1.65 19.2 1.60 -0.1 0.05 
  1.71  1.64  0.07 
3 39.4 1.27 39.5 1.21 -0.1 0.06 
  1.33  1.26  0.07 
4 31.7  31.5  0.2  
5 50.8 1.54 50.9 1.48 -0.1 0.06 
  1.98  1.95  0.03 
6 170.7  170.8  -0.1  
7 41.6 4.40 41.6 4.35 0.0 0.05 
8 131.9  131.7  0.2  
9 148.7  148.7  0.0  
10 38.9  39.0  -0.1  
11 129.2 7.52 129.3 7.48 -0.1 0.04 
12 122.3 7.36 122.4 7.32 -0.1 0.04 
13 133.3  133.3  0.0  
14 137.8  137.8  0.0  
15 100.3 7.01 99.9 7.04 0.4 -0.03 
16 101.9 7.27 101.7 7.22 0.2 0.05 
17 17.3 1.76 17.0 1.71 0.3 0.05 
18 27.5 0.52 27.5 0.46 0.0 0.06 
19 32.5 0.97 32.6 0.91 -0.1 0.06 
20 32.7 1.23 32.8 1.17 -0.1 0.06 
CO2CH3 169.6  169.7  -0.1  
CO2CH3 20.8 2.17 20.9 2.10 -0.1 0.07 
a 
For 
1
H, 500 MHz, ppm; for 
13
C, 125 MHz, ppm. 
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Figure 4.14.  Proposed methanolysis mechanism for generation of membranolides C, D, 
G and H from aplysulphurin. 
 
 
4.5   Results and discussion for feeding assay 
Previous investigations have demonstrated that extracts and fractions of D. membranosa, 
significantly deter feeding against the omnivorous amphipod Gondogeneia antarctica.
4
 
To assess the defensive nature of the pure compounds, artificial food discs spiked with 
membranolide (4.7), membranolide B (4.17), and mixture of membranolide E (4.22) and 
F (4.23) (also containing minor amounts of fused furan membranolides) were evaluated 
in the amphipod feeding assay. The omnivorous amphipod Gondogeneia antarctica 
displayed feeding deterrence against alginate food containing membranolide (P = 0.005) 
as shown in Figure 4.15.  G. antarctica showed modest and insignificant feeding 
deterrence to food containing membranolide B (P = 0.241), and membranolides E & F (P 
= 0.386 ).   
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Figure 4.15.  Results of bioassays offering artificial foods containing membranolides to 
the sympatric amphipod Gondogeneia antarctica. Means ± standard error of mean. 
Asterisks indicate significant differences (P≤0.05) between extract and control with 
controls significantly preferred to extracts.  Based on Wilcoxon signed-ranks test. 
 
Although the narrative to describe feeding deterrence of the metabolites from D. 
membranosa is incomplete, the observation that the major metabolite membranolide 
significantly inhibits feeding by the amphipod is noteworthy.  Membranolide has been 
isolated from sponges collected in diverse locations from Antarctic and previously 
implicated to serve as a defensive metabolite.
30
 Research herein verifies the defensive 
nature of the compound by directly deterring feeding by amphipods.  The ecological roles 
of membranolide B, E and F remained unclear. The observation of insignificant feeding 
deterrence from these compounds as well as the presence methyl acetal functionalities 
raise the possibility that these compounds are non-natural products. 
 
4.6 Research summary and future directions 
Dendrilla membranosa is a dominant demosponge that prior studies have shown is rarely 
preyed upon and deters feeding against amphipods, the principal mesograzers of the 
Western Antarctic Peninsula. To assess the defensive nature of the pure compounds, 
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artificial food disks spiked with membranolides were evaluated in the feeding assay 
against the omnivorous amphipod Gondogeneia antarctica. Only artificial food 
containing membranolide exhibited significant feeding deterrence. Membranolide is a 
major metabolite which supports the hypothesis that the producing sponge must defend 
itself against the high density of amphipods found in the Antarctic benthos. The extent to 
which other natural products identified from D. membranosa (i.e., aplysulfurin, 
tetrahydroaplysulfurin-1) deter amphipod feeding remains to be fully investigated. 
Experiments to quantitate differences in metabolite concentrations at depths within and 
across locations have begun by researchers in our lab. 
The research reported herein demonstrates that membranolides C and D were originally 
misassigned. Reevaluation of new extracts resulted in additional fused furan 
membranolides G and H, and allowed complete characterization of the four epimers.  
Extraction of sponge in CD3OD resulted in incorporation of a deuterated methyl group as 
evidenced from LC/MS chromatograms establishing that these metabolites are artifacts of 
the experimental method. These compounds arise from a singular, unstable metabolite 
with a m/z of 313.3 as evidenced from LC/MS. Re-extraction of the sponge sans 
methanol identified this compound as aplysulphurin, previously identified from WAP 
collections of D. membranosa.  
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Chapter 5.  Experimental 
5.1 General procedures 
HPLC was performed on a Shimadzu LC-8A multisolvent delivery system connected to a 
Shimadzu SPD-10A UV-VIS tunable absorbance detector and using either a preparative 
SunFire Prep Silica OBD column (19 X 150 mm, 5 μm) or Phenomenex Luna 5μ Silica 
(2) column (250 X 10 mm) for normal phase chromatography and either a preparative 
YMC-Pack ODS-AQ C-18 column (250 X 20 mm) or Phenomenex Luna 5μ C18 (2) 
column (250 X 4.6 mm) for reversed-phase chromatography. Thin layer chromatography 
(TLC) was carried out using Whatman normal phase silica gel 60Å Partisil®. TLC plates 
were visualized with 5% phosphomolybdic acid in ethanol (EtOH) with heating and/or 
UV (254 nm). Extracts were chromatographed on a Teledyne Isco Combiflash 
Companion medium pressure liquid chromatography (MPLC) instrument using normal 
phase silica gel cartridges purchased from Teledyne Isco. Specific rotations were 
measured on an Autopol IV automatic polarimeter using Na lamp corrected to 20°C. 
Infrared and ultraviolet spectra were obtained with a Nicolet Avatar Smart Miracle 
320FT-IR and Varian Cary 50 Bio Spectrophotometer, respectively. Low-resolution mass 
spectrometry (LRESIMS) data were recorded on an Agilent 1100 series system equipped 
with an Aglient LC/MSD VL electrospray ionization mass spectrometer. High resolution 
mass spectrometry (HRESIMS) data were obtained on an Agilent 6210 LC/MSD TOF 
electrospray ionization mass spectrometer.  
1
H and 
13
C NMR spectra were recorded on a 
Varian 500 MHz or 600 MHz instrument using residual protonated solvent as 
1
H internal 
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standard (δ 7.27) or 13C absorption lines of solvents for 13C internal standard (δ 77.0). 
NMR data was obtained in CDCl3 (Sigma-Aldrich). 
 
5.1.1 Collection of biological materials 
Collection of the nudibranch Austrodoris kerguelenensis, the rhodophyte Gigartina 
skottsbergii, the sponge Dendrilla membranosa was done by hand via SCUBA within 3.5 
km of Palmer Station on Anvers Island off the Western Antarctic Peninsula (64° 46.5’ S, 
64° 03.3’ W) at depths between 3 - 40 m. All specimens were immediately frozen while 
taxonomic vouchers of the sponge were preserved in 70% EtOH.  The omnivorous, 
sponge-consuming amphipod Gondogeneia antarctica was obtained by collecting 
macroalgae at depths of 3 - 10 m via SCUBA at a various sites within the Palmer Station 
vicinity. The brown alga Desmarestia menziesii was the most common algal source. 
Individuals of G. antarctica were sorted from other algal-associated mesofauna and 
maintained in 4L Nalgene bottles with mesh windows that facilitates water transfer while 
retaining amphipods.  The amphipod bottles were floated in flow-through seawater 
aquaria at approximately 1°C.  Identifications were made by Prof. Bill J. Baker 
(University of South Florida), Prof. Charles D. Amsler (University of Alabama at 
Birmingham), and Prof. James B. McClintock (University of Alabama at Birmingham) 
 
5.2 Experimental supporting Chapter 2 
5.2.1 Collection protocol for nudibranchs 
Freshly collected nudibranchs were placed onto a measuring board, a label with their 
appropriate collection number enclosed in a sealed plastic bag was placed above the 
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specimen and a photo was taken.  Length and width measurements, along with color were 
recorded. A small excision (0.5 - 1.0 cm in length) of the foot was made and placed into 
an eppendorf tube with 95% nondenatured EtOH and stored at -20 °C.  Each nudibranch 
was gently blotted dry and its mass recorded, then it was placed in a sealing baggie along 
with the sealed bag containing their individual label followed by storage at -20 °C. 
 
5.2.2 Bulk isolation of palmadorins from the Antarctic nudibranch Austrodoris 
kerguelenensis 
Thawed nudibranchs (approximately 70 organisms, 660 g) were extracted 3X with 
CH2Cl2:MeOH (1:1) for 24h. After concentration under reduced pressure, a gummy, dark 
solid (35 g) was obtained. The solid was reconstituted in EtOAc and partitioned against 
H2O three times; the organic layer was separated, dried and concentrated leaving a 
gummy, dark solid (1.4 g). This lipophilic crude was further purified using NP MPLC 
with a linearly increasing polarity gradient from 100% hexanes to 100% EtOAc over a 
period of 30 minutes on silica gel deriving 10 fractions. Fractions with 
1
H NMR signals 
indicative of terpene glycerides (see sections 2.3.1 and 2.3.2) were pooled (3-9). Further 
purification of the pooled fractions continued by RP HPLC on C18 by gradient elution 
starting with 60% Aq. MeOH for a period of ten minutes, followed by a linear 
progression to 100% MeOH over 35 minutes affording crude palmadorins. Separation of 
these subfractions continued by HPLC, first on SiO2 using EtOAc:hexanes (4:6) and then 
on C18 with MeCN:H2O (7.5:2.5) to provide palmadorin A (2.18, 9.0 mg, 0.0014%), B 
(2.19, 8.1 mg, 0.0012%), C (2.20, 3.4 mg, 0.00051%), D (2.32, 36.2 mg, 0.0055%), E 
(2.33, 3.0 mg, 0.00045%), F (2.34, 2.9 mg, 0.00044%), G (2.35, 1.5 mg, 0.00023%), H 
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(2.36, 3.7 mg, 0.00056%), I (2.37, 1.9 mg, 0.00029%), J (2.38, 0.9 mg, 0.00014%), K 
(2.39, 0.6 mg, 0.000091%), L (2.40, 0.8 mg, 0.00012%), M (2.41, 10.1 mg, 0.0015%), N 
(2.42 7.8 mg, 0.0012%), O (2.43, 5.0 mg, 0.00076%), P (2.44, 1.4 mg, 0.00021%), Q 
(2.45, 1.3 mg, 0.0002%), R (2.46, 2.1 mg, 0.00032%) and S (2.47, 2.4 mg, 0.00036%).  
NMR data matched that of previously reported palmadorins (see Chapter 2, ref. 30). 
 
Palmadorin D (2.32).  Colorless oil; [α]20D +15 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 228 
(3.44) nm; IR (thin film) 3364 (br), 2927, 1716, 1641, 1149 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment):  5.68 (1H, s, H-14), 4.52 (2H, s, H2-
18), 4.21 (2H, m, H2-1′), 3.95 (1H, m, H-2′), 3.67 (2H, m, H2-3′), 2.30 (1H, m, H-3a), 
2.16 (3H, s, H3-16), 2.12 (1H, m, H-3b), 2.00 (1H, m, H-12a), 1.91 (2H, m, H2-2), 1.88 
(1H, m, H-12b), 1.62 (1H, m, H-6b), 1.53 (1H, m, H-6a), 1.52 (1H, m, H-1b), 1.50 (1H, 
m, H-7b), 1.46 (1H, m, H-7a), 1.46 (1H, m, H-1a), 1.44 (1H, m, H-11b), 1.43 (1H, m, H-
8), 1.36 (1H, m, H-11a), 1.07 (1H, m, H-10), 1.06 (3H, s, H3-19), 0.82 (3H, d, 6.4, H3-
17), 0.76 (3H, s, H3-20); See Table 2.2; LRESIMS m/z 401.2 (100, [M+Na]
+
), 259.2 (10); 
HRESIMS m/z 379.2848 [M+H]
+
 (C23H39O4 requires 379.2843). 
 
Palmadorin E (2.33).  Colorless oil; [α]20D +6 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 234 
(4.31) nm; IR (thin film) 3396 (br), 2925, 1717, 1214 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
δH (integration, multiplicity, assignment): 5.71 (1H, s, H-3), 5.68 (1H, s, H-14), 4.21 (2H, 
m, H2-1′), 4.12 (1H, m, H-7), 3.96 (1H, m, H-2′), 3.67 (2H, m, H2-3′), 2.51 (1H, m, H-
1b), 2.35 (1H, m, H-1a), 2.23 (1H, m, H-6b), 2.18 (3H, s, H3-16), 1.94 (2H, m, H2-12), 
1.94 (3H, s, H3-18), 1.92 (1H, m, H-10), 1.56 (1H, m, H-6a), 1.56 (1H, m, H-8), 1.45 
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(2H, m, H2-11), 1.42 (3H, s, H3-19), 1.11 (3H, s, H3-20), 1.07 (3H, d, 7.1, H3-17); See 
Table 2.2; LRESIMS m/z 431.2 (100, [M+Na]
+
), 409.2 (15), 391.2 (20); HRESIMS m/z 
409.2581 [M+H]
+
 (C23H37O6 requires 409.2585. 
 
Palmadorin F (2.34).  Colorless oil; [α]20D +41 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 229 
(4.70) nm; IR (thin film) 3400 (br), 3019, 1718 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δH 
(integration, multiplicity, assignment): 5.71 (1H, s, H-14), 5.17 (1H, s, H-3), 4.22 (2H, m, 
H2-1′), 4.05 (1H, m, H-7), 3.96 (1H, m, H-2′), 3.67 (2H, m, H2-3′), 2.18 (3H, s, H3-16), 
2.12 (1H, m, H-6a), 2.09 (1H, m, H-2b), 1.97 (2H, m, H2-12), 1.92 (1H, m, H-2a), 1.64 
(3H, s, H3-18), 1.60 (2H, m, H2-1), 1.55 (1H, m, H-8), 1.51 (1H, m, H-11b), 1.40 (1H, m, 
H-10), 1.40 (1H, m, H-6a), 1.36 (1H, m, H-11a), 1.31 (3H, s, H3-19), 1.04 (3H, d, 7.1, 
H3-17), 1.03 (3H, s, H3-20); See Table 2.2; LRESIMS m/z 417.3 (100, [M+Na]
+
), 377.2 
(25); HRESIMS m/z 417.2619 [M+Na]
 +
 (C23H38O5Na requires 417.2617) 
 
Palmadorin G (2.35).  Colorless oil; [α]20D +13 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 230 
(4.52) nm; IR (thin film) 3400 (br), 3018, 2969, 1710, 1680, 1214 cm
-1
; 
1
H NMR (500 
MHz, CDCl3) δH (integration, multiplicity, assignment): 5.73 (1H, s, H-3), 5.68 (1H, s, 
H-14), 4.20 (2H, m, H2-1′), 3.96 (1H, m, H-2′), 3.67 (2H, m, H2-3′), 2.37 (2H, m, H2-1), 
2.16 (3H, s, H3-16), 2.00 (1H, m, H-12b), 1.90 (3H, s, H3-18), 1.89 (1H, m, H-12a), 1.88 
(2H, m, H2-6), 1.86 (1H, m, H-10), 1.51 (1H, m, H-8), 1.52 (2H, m, H2-7), 1.44 (2H, m, 
H2-11), 1.13 (3H, s, H3-17), 0.85 (3H, d, 6.2, H3-19), 0.83 (3H, s, H3-20); See Table 2.2; 
LRESIMS m/z 415.2 (100, [M+Na]
+
), 393.2 (17), 375.2 (23); HRESIMS m/z 393.2629 
[M+H]
+
 (C23H37O5 requires 393.2641). 
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Palmadorin H (2.36).  Colorless oil; [α]20D +16 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 227 
(4.85) nm; IR (thin film) 3400 (br), 2969, 2864, 1712, 1640, 1488, 1382, 1281, 1147, 
1100, 1040, 975 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δH (integration, multiplicity, 
assignment): 5.71 (1H, s, H-14), 5.17 (1H, s, H-3), 5.11 (1H, m, H-2′), 4.30 (2H, m, H2-
1′), 4.05 (1H, m, H-7), 3.77 (2H, m, H2-3′), 2.18 (3H, s, H3-16), 2.12 (1H, m, H-6b), 2.10 
(3H, s, CO2CH3), 2.08 (1H, m, H-2b), 2.02 (1H, m, H-2a), 1.97 (2H, m, H2-12), 1.64 (3H, 
s, H3-18), 1.60 (2H, m, H2-1), 1.55 (1H, m, H-8), 1.51 (1H, m, H-11b), 1.41 (1H, m, H-
11a), 1.41 (1H, m, H-6a), 1.40 (1H, m, H-10), 1.30 (3H, s, H3-17), 1.04 (3H, d, 7.3, H3-
19), 1.03 (3H, s, H3-20); See Table 2.2; LRESIMS m/z 459.3 (100, [M+Na]
+
), 419.2 (15); 
HRESIMS m/z 459.2715 [M+Na]
+
 (C25H40O6Na requires 459.2717). 
 
Palmadorin I (2.37).  Colorless oil; [α]20D +11 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 234 
(4.20) nm; IR (thin film) 3400 (br), 3019, 1710, 1214 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
δH (integration, multiplicity, assignment): 5.81 (1H, s, H-3), 5.72 (1H, s, H-14), 4.22 (2H, 
m, H2-1′), 3.96 (1H, m, H-2′), 3.68 (2H, m, H2-3′), 2.63 (1H, m, H-8), 2.60 (1H, m, H-
6b), 2.48 (1H, m, H-6a), 2.48 (1H, m, C-10), 2.47 (1H, m, H-1b), 2.19 (3H, s, H3-16), 
2.08 (2H, m, H2-12), 1.90 (3H, s, H3-18), 1.63 (1H, m, H-11b), 1.54 (1H, m, H-1a), 1.43 
(1H, m, H-11a), 1.12 (3H, s, H3-19), 0.99 (3H, d, 6.6, H3-17), 0.82 (3H, s, H3-20); See 
Table 2.2; LRESIMS m/z 429.2 (100, [M+Na]
+
), 407.2 (12), 389.2 (20); HRESIMS m/z 
429.2248 [M+Na]
+
 (C23H34NaO6 requires 429.2248). 
 
Palmadorin J (2.38). Colorless oil; [α]20D +8 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 268 
(3.92) nm; IR (thin film) 3400 (br), 2930, 1715, 1214 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
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δH (integration, multiplicity, assignment): 5.71 (1H, s, H-14), 5.70 (1H, s, H-3), 4.94 (1H, 
m, H-1′), 4.11 (1H, m, H-7), 3.86 (2H, m, H2-2′), 3.86 (2H, m, H2-3′), 2.50 (1H, m, H-
1b), 2.33 (1H, m, H-1a), 2.23 (1H, m, H-6b), 2.18 (3H, s, H3-16), 1.97 (1H, m, H-12b), 
1.93 (3H, s, H3-18), 1.93 (1H, m, H-10), 1.90 (1H, m, H-12a), 1.57 (1H, m, H-8), 1.54 
(1H, m, H-6a), 1.50 (1H, m, H-11b), 1.42 (3H, s, H3-19), 1.38 (1H, m, H-11a), 1.10 (3H, 
s, H3-20), 1.07 (3H, d, 7.2, H3-17); See Table 2.2; LRESIMS m/z 431.2 (100, [M+Na]
+
), 
391.2 (30); HRESIMS m/z 431.2422 [M+Na]
+
 (C23H36O6Na requires 431.2404). 
 
Palmadorin K (2.39).  Colorless oil; 
1
H NMR (500 MHz, CDCl3) δH (integration, 
multiplicity, assignment): 5.81 (1H, s, H-3), 5.72 (1H, s, H-14), 4.96 (1H, m, H-2′), 3.88 
(2H, m, H2-1′), 3.88 (2H, m, H2-3′), 2.63 (1H, m, H-8), 2.60 (1H, m, H-6b), 2.48 (1H, m, 
H-6a), 2.48 (1H, m, C-10), 2.47 (1H, m, H-1b), 2.19 (3H, s, H3-16), 2.08 (2H, m, H2-12), 
1.90 (3H, s, H3-18), 1.63 (1H, m, H-11b), 1.54 (1H, m, H-1a), 1.43 (1H, m, H-11a), 1.12 
(3H, s, H3-19), 0.99 (3H, d, 6.6, H3-17), 0.82 (3H, s, H3-20); See Table 2.2; LRESIMS 
m/z 429.2 (100, [M+Na]
+
), 407.2 (12), 389.2 (20); HRESIMS m/z 429.2256 [M+Na]
+
 
(C23H34NaO6 requires 429.2248). 
 
Palmadorin L (2.40).  Colorless oil; [α]20D +0 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 269 
(3.84) nm; IR (thin film) 3390 (br), 3019, 1700, 1214 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
δH (integration, multiplicity, assignment): 5.72 (1H, s, H-14), 4.21 (2H, m, H2-1′), 3.95 
(1H, m, H-2′), 3.83 (1H, d, 10.7, H-18a), 3.67 (2H, m, H2-3′), 3.62 (1H, d, 10.7, H-18b), 
2.18 (3H, s, H3-16), 2.05 (2H, m, H2-12b), 1.92 (1H, m, H-10), 1.83 (1H, m, H-6b), 1.82 
(1H, m, H-3b), 1.64 (2H, m, H2-2), 1.64 (1H, m, H-1b), 1.52 (1H, m, H-3a), 1.49 (1H, m, 
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H-11b), 1.47 (1H, m, H-8), 1.44 (1H, m, H-1a), 1.40 (2H, m, H2-7), 1.37 (1H, m, H-11a), 
1.32 (1H, m, H-6a), 0.99 (3H, s, H3-19), 0.80 (3H, d, 6.6, H3-17), 0.74 (3H, s, H3-20); See 
Table 2.2; LRESIMS m/z 456.2 (10), 455.2 (37), 454.2 (25), 453.2 (100, [M+Na]
+
), 293.1 
(10); HRESIMS m/z 453.2392 [M+Na]
+
 (C23H39ClO5Na requires 453.2379). 
 
Palmadorin M (2.41).  Colorless oil; [α]20D -18 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 230 
(4.38) nm; IR (thin film) 3429 (br), 2935, 1696, 1645, 1214 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment): 5.72 (1H, s, H-14), 4.93 (1H, s, H-2′), 
4.71 (1H, t, H-17b), 4.52 (1H, t, H-17a), 3.83 (2H, m, H2-1′), 3.83 (2H, m, H2-3′), 2.18 
(1H, m, H-7b), 2.15 (3H, s, H3-16), 2.04 (1H, m, H-7a), 2.04 (1H, m, H-12b),  1.87 (1H, 
m, H-12a), 1.70 (1H, m, H-11b), 1.63 (1H, m, H-2b), 1.62 (1H, m, H-6b), 1.53 (1H, m, 
H-1b), 1.51 (1H, m, H-9), 1.47 (1H, m, H-11a), 1.44 (1H, m, H-2a), 1.42 (1H, m, H-3b), 
1.29 (1H, m, H-6a), 1.28 (1H, m, H-5), 1.18 (1H, m, H-3a), 1.06 (1H, m, H-1a),  0.92 
(3H, s, H3-20), 0.88 (3H, s, H3-19), 0.81 (3H, s, H3-18); See Table 2.2; LRESIMS m/z 
401.2 (100, [M+Na]
+
), 379.2 (7), 267.2 (10), 259.2 (7); HRESIMS m/z 401.2648 
[M+Na]
+
 (C23H38O4Na requires 401.2668). 
 
Palmadorin N (2.42).  Colorless oil; [α]20D -10 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 230 
(4.53) nm; IR (thin film) 3400 (br), 2935, 1711, 1644, 1214 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment): 5.69 (1H, s, H-14), 4.72 (1H, s, H-
17b), 4.51 (1H, s, H-17a) 4.19 (2H, s, H2-1′), 3.94 (1H, m, H-2′), 3.69 (2H, m, H2-3′), 
2.19 (1H, m, H-7b), 2.17 (3H, s, H3-16), 2.04 (1H, m, H-7a), 2.06 (1H, m, H-12b),  1.88 
(1H, m, H-12a), 1.71 (1H, m, H-11b), 1.63 (1H, m, H-2b), 1.62 (1H, m, H-6b), 1.53 (1H, 
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m, H-1b), 1.52 (1H, m, H-9), 1.47 (1H, m, H-11a), 1.44 (1H, m, H-2a), 1.41 (1H, m, H-
3b), 1.29 (1H, m, H-6a), 1.29 (1H, m, H-5), 1.17 (1H, m, H-3a), 1.06 (1H, m, H-1a), 0.94 
(3H, s, H3-20), 0.89 (3H, s, H3-19), 0.82 (3H, s, H3-18); See Table 2.2; LRESIMS m/z 
401.2 (100, [M+Na]
+
); HRESIMS m/z 379.2841 [M+H]
+
 (C23H38O4 requires 379.2848). 
 
Palmadorin O (2.43).  Colorless oil; [α]20D -10 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 230 
(4.34) nm; IR (thin film) 3380 (br), 3019, 2864, 1710, 1214 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment): 5.71 (1H, s, H-14), 5.11 (1H, s, H-2′), 
4.72 (1H, bs, H-17b), 4.53 (1H, bs, H-17a), 4.30 (2H, m, H2-3′), 3.77 (2H, m, H2-1′), 2.19 
(2H, m, H2-7), 2.16 (3H, s, H3-16), 2.09 (3H, s, CO2CH3), 2.07 (1H, m, H-12b), 1.89 (1H, 
m, H-12a), 1.70 (1H, m, H-11a), 1.64 (1H, m, H-2b), 1.64 (1H, m, H-6b), 1.52 (1H, m, 
H-1b), 1.52 (1H, m, H-9), 1.50 (1H, m, H-11a), 1.45 (1H, m, H-2a), 1.42 (1H, m, H-3b), 
1.29 (1H, m, H-5), 1.29 (1H, m, H-6a), 1.18 (1H, m, H-3a), 1.07 (1H, m, H-1a),  0.93 
(3H, s, H3-20), 0.89 (3H, s, H3-18), 0.82 (3H, s, H3-19); See Table 2.2; LRESIMS m/z 
443.3 (100 [M+Na]
+
); HRESIMS m/z 443.2759 [M+Na]
+
 (C25H40O5Na requires 
443.2768). 
 
Palmadorin P (2.44).  Colorless oil; [α]20D -9 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 222 
(4.69) nm; IR (thin film) 3357 (br), 2923, 2951, 1710, 1646 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment): 5.73 (1H, s, H-14), 4.21 (2H, m, H2-
1′), 3.95 (1H, m, H-2′), 3.66 (2H, m, H2-3′), 2.19 (3H, s, H3-16), 2.18 (2H, m H2-12), 1.76 
(1H, m, H-7b), 1.68 (1H, m, H-1b), 1.62 (1H, m, H-11b), 1.61 (1H, m, H-6b), 1.53 (2H, 
m, H2-2), 1.51 (1H, m, H-7a), 1.44 (1H, m, H-11a), 1.42 (1H, m, H-6a), 1.41 (1H, m, H-
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3b), 1.16 (3H, s, H3-17), 1.14 (1H, m, H-3a), 0.96 (3H, s, H3-20), 0.88 (3H, s, H2-19), 
0.87 (1H, m, H-1a), 0.86 (1H, m, H-5), 0.84 (3H, s H3-18), 0.82 (1H, m, H-9); See Table 
2.2; LRESIMS m/z 419.3 (100, [M+Na]
+
), 259.2 (17); HRESIMS m/z 419.2772 [M+Na]
+
 
(C23H40O5Na requires 419.2768). 
 
Palmadorin Q (2.45).  Colorless oil; [α]20D -3 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 219 
(4.57) nm; IR (thin film) 3410 (br), 2922, 2850, 1711, 1644 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment): 5.70 (1H, s, H-14), 4.19 (2H, m, H2-
1′), 3.93 (1H, m, H-2′), 3.61 (2H, m, H2-3′), 2.30 (1H, m, H-12b), 2.18 (1H, M, H-12a), 
2.16 (3H, s, H3-16), 1.85 (1H, m, H-7b), 1.63 (1H, m, H-6b), 1.61 (1H, m, H-1b), 1.59 
(1H, m, H-11b), 1.42 (2H, m, H2-2), 1.41 (1H, m, H-11a), 1.40 (1H, m, H-7a), 1.35 (1H, 
m, H-3b), 1.25 (1H, m, H-6a), 1.14 (3H, s, H3-17), 1.12 (1H, m, H-3a), 1.04 (1H, m, H-
9), 0.92 (1H, m, H-1a), 0.91 (1H, m, H-5), 0.85 (3H, s, H3-19), 0.78 (3H, s, H3-20), 0.77 
(3H, s, H3-18); See Table 2.2; LRESIMS m/z 419.3 (100, [M+Na]
+
), 259.2 (12), 249.1 
(5); HRESIMS m/z 419.2777 [M+Na]
+
 (C23H40O5Na requires 419.2768). 
 
Palmadorin R (2.46).  Colorless oil; [α]20D +53 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 223 
(4.24) nm; IR (thin film) 3400 (br), 3019, 1716, 1215 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 
δH (integration, multiplicity, assignment): 5.87 (1H, s, H-1), 4.18 (2H, m, H2-1′), 4.17 
(2H, m, H2-3′), 4.10 (1H, m, H-2′), 2.38 (1H, m, H-14b), 2.33 (1H, m, H-3b), 2.14 (1H, 
m, H-14a), 2.12 (3H, s, CO2CH3), 2.03 (1H, m, H-3a), 2.03 (1H, m, H-6b), 2.01 (1H, m, 
H-5), 1.88 (1H, m, H-13), 1.83 (1H, m, H-11b), 1.62 (1H, m, H-7b), 1.55 (1H, m, H-7a), 
1.39 (1H, m, H-8), 1.29 (1H, m, H-6), 1.19 (1H, m, H-11a), 1.19 (1H, m, H-12a), 1.10 
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(3H, s, H3-20), 1.02 (3H, s, H3-19), 0.99 (3H, s, H3-18), 0.94 (3H, d, 6.6, H3-16), 0.94 
(3H, d, 6.8, H3-17), 0.84 (1H, m, H-12a); See Table 2.2; LRESIMS m/z 459.3 (100, 
[M+Na]
+
), 437.3 (30); HRESIMS m/z 437.2898 [M+H]
+
 (C25H40O6 requires 437.2911). 
 
Palmadorin S (2.47).  Colorless oil; [α]20D +29 (c 0.1, CDCl3); UV (MeOH) λmax (ε) 
222 (4.58) nm; IR (thin film) 3350 (br), 2917, 1714, 1651 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3) δH (integration, multiplicity, assignment): 5.87 (1H, s, H-1), 4.18 (2H, m, H2-1′), 
3.94 (1H, m, H-2′), 3.65 (2H, m, H2-2′), 2.37 (1H, m, H-3b), 2.34 (1H, m, H-14b), 2.20 
(1H, m, H-14a), 2.06 (1H, m, H-3a), 2.03 (1H, m, H-6b), 2.03 (1H, m, H-5), 1.91 (1H, m, 
H-13), 1.86 (1H, m, H-11b), 1.63 (1H, m, H-7b), 1.49 (1H, m, H-7a), 1.43 (1H, m, H-8), 
1.22 (1H, m, H-11a), 1.18 (1H, m, H-12b), 1.10 (3H, s, H3-20), 1.02 (3H, s, H3-19), 0.99 
(3H, s, H3-18), 0.95 (3H, d, 5.7, H3-16), 0.93 (3H, d, 6.0, H3-17), 0.76 (1H, m, H-12a); 
See Table 2.2; LRESIMS m/z 417.2 (100, [M+Na]
+
), 395.3 (35); HRESIMS m/z 
417.2612 [M+Na]
+
 (C23H38O5Na requires 417.2612). 
 
5.2.3 Collection of LC/MS data 
The LC/MS method “Palmadorin Test” utilized the following settings.  Column: Agilent 
Eclipse XDB-C18 (5 um, 4.6 cm X 150 mm).  Column flow: 1.0 mL/min.  Stoptime: 20 
min.  Posttime: 3 min. Solvent A: H2O (0.05% TFA). Solvent B: ACN (0.05% TFA).  
Gradient from time 0 to 11 min, 40% B to 100% B; 11 to 15 min at 100% B; 15 to 17 
min to 40%B; 17 to 20 min at 40% B.  Diode array detector (DAD) monitored at 254 nm. 
Ionization mode: API-ES with positive polarity. Mass range: 200 - 500 amu.  
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Fragmentor: 70 V.  Spray chamber: gas temp 350 °C.  Drying gas flow: 10 l/min.  
Nebulizer pressure: 35 psig.  Voltage cap: 3000V.  Injection volume: 20 µL. 
 
5.3 Experimental supporting Chapter 3 
5.3.1 Preparation of fraction PSC07-52-A-I 
Thawed alga (PSC07-52; 12.1 kg) was extracted with MeOH (4 L X 3). The combined 
extract was concentrated (344.4 g), and the residue was partitioned between CH2Cl2 and 
H2O. Subsequently, the organic layer was concentrated to give a dark green crude 
(PSC07-52-A; 20.2 g). The residue was subjected to NP MPLC over silica gel using a 
gradient starting with 100% hexanes increasing linearly to 100% EtOAc over a period of 
30 minutes, and then increasing linearly to 100% MeOH over a period of 15 minutes 
affording 12 fractions. The active fraction (PSC07-52-A-I; 2.9 g) eluted with 
approximately 50-75% MeOH/EtOAc and then fractionated by RP HPLC with a linear 
gradient of 50% aqueous MeOH to 100% MeOH over 25 minutes to yield 8 fractions. 
 
5.3.2 Preparation of fraction PSC08-8-3 
Thawed alga (PSC08-08; 400 g) was blended and extracted in H2O, then after 
concentration the light red gel was applied to XAD-1180 resin (Amberlite) and eluted 
sequentially with 0.5% HCl, 1 M NaOH, and MeOH to produce three fractions. The basic 
fraction was expected to elute peptides and proteins and subsequent bioassay identified 
this fraction as active (PSC08-8-3). 
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5.3.2 Preparation of 319-A fractions 
Thawed alga was extracted in ddH20, subsequently freeze-dried and brought up to a 
concentration of 2 - 10 mg/mL in 50% aq. EtOH and placed on ice.  Following an 
overnight precipitation, the extract was centrifuged at 10K G for 60 min at 4°C, the 
supernatant was decanted, transferred to 100 mL round bottom flask (RBF), freeze dried 
and resuspended in ddH2O (10 mg/mL) then slowly brought to 75% saturation (476 
mg/mL) with (NH4)2SO4.  The supernatant was allowed to precipitate overnight on ice, 
and the solution was then centrifuged at 10K for 60 min at 4°C.  After precipitation, the 
supernatant was decanted and the white pellet was resuspended in a minimum amount of 
50 mM PBS (phosphate buffered saline) + 0.02% sodium azide and quantitated via 
Bradford assay. 
 
5.3.4 Chromatography on POROS PE column 
The resuspended ammonium sulfate pellet was applied to a POROS PE (phenyl ether) 
column (4.6 X 100 mm) (Boehringer  Mannheim  GmbH, Germany) previously 
equilibrated with buffer containing  95% 3 M (NH4)2SO4 (4% 500 mM disbasic sodium 
phosphate pH 8, 1% 500 mM monobasic sodium phosphate pH 4). HPLC was run 
conducted with a BioCAD SPRINT Perfusion Chromatography System (Applied 
Biosystems, Carlsbad, California). The protein was eluted under a linear gradient to 95% 
H2O (+ 5% sodium phosphates as above) over 30 column volumes (CV) (approximately 
30 min).  Fractions containing binding activity towards gp120/HIV-1 (see Sect. 5.3.10) 
were pooled and concentrated on 3 kD and 10 kD molecular weight cut off Millipore 
Centricon Plus-70 Centrifugal Filter Devices (Ireland). 
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5.3.5 Chromatography on POROS HQ column 
Concentrated fractions exhibiting antiviral activity were de-salted and applied to a 
POROS HQ (quaternary ammonium) column (4.6  X 100 mm) (Boehringer  Mannheim  
GmbH, Germany) previously equilibrated with buffer containing  95% H2O, 4.5% 500 
mM disbasic sodium phosphate pH 8, and 0.5% 500 mM monobasic sodium phosphate 
pH 4. HPLC was conducted with a BioCAD SPRINT.  The protein was eluted under a 
linear gradient to 95% 1M NaCl (+ 5% sodium phosphates as above) over 50 CV 
(approximately 25 min).  Fractions containing antiviral activity towards gp120/HIV-1 
were pooled and concentrated on Millipore Centricon Plus-70 Centrifugal Filter Devices 
10,000 MWCO. 
 
5.3.6 Chromatography on RP column HPLC 
Concentrated fractions exhibiting antiviral activity were de-salted and applied to a 
Hamilton PRP-3 polymeric 300 angstrom column previously equilibrated with 100% 
H2O.  HPLC was conducted with a BioCAD SPRINT.  The protein was eluted under a 
linear gradient from 100% water to 50% ACN over 30 min at 1mL/min, then to 100% 
ACN over 10 min. Aliquots of sodium azide were added to all fractions (0.02% sodium 
axide), then they were concentrated on Millipore Centricon Plus-70 Centrifugal Filter 
Devices 10,000 MWCO. 
 
5.3.7 MALDI-TOF analysis 
MALDI-TOF samples were prepared by adding 1 µL of sample to a MALDI-TOF plate, 
followed by the addition of 1 μl of matrix solution of sinapinic acid (25 mg/ml, 70% 
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acetonitrile, 0.1% trifluoroacetic acid).  Samples were dried then processed in the 
MALDI-TOF-MS spectrometer (Autoflex; Bruker Daltonics) with flex control software 
(Bruker Daltonics). Positive ions were extracted with an accelerating voltage of 20 Hz in 
linear mode. Each spectrum was the sum of the ions obtained from 200 laser shots 
performed in five different regions of the same well. The spectra have been analyzed in 
an m/z range of 5,000 to 20,000. The analysis was performed with the flex analysis 
software and calibrated with protein calibration standard II (Protein II; Bruker Daltonics). 
 
5.3.8 LC/MS/MS chromatography of 319A-103E 
Fraction 319A-103E was dispersed in 0.5% trifluoroacetic acid (1/15 dilution) and 
separated on a Eskigent nanoLC ultra (Eskigent Technologies, Dublin, CA) equipped 
with a New Objective (Woburn, MA) picofrit nanobore column with a 100 µm ID, 15 µm 
tip packed with 5 µm ProteoPrep II C18 beads with 300 angstrom pores, and Eskigent 
nanoLC-AS1 autosampler. Solvent A consisted of 0.1% formic acid in water and solvent 
B was 0.1% formic acid in acetonitrile (Mallinckrodt Baker, Phillipsburg, NJ), with an 
elution profile of a 60 min gradient to 40% B, 5 min to 80% B, and 5 min of 80% B (total 
run time 70 min). Injection volume was 10 µL, HPLC flow rate was 250 nL/min. Peptide 
masses and peptide fragmentation were detected with positive electrospray ionization 
mode. The five most abundant trypsin digestion products in each chromatograph peak 
were detected and fragmented using LT-Q-Orbitrap XL (Thermo Scientific, Waltham, 
MA). Mass spectrophotometry (MALDI-MS and Orbitrap-MS) was performed at the 
University of South Florida Center for Drug Discovery and Innovation - Proteomics 
Facility.  
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Bioinformatics: MS data were formatted using LCQ-DTA (Thermo Scientific) and 
analyzed using MASCOT (www.matrixscience.com) for protein identification against the 
National Center for Biotechnology Information (NCBI) nonredundant protein database.  
The peptide mass tolerance was set to 7 ppm and MS/MS tolerance was set to 0.6 d. 
Variable modifications were set as Propionamide (C) and oxidation (Met). EST (a 
database maintained by GenBank that contains sequence data and other information on 
"single-pass" cDNA sequences, or "Expressed Sequence Tags", from a number of 
organisms) sequences with a significant MASCOT score (30) were submitted to the Basic 
Local Alignment Search Tool (BLAST) procedure (NCBI). Only BLAST results with a 
significant E-value (E 105) are reported.  
 
5.3.9 SDS-PAGE experiments 
All reagents used for SDS-PAGE were from Invitrogen or Bio-Rad. For SDS-PAGE 
analysis, samples were mixed with Tricine-SDS sample buffer containing 2% 2-
mercaptoethanol, pre-heated for five minutes at 100°C, and analyzed on a 4 - 12% Bis-
Tris gradient gel with Tricine-SDS running buffer, and stained by Coomassie brilliant 
blue. Current was run at 220V with constant voltage at room temperature with a run time 
of approximately 35 min. Pre-stained molecular weight standards (SeeBlue Plus2) were 
used. 
 
5.3.10 Immunoblotting and gp120 dot blot assay 
A 20 square (four X five) grid was drawn with pencil onto a covered polyvinylidene 
fluoride (PVDF) membrane (Biorad Immuno-BLOT, catalog # 162-0174; 7 X 8.4 cm).  
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The membrane is pre-wet in 100% MeOH for 5 min, the methanol decanted, then soaked 
in 50 mM PBS + 0.02% sodium azide for 5 min and then transferred onto filter paper 
(Whatman qualitative 4) pre-wetted with 50 mM PBS.  Samples are spotted onto a grid 
(10-20 µL per sample) and allowed to absorb onto the membrane (10-30 min).  A 
positive control of his-tagged GRFT protein (supplied by NCI-Frederick; 10 µL of 1 
mg/mL) and a negative control (blank) were applied to the PVDF grid.  The membrane 
was transferred into a 1% BSA in 50 mM PBS, 0.05% Tween20, 0.02% soidum azide 
bath (25 mL total) for at least 3 hr in 4°C.  The membrane was washed while rocking 
with 25 mL of buffer 6 times for 5 min each.  In 50 mM PBS, reconstituted gp120 stock 
(recombinant gp120 (HIV-1)-HRP, lot # 93-391, catalog # 012002, 50 µg/vial, 
lyophilized, Intracel Corporation) with 50 mM PBS was incubated with the membrane 
for 3 hr while rocking.  The reconstituted gp120-HRP could be decanted into Falcon 
tubes and used a total of 3 times within one week of initial reconstitution.  The membrane 
was washed with 50 mL ddH2O 6 times for 5 minutes while rocking.  The water was 
decanted and 50 mL of 50 mM PBS with 10 µg DBA (3,3′-diaminobenzidine) and 100 
µL of 30% H2O2 for 10 min or until red spots were visualized.  The membrane was rinsed 
with H2O and scanned for data records. 
 
5.4 Experimental supporting Chapter 4 
5.4.1 Purification of membranolides in the field laboratory 
Purification was conducted by high performance liquid chromatography (HPLC) using an 
Agilent 1100 Series HPLC outfitted with a diode array detector. The analytical method 
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utilized two Water RP cartridges (25 X 100) in series with a gradient solvent system of 
50% ACN-H2O to 100% ACN over 45 minutes.  
 
5.4.2 Amphipod feeding bioassays 
Details of the bioassay protocol have been published (see Chapter 4, reference 4).  First, 
natural concentrations of solubilized in membranolides in dlochlormethane were coated 
onto freeze-dried krill powder, reduced on a rotary vacuum concentrator, and then 
incorporated at 2% dry weight into a 2.2% alginate matrix.  The krill powder was 
transferred into 5.7 cm diameter plastic Petri dishes. Room temperature alginate solution 
was added to the dishes, mixed thoroughly with krill powder/membranolide, and then 
gelatinized using a minimal amount of cold 1 M CaCl2 (approximately 5 mL). This 
yielded artificial food discs approximately 2 mm thick which were then cut into 1 cm 
diameter disks with a cork borer. Control alginate food disks were prepared identically, 
but only with solvent treated krill powder.  In each experiment, ten replicate treatments 
consisting of one solvent control and one membranolide-containing alginate disk were 
pre-weighed and placed into one of ten 250 mL Nalgene bottles. Each such experimental 
bottle contained 20 adult individuals of G. antarctica.  Paired, autogenic controls were 
prepared from disks bored from the alginate food immediately next to those used as 
solvent control and membranolide-containing disks and placed into ten bottles without 
amphipods. Disks were removed and re-weighed after an appreciable amount of the disks 
had been consumed by the amphipods, typically 24-48 hrs. Consumption was calculated 
as the initial weight multiplied by the ratio of the final:initial wet weights of the pairs 
autogenic control disks minus the final weight of the experimental disk. 
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5.4.3 Statistical analyses 
The significance of differences between amphipod feeding rates on control and 
membranolide-containing feeding disks was determined using Wilcoxon signed-rank test 
with SPSS software (SPSS Inc, Chicago, IL).  
 
5.4.4 Isolation of membranolides from the Antarctic sponge Dendrilla membranolsa 
Membranolide E (4.22).  Colorless oil; [α]20D + (c 0.14, CHCl3); 
1
H and 
13
C NMR data 
table see Table 4.1; LRESIMS m/z 345.1 (100, [M+H]
+
), 124.1 (25), 102.2 (50); 
HRESIMS m/z  [M+H]
+
 345.2060 (C21H29O4 requires 345.2074). 
 
Membranolide F (4.23).  Colorless oil; [α]20D +135 (c 0.14, CHCl3); UV (MeOH) λmax 
(log ε) (3.32) 223 nm; 1H and 13C NMR data table see Table 4.1; LRESIMS m/z 361.2 
(100, [M+H]
+
), 102.1 (80); HRESIMS m/z  [M+H]
+
 361.1994 (C21H29O5 requires 
361.2010). 
 
Membranolide G (4.24).  Faint yellow oil; [α]20D + 33 (c 0.6, CHCl3); UV (MeOH) λmax 
(log ε) (3.41) 267 nm; 1H and 13C NMR data table see page 255; LRESIMS m/z 345.3 
(100, [M-OMe]
+
), 399.2 (30, [M]+Na); HRESIMS m/z  [M+Na]+ 399.2158 (C22H32O5Na 
requires 399.2142). 
  
Membranolide H (4.25).  Faint yellow oil; [α]20D - 37 (c 0.6, CHCl3); UV (MeOH) λmax 
(log ε) (3.48) 269 nm; 1H and 13C NMR data table see page 261; LRESIMS m/z 345.3 
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(100, [M-OMe]
+
), 399.2 (30, [M+Na]
+
); HRESIMS m/z  [M+Na]+ 399.2154 
(C22H32O5Na requires 399.2142). 
 
Membranolide C (4.26).  Faint yellow oil; [α]20D -12 (c 0.6, CHCl3); UV (MeOH) λmax 
(ε) (3.31) 267 nm; 1H and 13C NMR data table see page 267; LRESIMS m/z 345.3 (100, 
[M-OMe]
+
), 399.2 (30, [M+Na]
+
);  
 
Membranolide D (4.27).  Faint yellow oil; [α]20D -87.4 (c 0.6, CHCl3); UV (MeOH) λmax 
(log ε) (3.57) 269 nm; 1H and 13C NMR data table see page 269; LRESIMS m/z 345.3 
(100, [M-OMe]
+
), 346.2 (25), 367.2 (15); HRESIMS m/z  [M-H]
-
 375.2177 (C22H31O5 
requires 375.2188). 
 
5.4.5 Collection of LC/MS data 
The LC/MS method “Membranolide” utilized the following settings.  Column: Agilent 
Eclipse XDB-C18 5.0 µm. Column flow rate: 1.0 mL/min.  Stoptime: 20 min.  Posttime: 
3 min. Solvent A: H2O (0.05% TFA). Solvent B: ACN (0.05% TFA).  Gradient from time 
0 to 12 min, 80% B; 12 to 15 min 80% B to 100% B; 15 to 17 min to 40%B; 17 to 20 min 
at 40% B.  Diode array detector (DAD) monitored at 254 nm and 225 nm. Ionization 
mode: API-ES with positive polarity. Mass range: 100 - 1000 amu.  Fragmentor: 70 V.  
Spray chamber: gas temp 350 °C.  Drying gas flow: 10 l/min.  Nebulizer pressure: 35 
psig.  Voltage cap: 3000V.  Injection volume: 20 µL. 
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1
H and 
13
C NMR  Data of Palmadorin D (2.32) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 21.7 1.46 (1H, m) 3, 9, 10 2, 10 20 
  1.52 (1H, m)    
2 28.7 1.26 (1H, m)  1, 3  
  1.91 (1H, m)    
3 33.0 2.12 (1H, m) 2, 4, 18 2, 3b 18 
  2.30 (1H, m) 1, 4, 5, 18 2, 3a 19 
4 160.4      
5 40.0      
6 37.3 1.53 (1H, m) 5, 8, 7, 10, 19 6b, 7  
  1.62 (1H, m) 7, 8, 9, 19 6a, 7 18 
7 27.4 1.46 (1H, m) 5, 6, 8, 9, 10 6, 8 19, 20 
  1.50 (1H, m)    
8 36.7 1.43 (1H, m) 6, 7, 17, 20 7, 17  
9 39.4      
10 48.7 1.07 (1H, m) 1, 2, 6, 5, 9, 19 20  
11 36.2 1.36 (1H, m) 9, 12, 20 12 17 
  1.44 (1H, m) 12a 12  
12 34.6 1.88 (1H, m) 11, 13, 14, 16 11  
  2.00 (1H, m)  11  
13 163.4      
14 114.2 5.68 (1H, br s) 12, 13, 15, 16 12 12 
15 167.1      
16 19.4 2.16 (3H, s) 12, 13, 14, 15   
17 16.0 0.82 (3H, d, 6.4) 7, 8, 9   
18 102.6 4.52 (2H) 3, 4, 5, 19 3 3a, 6b 
19 20.8 1.06 (3H, s) 5, 6, 10  20 
20 18.1 0.76 (3H, s) 8, 9, 10, 11, 12   
1′ 64.5 4.21 (2H, m) 15, 2′, 3′ 2′ 2′ 
2′ 70.4 3.95 (1H, m) 1′, 3′ 1′, 3′  
3′ 63.3 3.67 (2H, m) 2′ 2′  
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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ROESY NMR spectrum of palmadorin D (2.32 ) (500 MHz, CDC13)
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gCOSY NMR spectrum of palmadorin D (2.32) (500 MHz, CDC13)
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LRESIMS of palmadorin D (2.32)
HRESIMS of palmadorin D (2.32)
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1
H and 
13
C NMR  Data of Palmadorin E (2.33) in CDCl3
a 
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 34.8 2.35 (1H, m) 2, 5, 10 1, 10 1b 
  2.51 (1H, m)   1a, 10, 19, 20 
2 200.0  (1H, m)    
3 125.0 5.71 (1H, s) 1, 5, 18 18 18 
4 172.8      
5 39.4      
6 41.4 1.56 (1H, m)  6, 7 6b, 7, 18 
  2.23 (1H, m) 7, 8, 10  6a, 8, 10, 19 
7 73.1 4.12 (1H, m)   17 
8 38.9 1.56 (1H, m)  17 17, 20, 11 
9 38.4      
10 45.9 1.92 (1H, m)   1a, 11 
11 36.5 1.45 (2H, m) 9, 12 12 12 
12 34.3 1.94 (2H, m) 13, 14  11 
13 161.7      
14 114.9 5.68 (1H, s) 12, 16 16 16 
15 166.8      
16 19.3 2.18 (3H, s) 12, 13, 14   
17 12.4 1.07 (3H, d, 7.1) 7, 8 8 8 
18 19.0 1.94 (3H, s) 3, 4, 5 3, 19 6 
19 20.1 1.42 (3H, s) 4, 5, 6, 10 18 20 
20 19.5 1.11 (3H, s) 9, 10, 11  19 
1′ 64.6 4.21 (2H, m)    
2′ 70.4 3.96 (1H, m) 15, 1′, 3′ 1′, 3′  
3′ 63.3 3.67 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz.  
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1H NMR spectrum of palmadorin E (2.33) (500 MHz, CDC13)
13C NMR spectrum of palmadorin E (2.33) (125 MHz, CDC13)
PROTON.esp
6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
1
.0
4
1
.0
6
1
.0
8
1
.1
1
1
.4
2
1
.4
5
1
.5
6
1
.5
9
1
.5
91
.9
2
1
.9
4
2
.0
2
2
.1
7
2
.1
8
2
.2
2
2
.2
5
2
.5
1
2
.5
1
2
.5
4
3
.6
4
3
.6
5
3
.7
0
3
.9
64
.1
2
4
.2
0
4
.2
1
4
.2
1
4
.2
4
4
.2
5
5
.6
8
5
.7
1
Palmadorin_E_carbon.esp
200 180 160 140 120 100 80 60 40 20
Chemical Shift (ppm)
0.05
0.10
0.15
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
CHLOROFORM-d
1
2
.3
8
1
9
.0
4
1
9
.3
5
1
9
.4
9
2
0
.1
2
2
9
.6
9
3
4
.3
3
3
4
.8
1
3
8
.3
5
3
8
.8
8
4
1
.4
3
4
5
.9
3
6
3
.3
2
6
4
.5
9
7
0
.3
57
3
.0
9
7
6
.7
4
7
7
.0
0
7
7
.2
5
1
1
4
.9
1
1
2
4
.9
8
1
6
1
.7
0
1
6
6
.8
1
1
7
2
.8
1
1
9
9
.9
8
H-14
H-3
H-16
H-19
H-20
H-17
H-1′
H-2′
H-3′
H-18
C-4
C-15
C-13
C-3
C-14
C-2′
C-1′
C-3′
C-7
C-2
C-17
H-7
173 
 
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shift (ppm)
20
40
60
80
100
120
F
1
 C
h
e
m
ic
a
l 
S
h
if
t 
(
p
p
m
)
gHSQC NMR spectrum of palmadorin E (2.33) (500 MHz, CDC13)
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shift (ppm)
50
100
150
200
F
1
 C
h
e
m
ic
a
l 
S
h
if
t 
(
p
p
m
)
gHMBC NMR spectrum of palmadorin E (2.33) (500 MHz, CDC13)
174 
 
ROESY NMR spectrum of palmadorin E (2.33) (500 MHz, CDC13)
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gCOSY NMR spectrum of palmadorin E (2.33) (500 MHz, CDC13)
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LRESIMS of palmadorin E (2.33)
HRESIMS of palmadorin E (2.33)
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1
H and 
13
C NMR  Data of Palmadorin F (2.34) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 17.9 1.60 (2H, m)  2  
       
2 26.7 1.92 (1H, m)  3, 18  
  2.09 (1H, m)    
3 119.8 5.17 (1H, s) 18, 19 18 2, 18 
4 144.9   10, 18   
5 37.6   6, 18, 19   
6 42.9 1.40 (1H, m) 7, 8, 10, 19 6, 7  
  2.12 (1H, m)    
7 73.7 4.05 (1H, m) 17 8 6, 8, 17 
8 39.3 1.55 (1H, m) 17, 20 6  
9 38.3   17   
10 46.6 1.40 (1H, m) 19, 20   
11 37.4 1.36 (1H, m) 12, 20   
  1.51 (1H, m)    
12 34.9 1.97 (2H, m) 13, 14, 16, 20 14, 16  
13 163.2   14, 16   
14 114.4 5.71 (1H, s) 15, 16 12, 16 12 
15 167.1      
16 19.4 2.18 (3H, s) 15   
17 12.7 1.04 (3H, d, 7.1)    
18 18.0 1.64 (3H, s)    
19 21.8 1.31 (3H, s)   1, 20 
20 20.0 1.03 (3H, s)    
1′ 64.5 4.22 (2H, m) 15, 2′, 3′  2′ 
2′ 70.4 3.96 (1H, m) 3′ 1′, 3′  
3′ 63.3 3.64 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin F (2.34) (500 MHz, CDC13)
13C NMR spectrum of palmadorin F (2.34) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin F (2.34) (500 MHz, CDC13)
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LRESIMS of palmadorin F (2.34)
HRESIMS of palmadorin F (2.34)
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1
H and 
13
C NMR  Data of Palmadorin G (2.35) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 35.0 2.37 (2H, m) 2, 3, 5, 10 3, 10, 19, 20 19, 20 
2 200.1      
3 125.5 5.73 (1H, s) 5, 18 1, 18 18 
4 172.6   18   
5 39.9   6, 10, 18, 19   
6 35.5 1.88 (2H, m) 8, 19 8 8, 10 
7 26.8 1.52 (1H, m) 9, 17 17 17, 19, 20 
8 36.0 1.52 (1H, m) 11, 17, 20  17 
9 38.8   10, 11, 17, 20   
10 45.7 1.86 (1H, m) 11, 19, 20 8, 20  
11 35.4 1.44 (2H, m) 13, 20 12 14, 17, 20 
12 34.1 1.89 (1H, m) 13, 14, 16, 20 14 14 
  2.00 (1H, m)   14 
13 162.0   16   
14 114.8 5.68 (1H, s) 16 16 16 
15 166.9   16   
16 19.4 2.16 (3H, s)    
17 15.7 0.85 (3H, d, 6.2)    
18 19.0 1.90 (3H, s)   19 
19 18.3 1.13 (3H, s)   20 
20 17.8 0.83 (3H, s)    
1′ 64.6 4.20 (2H, m) 15, 2', 3'   
2′ 70.3 3.96 (1H, m) 3' 1', 3'  
3′ 63.3 3.67 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin G (2.35) (500 MHz, CDC13)
13C NMR spectrum of palmadorin G (2.35) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin G (2.35) (600 MHz, CDC13)
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LRESIMS of palmadorin G (2.35)
HRESIMS of palmadorin G (2.35)
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1
H and 
13
C NMR  Data of Palmadorin H (2.36) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 18.0 1.60 (2H, m) 2, 10 2, 10  
       
2 26.7 2.02 (1H, m) 3, 4, 10 3  
  2.08 (1H, m)    
3 119.8 5.17 (1H, s) 18 18 18 
4 144.9   10, 18, 19   
5 37.6   6, 7, 18, 19   
6 42.9 1.41 (1H, m) 19, 7 7, 19 7 
  2.12 (1H, m)   7 
7 73.7 4.05 (1H, m) 8, 9, 19 8 8, 17 
8 39.3 1.55 (1H, m) 9, 17, 20 17  
9 38.3   10, 11, 17, 20  19 
10 46.6 1.40 (1H, m) 11, 19, 20 20  
11 37.3 1.41 (1H, m) 12, 20 12  
  1.51 (1H, m)    
12 34.9 1.97 (2H, m) 13, 14, 16, 20 14 14 
13 163.2   16   
14 114.5 5.71 (1H, s) 15, 16 12, 16  
15 166.1   2', 16   
16 19.4 2.18 (3H, s)    
17 12.5 1.04 (3H, d, 7.3)    
18 17.9 1.64 (3H, s)    
19 21.8 1.30 (3H, s)    
20 20.0 1.03 (3H, s)    
1′ 62.4 4.30 (2H, m) 2', 3', CO2CH3   
2′ 71.4 5.11 (1H, quin, 4.9) 3' 1', 3' 1', 3' 
3′ 61.7 3.77 (2H, m)    
CO2CH3 20.8 2.10 (3H, s)    
CO2CH3 171.0   CO2CH3   
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin H (2.36) (500 MHz, CDC13)
13C NMR spectrum of palmadorin H (2.36) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin H (2.36) (600 MHz, CDC13)
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LRESIMS of palmadorin H (2.36)
HRESIMS of palmadorin H (2.36)
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1
H and 
13
C NMR  Data of Palmadorin I (2.37) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 35.1 1.54 (1H, m) 2, 3 3  
  2.47 (1H, m)   19, 20 
2 198.4      
3 126.0 5.81 (1H, s) 5, 18 18 1b/6a/10, 18, 19 
4 169.3   18, 19   
5 44.3   18, 19   
6 51.1 2.48 (1H, m) 5, 7, 10, 19 10  
  2.60 (1H, m)    
7 210.6   8, 17   
8 50.1 2.63 (1H, m) 9, 17, 20  6b, 10, 17 
9 44.3   10, 11, 20   
10 45.7 2.48 (1H, m) 19, 20   
11 35.8 1.43 (1H, m) 12, 20 12  
  1.63 (1H, m)    
12 34.4 2.08 (2H, m) 12, 14, 16   
13 160.4   16   
14 115.4 5.72 (1H, s) 15, 16 12, 16 11, 12, 17 
15 166.6   16, 1'   
16 19.3 2.19 (3H, s)    
17 7.8 0.99 (3H, d, 6.6)   11a 
18 18.8 1.90 (3H, s) 19  19 
19 19.4 1.12 (3H, s) 20   
20 19.0 0.82 (3H, s)   11, 17, 18 
1′ 64.7 4.22 (2H, m) 2', 3'   
2′ 70.3 3.96 (1H, m) 3' 1', 3'  
3′ 63.3 3.68 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin I (2.37) (500 MHz, CDC13)
13C NMR spectrum of palmadorin I (2.37) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin I (2.37) (600 MHz, CDC13)
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LRESIMS of palmadorin I (2.37)
HRESIMS of palmadorin I (2.37)
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1
H and 
13
C NMR  Data of Palmadorin J (2.38) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 34.9 2.33 (1H, m) 2, 10 10 1b 
  2.50 (1H, m)   19, 20 
2 200.2   18   
3 125.0 5.70 (1H, s) 18 1, 18  
4 172.9   6, 18, 19   
5 39.4   6, 7, 10, 18, 19   
6 41.4 1.54 (1H, m) 7, 8, 19 7 6b 
  2.23 (1H, m)   18, 19 
7 73.1 4.11 (1H, m) 8, 9, 17 8 8 
8 38.9 1.57 (1H, m) 9, 17, 20 17  
9 38.4   10, 11, 17, 20   
10 45.9 1.93 (1H, m) 11, 19, 20   
11 36.3 1.38 (1H, m) 12, 13 12  
  1.50 (1H, m)    
12 34.3 1.90 (1H, m) 13, 14   
  1.97 (1H, m)    
13 161.8   16   
14 115.2 5.71 (1H, s) 15 16 12 
15 166.5   16   
16 19.4 2.18 (3H, s)    
17 12.4 1.07 (3H, d, 7.2)    
18 19.0 1.93 (3H, s) 19  19 
19 20.1 1.42 (3H, s)   20 
20 19.5 1.10 (3H, s)    
1′ 62.9 3.86 (2H, m)    
2′ 74.6 4.94 (1H, m) 1', 3' 1', 3'  
3′ 62.7 3.86 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin J (2.38) (500 MHz, CDC13)
13C NMR spectrum of palmadorin J (2.38) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin J (2.38) (600 MHz, CDC13)
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LRESIMS of palmadorin J (2.38)
HRESIMS of palmadorin J (2.38)
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1
H and 
13
C NMR  Data of Palmadorin K (2.39) in CDCl3
a 
position δC δH (J (Hz))  
1 35.1 1.54 (1H, m) 
  2.47 (1H, m) 
2 198.5   
3 126.0 5.81 (1H, s) 
4 169.4   
5 44.3   
6 51.1 2.48 (1H, m) 
  2.60 (1H, m) 
7 210.7   
8 50.1 2.63 (1H, m) 
9 44.3   
10 45.7 2.48 (1H, m) 
11 35.6 1.43 (1H, m) 
  1.63 (1H, m) 
12 34.4 2.08 (2H, m) 
13 160.6   
14 115.4 5.72 (1H, s) 
15 166.6   
16 19.3 2.19 (3H, s) 
17 7.8 0.99 (3H, d, 6.6) 
18 18.9 1.90 (3H, s) 
19 19.3 1.12 (3H, s) 
20 19.0 0.82 (3H, s) 
1′ 62.7 3.88 (2H, m) 
2′ 74.7 4.96 (1H, m) 
3′ 62.7 3.88 (2H, m)  
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin K (2.39) (500 MHz, CDC13)
13C NMR spectrum of palmadorin K (2.39) (125 MHz, CDC13)
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LRESIMS of palmadorin K (2.39)
HRESIMS of palmadorin K (2.39)
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1
H and 
13
C NMR  Data of Palmadorin L (2.40) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 21.0 1.44 (1H, m) 10 10  
  1.64 (1H, m)    
2 21.5 1.64 (2H, m) 3, 18 3  
3 30.5 1.52 (1H, m) 4, 18   
  1.82 (1H, m)    
4 75.2   10, 18, 19   
5 42.1   6, 10, 18, 19   
6 31.6 1.32 (1H, m) 7, 10, 18, 19 7, 10, 19  
  1.83 (1H, m)    
7 27.0 1.40 (2H, m) 8, 9, 17  17 
8 35.9 1.47 (1H, m) 9, 11, 17, 20 17  
9 39.0   10, 11, 17, 20   
10 40.7 1.92 (1H, m) 19, 20   
11 36.5 1.37 (1H, m) 12, 20 12  
  1.49 (1H, m)    
12 34.8 1.88 (2H, m) 14, 16, 20 13, 14, 16  
  2.05     
13 163.5   16   
14 114.4 5.72 (1H, s) 15, 16 16  
15 167.1   1′   
16 19.4 2.18 (3H, s)    
17 15.9 0.80 (3H, d, 6.6)    
18 53.3 3.62 (1H, d, 10.7) 19  18b, 19 
  3.83 (1H, d, 10.7)   6a 
19 17.3 0.99 (3H, s)   6a, 7 
20 18.4 0.74 (3H, s)   11a 
1′ 64.5 4.21 (2H, m) 2′, 3′ 2′, 3′  
2′ 70.4 3.95 (1H, m) 3′ 3′  
3′ 63.3 3.67 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin L (2.40) (500 MHz, CDC13)
13C NMR spectrum of palmadorin L (2.40) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin L (2.40) (500 MHz, CDC13)
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HRESIMS of palmadorin L (2.40)
LRESIMS of palmadorin L (2.40)
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1
H and 
13
C NMR  Data of Palmadorin M (2.41) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY nOe 
1 36.7 1.06 (1H, m) 2, 3, 10, 20  1b, 9, 20 1b, 2, 9, 20 
  1.53 (1H, m)     
2 19.1 1.44 (1H, m) 3 1, 3   
  1.63 (1H, m)   18, 19, 20 19, 20 
3 42.6 1.18 (1H, m) 4, 18  2a, 3b, 18, 19 3b, 19 
  1.42 (1H, m)   18, 19 18 
4 33.2   18, 19    
5 45.8 1.28 (1H, m) 6, 10, 11  7a, 9 20 
6 23.5 1.29 (1H, m) 7, 8 7  18, 20 
  1.62 (1H, m)    19, 20 18 
7 31.5 2.04 (1H, m) 8, 17  9? 6, 7b 
  2.18 (1H, m)   17b 5, 6, 7a, 
17b 
8 148.7   9, 17    
9 57.8 1.51 (1H, m) 10, 11, 17, 20  1a, 20 20 
10 38.0   19, 20    
11 24.2 1.47 (1H, m) 12, 13, 20 12  20 
  1.70 (1H, m)   7a  
12 39.8 1.87 (1H, m) 13, 14, 16    
  2.04 (1H, m)    12b 
13 163.2   14, 16    
14 114.5 5.72 (1H, bs) 15, 16  11, 12  
15 166.8       
16 19.4 2.15 (3H, s) 13, 14    
17 109.9 4.52    9, 20 17b 
  4.71    7b  
18 22.1 0.81 (3H, s) 3, 4, 5  5, 19, 20 19, 20 
19 33.4 0.88 (3H, s) 5  5, 20 3, 5, 6a, 18 
20 22.3 0.92 (3H, s) 5  5 11a, 17a 
1′ 62.3 3.83 (2H, m, 4.6)     
2′ 74.2 4.93 (1H, m) 15, 1', 3' 1', 3'   
3′ 62.3 3.83 (2H, m, 4.6)     
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin M (2.41) (500 MHz, CDC13)
13C NMR spectrum of palmadorin M (2.41) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin M (2.41) (600 MHz, CDC13)
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NOE enhancements of palmadorin M (2.41) (600 MHz, CDC13)
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LRESIMS of palmadorin M (2.41)
HRESIMS of palmadorin M (2.41)
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1
H and 
13
C NMR  Data of Palmadorin N (2.42) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 36.7 1.06 (1H, m) 2, 20 2, 9, 20 20 
  1.53 (1H, m)    
2 19.1 1.44 (1H, m) 3, 10, 19 3, 5  
  1.63 (1H, m)   20 
3 42.6 1.17 (1H, m) 4, 18, 19 4, 18  
  1.41 (1H, m)    
4 33.2   6   
5 45.8 1.29 (1H, m) 6  20 
6 23.6 1.29 (1H, m) 7, 8, 10, 19 7, 17 20 
  1.62 (1H, m)    
7 31.5 2.04 (1H, m) 8, 17 17  
  2.19 (1H, m)    
8 148.7   9, 11  20 
9 57.8 1.52 (1H, m) 11, 12, 17, 20 11, 12, 17, 20  
10 38.0   20   
11 24.1 1.47 (1H, m) 12, 13, 20 9, 12  
  1.71 (1H, m)    
12 39.8 1.88 (1H, m) 13, 14, 16 14  
  2.06 (1H, m)    
13 163.0   14, 16   
14 114.4 5.69 (1H, s) 15 16 12, 3' 
15 167.2   16   
16 19.3 2.17 (3H, s)    
17 110.0 4.51    7b, 17b 
  4.72    9, 20 
18 22.1 0.82 (3H, s) 19 3, 19 20 
19 33.5 0.89 (3H, s) 4, 18   
20 22.3 0.94 (3H, s)    
1′ 64.4 4.19 (2H, m) 15, 2', 3'   
2′ 70.4 3.94 (1H, m) 3' 1', 3'  
3′ 63.4 3.69 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin N (2.42) (500 MHz, CDC13)
13C NMR spectrum of palmadorin N (2.42) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin N (2.42) (600 MHz, CDC13)
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LRESIMS of palmadorin N (2.42)
HRESIMS of palmadorin N (2.42)
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1
H and 
13
C NMR  Data of Palmadorin O (2.43) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 36.8 1.07 (1H, m) 2, 3, 10, 20  20 
  1.52 (1H, m)    
2 19.1 1.45 (1H, m) 3, 4, 18 18  
  1.64 (1H, m)    
3 42.6 1.18 (1H, m) 4, 18, 19  18 
  1.42 (1H, m)    
4 33.2   18, 19   
5 45.8 1.29 (1H, m) 6, 10, 18, 19, 20 19  
6 23.6 1.29 (1H, m) 7 7, 17  
  1.64 (1H, m)    
7 31.5 2.19 (1H, m) 8, 17 17  
8 148.7   9, 17   
9 57.9 1.52 (1H, m) 10, 11, 17, 20 17 20 
10 38.0      
11 24.2 1.50 (1H, m) 12,13, 20 12  
  1.73 (1H, m)    
12 39.9 1.89 (1H, m) 13, 14 14  
  2.07 (1H, m)    
13 163.2   14   
14 114.4 5.71 (1H, s) 15, 16 16 12, 11 
15 166.2   16   
16 19.4 2.16 (3H, s)    
17 109.9 4.53 (1H, bs)   9, 20 
  4.72 (1H, bs)   7 
18 22.1 0.82 (3H, s)   5 
19 33.5 0.89 (3H, s) 19 2, 19 2b, 6b 
20 22.3 0.93 (3H, s)    
1′ 62.5 4.30 (2H, m) CO2CH3, CO2CH3 CO2CH3  
2′ 71.3 5.11 (1H, m) 15, 3' 1', 3' 1', 3' 
3′ 61.7 3.77 (2H, m) 1', 3'   
CO2CH3 171.0      
CO2CH3 20.8 2.09 (3H, s) CO2CH3   
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin O (2.43) (500 MHz, CDC13)
13C NMR spectrum of palmadorin O (2.43) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin O (2.43) (500 MHz, CDC13)
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LRESIMS of palmadorin O (2.43)
HRESIMS of palmadorin O (2.43)
225 
 
1
H and 
13
C NMR  Data of Palmadorin P (2.44) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 39.2 0.87 (1H, m) 20 2  
  1.68 (1H, m)    
2 18.2 1.53 (1H, m)  3 20 
3 42.0 1.14 (1H, m) 18, 19   
  1.41 (1H, m)   5 
4 33.4   18, 19   
5 55.9 0.86 (1H, m) 7, 18, 19, 20  7a 
6 18.1 1.42 (1H, m) 7 7  
  1.61 (1H, m)   18, 20 
7 42.3 1.51 (1H, m) 8, 9, 17  17 
  1.76 (1H, m)   17 
8 73.1   9, 17   
9 58.8 0.82 (1H, m) 10, 11, 12, 17, 20  17 
10 39.0   20   
11 23.5 1.44 (1H, m) 12 12  
  1.62 (1H, m)   17 
12 44.7 2.18 (2H, m) 14, 16 14  
13 162.5   16   
14 114.3 5.73 (1H, s) 16 16 11a, 12 
15 167.1   16   
16 19.3 2.19 (3H, s)    
17 30.6 1.16 (3H, s) 7, 8, 9   
18 21.6 0.84 (3H, s) 19 19 20 
19 33.3 0.88 (3H, s)    
20 15.1 0.96 (3H, s)    
1′ 64.5 4.21 (2H, m) 2', 3'   
2′ 70.4 3.95 (1H, m) 3' 1', 3'  
3′ 63.3 3.66 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin P (2.44) (500 MHz, CDC13)
13C NMR spectrum of palmadorin P (2.44) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin P (2.44) (500 MHz, CDC13)
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LRESIMS of palmadorin P (2.44)
HRESIMS of palmadorin P (2.44)
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1
H and 
13
C NMR  Data of Palmadorin Q (2.45) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 39.2 0.92 (1H, m)  1b, 2, 20 1b 
  1.61 (1H, m)    
2 18.4 1.42 (1H, m)  3a 3a 
3 41.9 1.12 (1H, m) 18, 19 3b 3b 
  1.35 (1H, m)    
4 33.4   18, 19   
5 56.1 0.91 (1H, m) 7, 18, 19, 20 6, 18 6a 
6 20.5 1.25 (1H, m)  6b, 7  
  1.63 (1H, m)  7 7b, 19 
7 44.8 1.40 (1H, m) 8, 9  7b 
  1.85 (1H, m)    
8 74.3   9, 17   
9 61.4 1.04 (1H, m) 17, 20 11, 17, 20  
10 39.7      
11 24.1 1.41 (1H, m)  12 11b, 12 
  1.59 (1H, m)  12 12 
12 44.5 2.18 (1H, m) 14, 16   
  2.30 (1H, m)    
13 163.2   16   
14 114.2 5.70 (1H, s) 12, 16 16 16 
15 167.2   16, 1'   
16 19.4 2.16 (3H, s)    
17 23.6 1.14 (3H, s) 8, 9 20 20 
18 21.5 0.77 (3H, s) 19  19 
19 33.2 0.85 (3H, s)    
20 15.4 0.78 (3H, s)    
1′ 64.5 4.19 (2H, m) 15, 2'   
2′ 70.4 3.93 (1H, m) 3' 1', 3' 1', 3' 
3′ 63.3 3.61 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin Q (2.45) (500 MHz, CDC13)
13C NMR spectrum of palmadorin Q (2.45) (125 MHz, CDC13)
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ROESY NMR spectrum of palmadorin Q (2.45) (600 MHz, CDC13)
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LRESIMS of palmadorin Q (2.45)
HRESIMS of palmadorin Q (2.45)
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1
H and 
13
C NMR  Data of Palmadorin R (2.46) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 121.9 5.87 (1H, s) 3, 5, 9, 10, 20 3, 20 20 
2 200.3   3, 19   
3 47.0 2.03 (1H, m) 4, 5, 6, 18, 19 18  
  2.33 (1H, m)    
4 34.4   18, 19   
5 45.7 2.01 (1H, m) 6, 10, 18, 19   
6 29.8 1.29 (1H, m)  7  
  2.03 (1H, m)    
7 30.6 1.55 (1H, m) 8   
  1.62 (1H, m)   5 
8 45.9 1.39 (1H, m) 9, 20 17 6a, 7a, 7b, 17 
9 44.8   11, 17, 20   
10 173.6   5, 11, 17, 20   
11 28.9 1.19 (1H, m) 12, 20 12, 20 17 
  1.83 (1H, m)   11a, 12a 
12 30.7 0.84 (1H, m) 13   
  1.19 (1H, m)    
13 31.1 1.88 (1H, m) 14, 16 12, 14, 16 16 
14 41.5 2.14 (1H, m) 15, 16   
  2.34 (1H, m)    
15 173.1   16   
16 19.9 0.94 (3H, d, 6.8)    
17 16.1 0.94 (3H, d, 6.6)   7b 
18 28.4 0.99 (3H, s) 19  3a, 5 
19 27.6 1.02 (3H, s)   3b, 3a/6b 
20 22.8 1.10 (3H, s)   20 
1′ 65.0 4.18 (2H, m) 15, 2', 3' 2', 3'  
2′ 68.3 4.10 (1H, m) 3' 3'  
3′ 65.3 4.17 (2H, m) CO2CH3 CO2CH3  
CO2CH3 171.0   CO2CH3   
CO2CH3 20.8 2.12 (3H, s)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin R (2.46) (500 MHz, CDC13)
13C NMR spectrum of palmadorin R (2.46) (125 MHz, CDC13)
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gHMBC NMR spectrum of palmadorin R (2.46) (500 MHz, CDC13)
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ROESY spectrum of palmadorin R (2.46) (125 MHz, CDC13)
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LRESIMS of palmadorin R (2.46)
HRESIMS of palmadorin R (2.46)
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1
H and 
13
C NMR  Data of Palmadorin S (2.47) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 121.9 5.87 (1H, s) 3, 5, 20 3, 20 20 
2 200.6   3   
3 47.0 2.06 (1H, m) 4, 18, 19  18, 19 
  2.37 (1H, m)   19 
4 34.5   5, 18, 19,   
5 45.8 2.03 (1H, m) 10, 18, 19   
6 29.8 1.29 (1H, m)   6b, 7a 
  2.03 (1H, m)    
7 30.6 1.49 (1H, m) 8, 17   
  1.63 (1H, m)    
8 45.8 1.43 (1H, m) 10, 11, 17, 20  20 
9 44.8   12, 17, 20   
10 173.7   11, 20   
11 28.9 1.22 (1H, m) 12, 20 12  
  1.86 (1H, m)   12 
12 30.6 0.76 (1H, m) 13, 14, 16 13  
  1.18 (1H, m)   20 
13 31.3 1.91 (1H, m) 16 14, 16  
       
14 41.7 2.20 (1H, m) 15, 16   
  2.34 (1H, m)    
15 173.4   1'   
16 19.9 0.95 (3H, d, 5.7)    
17 16.1 0.93 (3H, d, 6.0)   20 
18 28.4 0.99 (3H, s) 19   
19 27.6 1.02 (3H, s)    
20 22.8 1.10 (3H, s)    
1′ 65.1 4.18 (2H, m)   2' 
2′ 70.2 3.94 (1H, m) 1', 3' 1', 3'  
3′ 63.4 3.65 (2H, m)    
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of palmadorin S (2.47) (500 MHz, CDC13)
13C NMR spectrum of palmadorin S (2.47) (125 MHz, CDC13)
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gHMBC NMR spectrum of palmadorin S (2.47) (500 MHz, CDC13)
243 
 
ROESY NMR spectrum of palmadorin S (2.47) (500 MHz, CDC13)
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shift (ppm)
1
2
3
4
5
F
1
 C
h
e
m
ic
a
l 
S
h
if
t 
(
p
p
m
)
COSY NMR spectrum of palmadorin S (2.47) (500 MHz, CDC13)
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LRESIMS of palmadorin S (2.47)
HRESIMS of palmadorin S (2.47)
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1H NMR spectrum of PSC10-10-CJ-2 (blue),  2.25 (green) and 2.34 (red) (500 
MHz, CDC13)
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1H NMR spectrum of  PSC10-10-I-16 (500 MHz, CDC13)
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PSC10-10-I-17_500_proton.esp
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1H NMR spectrum of PSC10-10-I-17 (500 MHz, CDC13)
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1H NMR spectrum of  PSC10-10-I-20 (500 MHz, CDC13)
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Appendix B: NMR and MS data supporting Chapter 4 
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LRESIMS of membranolide E (4.22) 
HRESIMS of membranolide E (4.22) 
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1H NMR spectrum of membranolide F (4.23) (500 MHz, CDC13)
13C NMR spectrum of membranolide F (4.23 ) (125 MHz, CDC13)
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ROESY spectrum of membranolide F (4.23 ) (500 MHz, CDC13)
COSY spectrum of membranolide F (4.23 ) (500 MHz, CDC13)
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NOESY spectrum of membranolide F (4.23 ) (500 MHz, CDC13)
LRESIMS of membranolide F (4.23 ) 
254 
 
 
  
HRESIMS of membranolide F (4.23 ) 
255 
 
1
H and 
13
C NMR  Data of Membranolide G (4.24) in CDCl3
a
 
position δC δH (J Hz)) gHMBC gCOSY ROESY 
1 41.29 1.43 (1H, m)    
  2.28 (1H, m) 5, 10 1a, 2, 5b  
2 20.0 1.65 (1H, m)  1, 2b, 3  
  1.83 (1H, m) 3 1a, 3  
3 39.9 1.25-
1.48 
(2H, m)    
       
4 31.7      
5 50.8 1.50 (1H, m)  5b, 18  
  2.08 (1H, m) 1, 3, 4, 10, 19, 20   
6 179.6      
7 41.25 4.62 (1H, q, 6.7) 6, 8, 9, 14 17 5b, 17, 20 
8 136.3      
9 148.8      
10 39.5      
11 128.8 7.54 (1H, q, 8.3) 8, 10, 13  1b, 12, 16 
12 121.2 7.20 (1H, q, 8.3) 9, 14, 16  15, 16 
13 137.4      
14 139.5      
15 106.1 6.14 (1H, s) 13, 16, 22  21 
16 105.6 6.30 (1H, s) 14, 15, 21  15, 22 
17 17.1 1.67 (3H, d, 7.2) 6, 7, 8  21 
18 27.5 0.47 (3H, s) 1, 3, 5, 10 5a, 19 5b, 17, 19 
19 32.9 0.92 (3H, s) 5, 10, 18, 20   
20 32.7 1.38 (3H, s) 1, 5, 9, 10   
21 53.3 3.40 (3H, s) 15  15 
22 54.2 3.31 (3H, s) 16  16 
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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gHSQC spectrum of membranolide G (4.24) ) (500 MHz, CDC13)
gHMBC spectrum of membranolide G (4.24) ) (500 MHz, CDC13)
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gCOSY spectrum of membranolide G (4.24) (500 MHz, CDC13)
ROESY spectrum of membranolide G (4.24) (500 MHz, CDC13)
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NOESY spectrum of membranolide G (4.24) (500 MHz, CDC13)
HRESIMS of membranolide G (4.24) 
260 
 
 
  
LRESIMS of membranolide G (4.24) 
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1
H and 
13
C NMR Data of Membranolide H (4.24) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 41.3 1.47 (1H, m) 9 1b, 2a, 5b, 
20 
 
  2.31 (1H, d, 12.4) 3, 5   
2 20.0 1.60 (1H, m) 1 3a  
  1.85 (1H, m)  20  
3 39.7 1.28 (2H, m) 1, 4, 18  19 
4 31.7      
5 50.9 1.47 (1H, m) 1, 4, 9, 18, 19   
  2.00 (1H, d, 14.3) 1, 4, 19, 20 20 19 
6 179.0   7   
7 40.3 4.59 (1H, m) 8, 9, 14, 17 17 5b, 17, 
20 
8 136.7      
9 148.3      
10 39.3      
11 129.0 7.54 (1H, m) 8, 10, 13 12 1b, 12 
12 121.1 7.19 (1H, m) 9, 14, 16 16 16 
13 136.3      
14 138.3      
15 105.7 6.04 (1H, m) 8, 16, 22  16, 17, 
21 
16 104.7 5.97 (1H, m) 14, 15, 21 22 17, 22 
17 14.9 1.57 (3H, d, 7.2) 6, 7, 8   
18 27.4 0.35 (3H, s) 4, 5, 10, 19 19, 20 5b, 17, 
19 
19 32.9 0.90 (3H, s) 3, 4, 5, 10   
20 32.8 1.45 (3H, s) 1, 9, 10   
21 53.4 3.38 (3H, s) 15   
22 55.8 3.34 (3H, s) 16   
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of  membranolide H (4.25) (500 MHz, CDC13)
13C NMR spectrum of membranolide H (4.25) (125 MHz, CDC13)
H-11
H-12
H-15
H-7
H3-21 H3-22
H3-18
H3-19
H3-20
H-1b
H3-17
H-16
C-6
C-16
C-9
C-8
C-14
C-11
C-13
C-12
C-15
263 
 
 
gHSQC spectrum of membranolide H (4.25) (500 MHz, CDC13)
gHMBC spectrum of membranolide H (4.25) (500 MHz, CDC13)
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gCOSY spectrum of membranolide H (4.25) (500 MHz, CDC13)
ROESY spectrum of membranolide H (4.25) (500 MHz, CDC13)
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NOESY spectrum of membranolide H (4.25) (500 MHz, CDC13)
LRESIMS of membranolide H (4.25) 
266 
 
 
  
HRESIMS of membranolide H (4.25) 
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1
H and 
13
C NMR  Data of Membranolide C (4.26) in CDCl3
a 
position δC δH (J (Hz))  
1 41.3 1.45 (1H, m) 
  2.28 (1H, m) 
2 20.0 1.65 (1H, m) 
  1.80 (1H, m) 
3 39.9 1.26 (1H, m) 
  1.32 (1H, m) 
4 31.7   
5 50.5 1.49 (1H, m) 
  2.11  
6 179.8   
7 41.3 4.60 (1H, m) 
8 136.2   
9 148.5   
10 39.4   
11 128.8 7.54 (1H, d, 8.2) 
12 121.3 7.22 (1H, d, 8.2) 
13 137.2   
14 139.4   
15 105.3 5.89 (1H, s) 
16 105.0 5.84 (1H, s) 
17 16.8 1.66 (3H, d, 7.1) 
18 27.4 0.47 (3H, s) 
19 33.0 0.91 (3H, s) 
20 32.8 1.37 (3H, s) 
21 54.2 3.41 (3H, s) 
22 54.8 3.49 (3H, s)  
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1
H and 
13
C NMR Data of Membranolide D (4.27) in CDCl3
a
 
position δC δH (J (Hz)) gHMBC gCOSY ROESY 
1 41.2 1.44 (1H, m)  1b, 2a, 5b, 
20 
 
  2.31 (1H, m) 3, 5   
2 20.0 1.60 (1H, m) 1, 3 3a  
  1.78 (1H, m)  20  
3 39.6 1.28 (1H, m)    
  1.32 (1H, m)    
4 31.7      
5 51.0 1.46 (1H, m)    
  2.01 (1H, m) 1, 3, 4, 19   
6 178.9      
7 40.1 4.61 (1H, m) 6, 8, 9, 14, 17 17 5b, 17, 20 
8 136.0      
9 148.6      
10 39.3      
11 129.3 7.57 (1H, m) 8, 10, 13 12 1b, 12 
12 121.3 7.23 (1H, m) 9, 14, 16   
13 137.1      
14 138.3      
15 106.2 6.32 (1H, s) 13, 16, 21 16 17, 21 
16 105.9 6.24 (1H, s) 14, 15, 22  12, 22 
17 15.3 1.57 (3H, d, 7.2) 7   
18 27.3 0.36 (3H, s) 3, 4, 5, 10, 19 5a, 19, 20  
19 32.9 0.90 (3H, s) 3, 4, 5, 10, 18   
20 32.9 1.43 (3H, s) 1, 5, 9, 10   
21 55.4 3.37 (3H, s) 15   
22 54.1 3.40 (3H, s) 16   
a
 For 
1
H, 500 MHz, ppm [integration, mult., J (Hz)]; for 
13
C, 125 MHz. 
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1H NMR spectrum of  membranolide D (4.27) (500 MHz, CDC13)
13C NMR spectrum of membranolide D (4.27) 125 MHz, CDC13)
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gHSQC spectrum of membranolide D (4.27) (500 MHz, CDC13)
gHMBC spectrum of membranolide D (4.27)(500 MHz, CDC13)
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F2 Chemical Shift (ppm)
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1
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h
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t 
(
p
p
m
)
I(6.23, 105.86, 0.97, 0)
H(6.32, 106.14, 0.77, 0)
E(7.23, 121.26, 0.68, 0)
AG(1.31, 32.92, 0.6, 0)
M(1.43, 15.29, 0.45, 0)
S(1.57, 32.93, 0.43, 0)
A(7.57, 129.28, 0.16, 0)
U(1.57, 50.96, -0.06, 0)
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t 
(
p
p
m
)
M,W(1.43, 41.45, 0.94, 0)
O,H+I(3.4, 105.86, 0.68, 0)
M,C(1.43, 39.52, 0.67, 0)
M,G(1.43, 148.66, 0.62, 0)
S+U,B(1.57, 136.07, 0.52, 0)
X,U(0.9, 51.01, 0.52, 0)
X,T(0.9, 31.97, 0.42, 0)
A,B(7.57, 136.07, 0.31, 0)
A,D(7.57, 137.15, 0.27, 0)
L,B(4.61, 136.07, 0.23, 0)
L,F(4.61, 138.39, 0.2, 0)
H,J(6.32, 55.65, 0.12, 0)
I,K(6.23, 54.26, 0.11, 0)
L,G(4.61, 148.66, 0.1, 0)
H+I(6.32, 105.86, 0.06, 0)
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gCOSY spectrum of membranolide D (4.27) (500 MHz, CDC13)
ROESY spectrum of membranolide D (4.27) (500 MHz, CDC13)
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NOESY spectrum of membranolide D (4.27) (500 MHz, CDC13)
LRESIMS of membranolide D (4.27)
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HRESIMS of membranolide D (4.27)
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LRESIMS of CD3OD treated Dendrilla membranosa extract.
LRESIMS of CD3OD treated Dendrilla membranosa extract.
